<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2959000-A1" country="EP" doc-number="2959000" kind="A1" date="20151230" family-id="50236357" file-reference-id="296092" date-produced="20180825" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="160453267" ucid="EP-2959000-A1"><document-id><country>EP</country><doc-number>2959000</doc-number><kind>A1</kind><date>20151230</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-14708460-A" is-representative="NO"><document-id mxw-id="PAPP193869502" load-source="patent-office" format="original"><country>EP</country><doc-number>14708460.2</doc-number><date>20140224</date><lang>EN</lang></document-id><document-id mxw-id="PAPP193869503" load-source="docdb" format="epo"><country>EP</country><doc-number>14708460</doc-number><kind>A</kind><date>20140224</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC162028192" ucid="US-201313776397-A" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201313776397</doc-number><kind>A</kind><date>20130225</date></document-id></priority-claim><priority-claim mxw-id="PPC162031535" ucid="US-2014018015-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2014018015</doc-number><kind>W</kind><date>20140224</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1724541089" load-source="docdb">C12N  15/113       20100101AFI20171130BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1724541090" load-source="docdb">A61K  31/00        20060101ALI20171130BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1987762953" load-source="docdb" scheme="CPC">C12N2310/352       20130101 LA20140523BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987763281" load-source="docdb" scheme="CPC">C12N2310/11        20130101 LA20140523BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987766452" load-source="docdb" scheme="CPC">A61K  31/713       20130101 LI20141024BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987774355" load-source="docdb" scheme="CPC">C12N2310/341       20130101 LA20140523BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987777556" load-source="docdb" scheme="CPC">C12N2310/321       20130101 LA20140523BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987778941" load-source="docdb" scheme="CPC">C12N2310/315       20130101 LA20140523BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987780193" load-source="docdb" scheme="CPC">C12N2310/113       20130101 LA20140523BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987784895" load-source="docdb" scheme="CPC">A61K  31/7125      20130101 LI20141024BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987787419" load-source="docdb" scheme="CPC">C12N2320/51        20130101 LA20140523BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987790868" load-source="docdb" scheme="CPC">C12N  15/113       20130101 LI20140902BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987791557" load-source="docdb" scheme="CPC">C12N  15/111       20130101 FI20140523BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987795339" load-source="docdb" scheme="CPC">C12N2310/14        20130101 LA20140523BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987795350" load-source="docdb" scheme="CPC">C12N2310/3231      20130101 LA20140523BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987799146" load-source="docdb" scheme="CPC">C12N2310/346       20130101 LA20140523BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT165551267" lang="DE" load-source="patent-office">MODIFIZIERUNGEN FÜR ANTISENSE-VERBINDUNGEN</invention-title><invention-title mxw-id="PT165551268" lang="EN" load-source="patent-office">MODIFICATIONS FOR ANTISENSE COMPOUNDS</invention-title><invention-title mxw-id="PT165551269" lang="FR" load-source="patent-office">MODIFICATIONS DE COMPOSÉS ANTISENS</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR1103344357" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>INTEGRATED DNA TECH INC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103325244" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>INTEGRATED DNA TECHNOLOGIES INC.</last-name></addressbook></applicant><applicant mxw-id="PPAR1101650630" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Integrated DNA Technologies Inc.</last-name><iid>101412360</iid><address><street>1710 Commercial Park</street><city>Coralville, IA 52241</city><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103321811" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>BEHLKE MARK AARON</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103325270" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>BEHLKE, MARK AARON</last-name></addressbook></applicant><applicant mxw-id="PPAR1101649861" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>Behlke, Mark Aaron</last-name><iid>101477436</iid><address><street>961 Timber Ridge Court</street><city>Coralville, IA 52241</city><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103322866" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>LENNOX KIMBERLY ANN</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103338667" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>LENNOX, KIMBERLY ANN</last-name></addressbook></applicant><applicant mxw-id="PPAR1101645464" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>Lennox, Kimberly Ann</last-name><iid>101477437</iid><address><street>3411 Forest Drive NE</street><city>North Liberty, IA 52317</city><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103302946" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>JACOBI ASHLEY MAE</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103344398" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>JACOBI, ASHLEY MAE</last-name></addressbook></applicant><applicant mxw-id="PPAR1101651807" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>Jacobi, Ashley Mae</last-name><iid>101477438</iid><address><street>295 Woodfield Drive</street><city>Tiffin, IA 52340</city><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103332044" load-source="docdb" sequence="5" format="epo"><addressbook><last-name>OWCZARZY RICHARD</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103307798" load-source="docdb" sequence="5" format="intermediate"><addressbook><last-name>OWCZARZY, RICHARD</last-name></addressbook></applicant><applicant mxw-id="PPAR1101647504" load-source="patent-office" sequence="5" format="original"><addressbook><last-name>Owczarzy, Richard</last-name><iid>101477439</iid><address><street>1710 Commercial Park</street><city>Coralville, IA 52241</city><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103323091" load-source="docdb" sequence="6" format="epo"><addressbook><last-name>WALDER JOSEPH ALAN</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103303181" load-source="docdb" sequence="6" format="intermediate"><addressbook><last-name>WALDER, JOSEPH ALAN</last-name></addressbook></applicant><applicant mxw-id="PPAR1101639708" load-source="patent-office" sequence="6" format="original"><addressbook><last-name>Walder, Joseph Alan</last-name><iid>101477440</iid><address><street>2709 W. Sherwin</street><city>Chicago, IL 60645</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR1103339995" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>BEHLKE MARK AARON</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103316796" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>BEHLKE, MARK, AARON</last-name></addressbook></inventor><inventor mxw-id="PPAR1101641780" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>BEHLKE, MARK, AARON</last-name><address><street>961 Timber Ridge Court</street><city>Coraville, IA 52241</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103306927" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>LENNOX KIMBERLY ANN</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103310603" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>LENNOX, Kimberly, Ann</last-name></addressbook></inventor><inventor mxw-id="PPAR1101643313" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>LENNOX, Kimberly, Ann</last-name><address><street>3411 Forest Drive NE</street><city>North Liberty, IA 52317</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103311084" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>JACOBI ASHLEY MAE</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103308454" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>JACOBI, Ashley, Mae</last-name></addressbook></inventor><inventor mxw-id="PPAR1101651237" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>JACOBI, Ashley, Mae</last-name><address><street>295 Woodfield Drive</street><city>Tiffin, IA 52340</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103321370" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>OWCZARZY RICHARD</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103310300" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>OWCZARZY, RICHARD</last-name></addressbook></inventor><inventor mxw-id="PPAR1101647081" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>OWCZARZY, RICHARD</last-name><address><street>1710 Commercial Park</street><city>Coralville, IA 52241</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103331122" load-source="docdb" sequence="5" format="epo"><addressbook><last-name>WALDER JOSEPH ALAN</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103329985" load-source="docdb" sequence="5" format="intermediate"><addressbook><last-name>WALDER, JOSEPH, ALAN</last-name></addressbook></inventor><inventor mxw-id="PPAR1101652428" load-source="patent-office" sequence="5" format="original"><addressbook><last-name>WALDER, JOSEPH, ALAN</last-name><address><street>2709 W. Sherwin</street><city>Chicago, IL 60645</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR1101639543" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Zwicker, Jörk</last-name><iid>100763101</iid><address><street>ZSP Patentanwälte Partnerschaftsgesellschaft Radlkoferstrasse 2</street><city>81373 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2014018015-W"><document-id><country>US</country><doc-number>2014018015</doc-number><kind>W</kind><date>20140224</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2014130945-A1"><document-id><country>WO</country><doc-number>2014130945</doc-number><kind>A1</kind><date>20140828</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS660717652" load-source="docdb">AL</country><country mxw-id="DS660635764" load-source="docdb">AT</country><country mxw-id="DS660743115" load-source="docdb">BE</country><country mxw-id="DS660723720" load-source="docdb">BG</country><country mxw-id="DS660714523" load-source="docdb">CH</country><country mxw-id="DS660743116" load-source="docdb">CY</country><country mxw-id="DS660634501" load-source="docdb">CZ</country><country mxw-id="DS660717654" load-source="docdb">DE</country><country mxw-id="DS660743117" load-source="docdb">DK</country><country mxw-id="DS660743118" load-source="docdb">EE</country><country mxw-id="DS660637976" load-source="docdb">ES</country><country mxw-id="DS660723721" load-source="docdb">FI</country><country mxw-id="DS660723722" load-source="docdb">FR</country><country mxw-id="DS660717667" load-source="docdb">GB</country><country mxw-id="DS660743123" load-source="docdb">GR</country><country mxw-id="DS660717668" load-source="docdb">HR</country><country mxw-id="DS660634502" load-source="docdb">HU</country><country mxw-id="DS660714524" load-source="docdb">IE</country><country mxw-id="DS660743124" load-source="docdb">IS</country><country mxw-id="DS660723727" load-source="docdb">IT</country><country mxw-id="DS660743125" load-source="docdb">LI</country><country mxw-id="DS660723728" load-source="docdb">LT</country><country mxw-id="DS660635765" load-source="docdb">LU</country><country mxw-id="DS660723729" load-source="docdb">LV</country><country mxw-id="DS660723730" load-source="docdb">MC</country><country mxw-id="DS660635766" load-source="docdb">MK</country><country mxw-id="DS660635771" load-source="docdb">MT</country><country mxw-id="DS660637977" load-source="docdb">NL</country><country mxw-id="DS660792402" load-source="docdb">NO</country><country mxw-id="DS660637978" load-source="docdb">PL</country><country mxw-id="DS660723751" load-source="docdb">PT</country><country mxw-id="DS660634507" load-source="docdb">RO</country><country mxw-id="DS660723752" load-source="docdb">RS</country><country mxw-id="DS660637991" load-source="docdb">SE</country><country mxw-id="DS660714525" load-source="docdb">SI</country><country mxw-id="DS660792403" load-source="docdb">SK</country><country mxw-id="DS660792404" load-source="docdb">SM</country><country mxw-id="DS660635772" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>ME</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA139071897" ref-ucid="WO-2014130945-A1" lang="EN" load-source="patent-office"><p num="0000">The invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve stability and provide protection from nuclease degradation. The modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miRNAs.</p></abstract><abstract mxw-id="PA139539546" ref-ucid="WO-2014130945-A1" lang="EN" source="national office" load-source="docdb"><p>The invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve stability and provide protection from nuclease degradation. The modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miRNAs.</p></abstract><abstract mxw-id="PA139071898" ref-ucid="WO-2014130945-A1" lang="FR" load-source="patent-office"><p num="0000">L'invention concerne des modifications d'oligonucléotides antisens, les modifications étant utilisées pour améliorer la stabilité et assurer la protection contre la dégradation par les nucléases. Les modifications peuvent également être intégrées dans des acides nucléiques bicaténaires, tels ques des ARNsi et des ARNmi.</p></abstract><abstract mxw-id="PA139539547" ref-ucid="WO-2014130945-A1" lang="FR" source="national office" load-source="docdb"><p>L'invention concerne des modifications d'oligonucléotides antisens, les modifications étant utilisées pour améliorer la stabilité et assurer la protection contre la dégradation par les nucléases. Les modifications peuvent également être intégrées dans des acides nucléiques bicaténaires, tels ques des ARNsi et des ARNmi.</p></abstract><description mxw-id="PDES78476284" ref-ucid="WO-2014130945-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> MODIFICATIONS FOR ANTISENSE COMPOUNDS </p><p id="p0002" num="0002">CROSS REFERENCE TO RELATED APPLICATION </p><p id="p0003" num="0003">[0001] This application claims priority to U.S. Patent Application No. 13/776,397, filed February 25, 2013, which is hereby incorporated by reference in its entirety. </p><p id="p0004" num="0004">STATEMENT REGARDING FEDERALLY-SPONSORED </p><p id="p0005" num="0005"> RESEARCH OR DEVELOPMENT </p><p id="p0006" num="0006">[0002] This invention was supported in part by Small Business Innovation Research (SBIR) Grants Nos. 2R44GM085863-02 and 5R44GM085863-03 from the National Institute of General Medical Sciences of the National Institutes of Health (NIH). The government may have certain rights in this invention. </p><p id="p0007" num="0007">FIELD OF THE INVENTION </p><p id="p0008" num="0008">[0003] This invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve binding affinity and provide protection from nuclease degradation. </p><p id="p0009" num="0009">BACKGROUND OF THE INVENTION </p><p id="p0010" num="0010">[0004] Antisense oligonucleotides (ASOs) are synthetic nucleic acids that bind to a complementary target and suppress function of that target. Typically ASOs are used to reduce or alter expression of RNA targets, particularly messenger RNA (mRNA) or microRNA (miRNA) species. As a general principle, ASOs can suppress gene expression via two different mechanisms of action: 1) by steric blocking, wherein the ASO tightly binds the target nucleic acid and inactivates that species, preventing its participation in cellular activities, or 2) by triggering degradation, wherein the ASO binds the target and leads to activation of a cellular nuclease that degrades the targeted nucleic acid species. One class of "target degrading" ASOs is "RNase H active", where formation of heteroduplex nucleic acids by hybridization of the target RNA with a DNA-containing RNase H active ASO forms a substrate for the enzyme RNase H. RNase H degrades the RNA portion of the heteroduplex molecule, thereby reducing expression of that species. Degradation of the target RNA releases the ASO, which is not degraded, and is then free to recycle and bind another RNA 
<!-- EPO <DP n="3"/>-->
 target of the same sequence. For an overview of antisense strategies, oligonucleotide design and chemical modifications, see Kurreck, 2003, Eur. J. Biochem., 270(8): 1628-44. </p><p id="p0011" num="0011">[0005] Unmodified DNA oligonucleotides have a half-life of minutes when incubated in human serum. Therefore, unmodified DNA oligonucleotides have limited utility as ASOs. The primary nuclease present in serum has a 3'-exonuclease activity (Eder et al., 1991, Antisense Res. Dev. 1(2): 141-51). Once an ASO gains access to the intracellular compartment, it is susceptible to endonuclease degradation. Historically, the first functional ASOs to gain widespread use comprised DNA modified with phosphorothioate groups (PS). PS modification of internucleotide linkages confers nuclease resistance, making the ASOs more stable both in serum and in cells. As an added benefit, the PS modification also increases binding of the ASO to serum proteins, such as albumin, which decreases the rate of renal excretion following intravenous injection, thereby improving pharmacokinetics and improving functional performance (Geary et al., 2001, Curr. Opin. Investig. Drugs, 2(4): 562-73). However, PS-modified ASOs are limited to a 1-3 day half-life in tissue, and the PS modifications reduce the binding affinity of the ASO for the target RNA, which can decrease potency (Stein et al., 1988, Nucleic Acids Res. 16(8): 3209-21). </p><p id="p0012" num="0012"> [0006] The PS modification is unique in that it confers nuclease stability, yet still permits formation of a heteroduplex with RNA that is a substrate for RNase H. Most other modifications that confer nuclease resistance, such as methyl phosphonates or </p><p id="p0013" num="0013">phosphoramidates, are modifications that do not form heteroduplexes that are RNase H substrates when hybridized to a target mRNA. Improved potency could be obtained using compounds that were both nuclease resistant and showed higher affinity to the target RNA, yet retain the ability to activate RNase H mediated degradation pathways. </p><p id="p0014" num="0014">[0007] Further design improvements were implemented to increase affinity for the target RNA while still maintaining nuclease resistance (see Walder et al., U.S. Patent No. 6, 197,944 for designs containing 3 '-modifications with a region containing unmodified residues with phosphodiester linkages; see also European Patent No. 0618925 for "Gapmer" compounds having 2'-methoxyethylriboses (MOE's) providing 2'-modified "wings" at the 3' and 5' ends flanking a central 2'-deoxy gap region). This new strategy allows for chimeric molecules that have distinct functional domains. For example, a single ASO can contain a domain that confers both increased nuclease stability and increased binding affinity, but itself does not form an RNase H active substrate; a second domain in the same ASO can be RNase H 
<!-- EPO <DP n="4"/>-->
 activating. Having both functional domains in a single molecule improves performance and functional potency in antisense applications. One successful strategy is to build the ASO from different chemical groups, with a domain on each end intended to confer increased binding affinity and increased nuclease resistance, each flanking a central domain comprising different modifications. This facilitates RNase H activation. This so-called "end blocked" or "gapmer" design is the basis for the improved function "second generation" ASOs. </p><p id="p0015" num="0015">Compounds of this design are typically significantly more potent as gene knockdown agents than the "first generation" PS-DNA ASOs. </p><p id="p0016" num="0016"> [0008] Typically ASOs that function using steric blocking mechanisms of action show higher potency when made to maximize binding affinity. This can be accomplished through use of chemical modifications that increase binding affinity, such as many of the 2'-ribose modifications discussed herein, minor groove binders, or the internal non-base modifiers of the present invention. Alternatively, increased binding affinity can be achieved by using longer sequences. However, some targets are short, such as miRNAs, which are typically only 20-24 bases long. In this case, making ASOs longer to increase binding affinity is not possible. Furthermore, short synthetic oligonucleotides gain access into cells more efficiently than long oligonucleotides, making it desirable to employ short sequences with modifications that increase binding affinity (see, e.g., Straarup et ah, 2010, Nucleic Acids Res. 38(20): 7100-1 1). The chemical modification and methods of the present invention enable synthesis of relatively short ASOs having increased binding affinity that show improved functional performance. </p><p id="p0017" num="0017"> [0009] ASO modifications that improve both binding affinity and nuclease resistance typically are modified nucleosides that are costly to manufacture. Examples of modified nucleosides include locked nucleic acids (LNA), wherein a methyl bridge connects the 2'- oxygen and the 4'-carbon, locking the ribose in an A-form conformation; variations of LNA are also available, such as ethylene-bridged nucleic acids (ENA) that contain an additional methyl group, amino-LNA and thio-LNA. Additionally, other 2'-modifications, such as 2'-0- methoxyethyl (MOE) or 2'-fluoro (2'-F), can also be incorporated into ASOs. Some modifications decrease stability, and some can have negative effects such as toxicity (see Swayze et ah, 2007, Nucleic Acids Res. 35(2): 687-700). </p><p id="p0018" num="0018"> [0010] The present invention provides for non-nucleotide modifying groups that can be inserted between bases in an ASO to improve nuclease resistance and binding affinity, 
<!-- EPO <DP n="5"/>-->
 thereby increasing potency. The novel modifications of the present invention can be employed with previously described chemical modifications (such as PS internucleotide linkages, LNA bases, MOE bases, etc.) and with naturally occurring nucleic acid building blocks, such as DNA or 2'-0-Methyl RNA (2'OMe), which are inexpensive and non-toxic. These and other advantages of the invention, as well as additional inventive features, will be apparent from the description of the invention provided herein. </p><p id="p0019" num="0019">BRIEF SUMMARY OF THE INVENTION </p><p id="p0020" num="0020"> [0011] The invention provides non-nucleotide modifications for antisense </p><p id="p0021" num="0021">oligonucleotides, wherein the modifications are used to increase binding affinity and provide protection from nuclease degradation. </p><p id="p0022" num="0022"> [0012] The invention also provides an antisense oligonucleotide comprising at least one modification that is incorporated at the terminal end of an antisense oligonucleotide, or between two bases of the antisense oligonucleotide, wherein the modification increases binding affinity and nuclease resistance of the antisense oligonucleotide. In one embodiment, the antisense oligonucleotide comprises at least one modification that is located within three bases of a terminal nucleotide. In another embodiment, the antisense oligonucleotide comprises at least one modification that is located between a terminal base and a penultimate base of either the 3'- or the 5 '-end of the oligonucleotide. In another embodiment, the antisense oligonucleotide comprises a modification at a terminal end of the oligonucleotide. In a further embodiment, the antisense oligonucleotide comprises a modification at the terminal end or between the terminal base and the penultimate base of both the 3'- and the 5'- ends of the antisense oligonucleotide. In yet a further embodiment, the oligonucleotide contains a non-base modifier at a terminal end or between the terminal base and the penultimate base at the 5 '-end and at the 3 '-end. The relative increase of binding affinity contributed by the non-base modifier may vary with sequence context (Example 8) which can influence which of the various design options taught herein is most potent. </p><p id="p0023" num="0023">[0013] The invention further provides an antisense oligonucleotide comprising at least one modification that is incorporated at the terminal end or between two bases of the antisense oligonucleotide, wherein the modification increases binding affinity and nuclease resistance of the antisense oligonucleotide, and wherein the modification is a napthyl-azo compound. 
<!-- EPO <DP n="6"/>-->
 [0014] The invention further provides an antisense oligonucleotide comprising at least one modification that is incorporated at a terminal end or between two bases of the antisense oligonucleotide, wherein the modification increases binding affinity and nuclease resistance of the antisense oligonucleotide, and wherein the modification has the structure: </p><p id="p0024" num="0024"><img id="imgf000006_0001" he="31" wi="68" file="imgf000006_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 wherein the linking groups Li and L2 positioning the modification at an internal position of the oligonucleotide are independently an alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, or alkoxy groups; R1-R5 are independently a hydrogen, alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, alkoxy, an electron withdrawing group, an electron donating group, or an attachment point for a ligand; and X is a nitrogen or carbon atom, wherein if X is a carbon atom, the fourth substituent attached to the carbon atom can be hydrogen or a C1-C8 alkyl group. </p><p id="p0025" num="0025"> [0015] The invention further provides an antisense oligonucleotide comprising at least one modification that is incorporated at a terminal end or between two bases of the antisense oligonucleotide, wherein the modification increases binding affinity and nuclease resistance of the antisense oligonucleotide, and wherein the modification has the structure: </p><p id="p0026" num="0026"><img id="imgf000006_0002" he="45" wi="119" file="imgf000006_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0027" num="0027"> ormu a 
<!-- EPO <DP n="7"/>-->
 wherein the linking groups Li and L2 positioning the modification at an internal position of the oligonucleotide are independently an alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, or alkoxy groups; Ri, R2, R4, 5 are independently a hydrogen, alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, alkoxy, an electron withdrawing group, or an electron donating group; R6, R7, R9-R12 are independently a hydrogen, alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, alkoxy, an electron withdrawing group, or an electron donating group; Rs is a hydrogen, alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, alkoxy, or an electron withdrawing group; and X is a nitrogen or carbon atom, wherein if X is a carbon atom, the fourth substituent attached to the carbon atom can be hydrogen or a C1-C8 alkyl group. In one embodiment, R<sub>8</sub> is NO2. </p><p id="p0028" num="0028"> [0016] The invention further provides an antisense oligonucleotide comprising at least one modification that is incorporated at a terminal end or between two bases of the antisense oligonucleotide, wherein the modification increases binding affinity and nuclease resistance of the antisense oligonucleotide, and wherein the modification has the structure: </p><p id="p0029" num="0029"><img id="imgf000007_0001" he="64" wi="89" file="imgf000007_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="8"/>-->
 Formula 3 </p><p id="p0030" num="0030">[0017] The antisense oligonucleotides of the invention can include natural, non-natural, or modified bases known in the art. The antisense oligonucleotides of the invention can also include, typically but not necessarily on the 3 Or 5' ends of the oligonucleotide, additional modifications such as minor groove binders, spacers, labels, or other non-base entities. In one embodiment, the antisense oligonucleotide further comprises 2'-0-methyl RNA, and optionally comprises at least one napthyl-azo compound. In another embodiment, the antisense oligonucleotide further comprises phosphorothioate linkages. In a further embodiment, the antisense oligonucleotide comprises a region of bases linked through phosphodiester bonds, wherein the region is flanked at one or both ends by regions containing phosphorothioate linkages. </p><p id="p0031" num="0031"> [0018] The invention further provides an antisense oligonucleotide having the structure: </p><p id="p0032" num="0032">5'-Xi-Z<sub>n</sub>-X<sub>2</sub>-X<sub>3</sub>-X4-Z<sub>n</sub>-X<sub>5</sub>-3' Formula 4 wherein Xi and X5 are independently 0-3 nucleotides wherein the internucleotide linkages are optionally phosphorothioate; wherein Z is a napthyl-azo compound; n is 0 or 1 ; X2 and X<sub>4</sub> are independently 1 -5 nucleotides wherein the internucleotide linkages are optionally </p><p id="p0033" num="0033">phosphorothioate; and X<sub>3</sub> is 10-25 nucleotides. </p><p id="p0034" num="0034"> [0019] In one embodiment, a third modification can be inserted around the middle of the antisense oligonucleotide. For longer nucleotides (greater than 25 bases), additional modifications could be used at intervals to confer greater stability. In the modifications of the invention, a modifying group is inserted between adjacent bases, thereby generating an ASO with reduced toxicity and improved affinity and stability. The bases can be DNA, 2'OMe RNA, or other modified bases. However, modified bases do not need to be employed. </p><p id="p0035" num="0035">Because the modifications are inserted between the bases, they can be added as </p><p id="p0036" num="0036">phosphoramidite compounds using standard phosphoramidite synthesis chemistry. </p><p id="p0037" num="0037">[0020] </p><p id="p0038" num="0038"> [0021] In a further aspect, the invention provides a method of reducing a level of a target mRNA in a cell, said method comprising contacting the cell with an oligonucleotide, wherein said oligonucleotide is at least partially complementary to the target mRNA and wherein said oligonucleotide comprises at least one modification that is incorporated at the terminal end or 
<!-- EPO <DP n="9"/>-->
 between two bases of the oligonucleotide and wherein the modification increases binding affinity and nuclease resistance of the antisense oligonucleotide, in an amount sufficient to reduce the target mRNA. </p><p id="p0039" num="0039"> [0022] In an additional aspect, the invention provides a method of reducing a level of a target miRNA in a cell, said method comprising contacting the cell with an oligonucleotide, wherein said oligonucleotide is at least partially complementary to the target miRNA and wherein said oligonucleotide comprises at least one modification that is incorporated at the terminal end or between two bases of the oligonucleotide and wherein the modification increases binding affinity and nuclease resistance of the antisense oligonucleotide, in an amount sufficient to reduce the target miRNA. </p><p id="p0040" num="0040"> [0023] In another aspect the invention provides an oligonucleotide complementary to a target mRNA comprising: a modified 3'-terminal internucleotide phosphodiester linkage, which modified 3 '-terminal internucleotide phosphodiester linkage is resistant to 3' to 5' exonuclease degradation; modifications on the 3 '-terminus and the 5'-terminus of the oligonucleotide, wherein the modifications increase binding affinity of the oligonucleotide to the target mRNA; one or more additional modifications, which additional modification(s) facilitate(s) intracellular transport of said oligodeoxynucleotide; and a continuous stretch of at least five nucleotide residues having four internucleotide phosphodiester linkages which are unmodified, wherein said oligodeoxynucleotide, when mixed with an RNA molecule for which it has complementarity under conditions in which an RNaseH is active, hybridizes to the RNA and forms a substrate that can be cleaved by the RNase H. </p><p id="p0041" num="0041">[0024] In one aspect, the invention provides a Dicer-substrate RNA (DsiRNA) oligonucleotide, comprising a sense strand and an antisense strand, wherein at least one modification on the antisense strand is incorporated near the 3 ' terminal end or between two bases of the antisense strand. </p><p id="p0042" num="0042"> [0025] In a certain aspect, the invention provides an anti-miRNA oligonucleotide (AMO) comprising, </p><p id="p0043" num="0043"> (a) at least one 2'-0-methyl RNA (2'OMe), and </p><p id="p0044" num="0044"> (b) at least one napthyl-azo compound modification that is incorporated at the terminal end of the AMO, wherein the modification increases stability of the AMO. </p><p id="p0045" num="0045">[0026] In a further aspect, the invention provides an RNase H antisense oligonucleotide (ASO) comprising, at least one napthyl-azo compound modification that is incorporated at 
<!-- EPO <DP n="10"/>-->
 the terminal end of the ASO, wherein each nucleotide is connected by a phosphorothioate group (PS) and wherein the modification increases stability of the ASO. </p><p id="p0046" num="0046">BRIEF DESCRIPTION OF THE DRAWINGS </p><p id="p0047" num="0047">[0027] Figure 1 is a gel photograph that illustrates the levels of degradation of synthetic DNA oligomers in fetal bovine serum. A series of 10-mer single-stranded DNA </p><p id="p0048" num="0048">oligonucleotides were trace labeled with <sup>32</sup>P at their 5 '-ends and were incubated in serum at 37°C for the indicated times (0-240 minutes). Reaction products were separated by polyacrylamide gel electrophoresis (PAGE) and visualized by phosphorimaging. Samples are identified in Table 4. </p><p id="p0049" num="0049"> [0028] Figure 2 illustrates relative miR-21 suppression by various anti-miRNA oligonucleotides (AMOs) using a luciferase reporter assay. A reporter plasmid that expresses both Renilla luciferase and firefly luciferase was transfected into HeLa cells. Cell extracts were studied for relative activity of both enzymes and Renilla luciferase activity was normalized to firefly luciferase activity. The Renilla luciferase gene contains a miR-21 binding site and miR-21 is highly expressed in HeLa cells. Different anti-miR-21 oligonucleotides (X-axis) were transfected into the cells and the relative ability of different designs to suppress miR-21 activity directly relate to the increase in Renilla luciferase activity (Y-axis). </p><p id="p0050" num="0050"> [0029] Figure 3 illustrates relative miR-21 suppression by various AMOs using a luciferase reporter assay comparing perfect match and compounds having 1, 2, or 3 mismatches (mismatch pattern 1). A reporter plasmid that expresses both Renilla luciferase and firefly luciferase was transfected into HeLa cells. Cell extracts were studied for relative activity of both enzymes and Renilla luciferase activity was normalized to firefly luciferase activity. The Renilla luciferase gene contains a miR-21 binding site and miR-21 is highly expressed in HeLa cells. Different anti-miR-21 oligonucleotides (X-axis) were transfected into the cells, and the relative ability of different designs to suppress miR-21 activity directly relate to the increase in Renilla luciferase activity (Y-axis). </p><p id="p0051" num="0051"> [0030] Figure 4 illustrates relative miR-21 suppression by various AMOs using a luciferase reporter assay comparing perfect match and compounds having 1, 2, or 3 mismatches (mismatch pattern 2). A reporter plasmid that expresses both Renilla luciferase and firefly luciferase was transfected into HeLa cells. Cell extracts were studied for relative 
<!-- EPO <DP n="11"/>-->
 activity of both enzymes, and Renilla luciferase activity was normalized to firefly luciferase activity. The Renilla luciferase gene contains a miR-21 binding site and miR-21 is highly expressed in HeLa cells. Different anti-miR-21 oligonucleotides (X-axis) were transfected into the cells, and the relative ability of different designs to suppress miR-21 activity directly relate to the increase in Renilla luciferase activity (Y-axis). </p><p id="p0052" num="0052"> [0031] Figure 5 illustrates knockdown of HPRT expression by DNA ASOs, with or without PS bonds or iFQ modification. ASOs were transfected into HeLa cells and RNA was prepared 24 hours post transfection. Relative HPRT levels were assessed by RT-qPCR and are reported on the Y-axis. </p><p id="p0053" num="0053"> [0032] Figure 6 illustrates knockdown of HPRT expression by chimeric "gapmer" ASOs, with or without PS bonds and with or without iFQ modification. ASOs were transfected into HeLa cells and RNA was prepared 24 hours post transfection. Relative HPRT levels were assessed by RT-qPCR and are reported on the Y-axis. </p><p id="p0054" num="0054"> [0033] Figure 7 illustrates knockdown of HPRT using DsiRNAs at doses ranging from 0.01 nM to 1.0 nM. DsiRNAs were modified with iFQ group(s) at positions within the duplexes as indicated in the schematic below the graph. DsiRNAs were transfected into HeLa cells and RNA was prepared 24 hours post transfection. Relative HPRT levels were assessed by RT-qPCR and are reported on the Y-axis. </p><p id="p0055" num="0055"> [0034] Figure 8 illustrates the toxicity profiles of various AMO chemistries when transfected for 24 hours at 50 nM or 100 nM in HeLa cells. The negative control or "NCI " sequence is not predicted to target any known human miRNAs or mRNAs, and so toxicity effects should be specific to the chemical composition of the oligonucleotide. The MultiTox- Glo Multiplex Cytotoxicity Assay was employed to measure cell viability following treatment with various chemically modified oligonucleotides (X-axis), and cell viability was calculated as a ratio of live/dead cells to normalize the data independent of cell number (Y- axis). A decrease of live/dead cell values correlates with decreased cell viability. </p><p id="p0056" num="0056">[0035] Figure 9 illustrates apoptosis induction profiles caused by various AMO chemistries when transfected for 24 hours at 50 nM or 100 nM in HeLa cells. The negative control or "NCI " sequence is not predicted to target any known human miRNAs or mRNAs, and so induction of apoptosis should be specific to the biological effects of chemical composition of the oligonucleotide in the cell. The Caspase-Glo 3/7 Assay was employed to measure the levels of caspase-3 and caspase-7, which are known effectors of apoptosis, using 
<!-- EPO <DP n="12"/>-->
 a luciferase assay. Apoptosis induction following treatment with various chemically modified oligonucleotides (X-axis) is proportional to increasing levels of luminescence (Y- axis). </p><p id="p0057" num="0057"> [0036] Figure 10 is a gel photograph that illustrates the levels of degradation of synthetic 2'OMe-RNA oligomers in fetal bovine serum. A series of 22-mer single-stranded 2'OMe- RNA oligonucleotides were incubated in 10% serum at 37°C for the indicated times (0-24 hours). Reaction products were separated by polyacrylamide gel electrophoresis (PAGE), stained with methylene blue, and visualized by transillumination. Samples are identified in Table 14. </p><p id="p0058" num="0058"> [0037] Figure 11 is a gel photograph that illustrates the levels of degradation of synthetic 2'OMe-RNA oligomers in fetal bovine serum. A series of 22-mer single-stranded 2'OMe- RNA oligonucleotides were incubated in 10% serum at 37°C for the indicated times (0-24 hours). Reaction products were separated by polyacrylamide gel electrophoresis (PAGE), stained with methylene blue, and visualized by transillumination. Samples are identified in Table 14. </p><p id="p0059" num="0059"> [0038] Figure 12 is a gel photograph that illustrates the levels of degradation of synthetic 2'OMe-RNA oligomers in cell extracts. A series of 22-mer single-stranded 2'OMe-RNA oligonucleotides were incubated in mouse liver cell extracts at 37°C for the indicated times (0-24 hours). Reaction products were separated by polyacrylamide gel electrophoresis (PAGE), stained with methylene blue, and visualized by transillumination. Samples are identified in Table 14. </p><p id="p0060" num="0060"> [0039] Figure 13 is a gel photograph that illustrates the levels of degradation of synthetic 2'OMe-RNA oligomers in cell extracts. A series of 22-mer single-stranded 2'OMe-RNA oligonucleotides were incubated in mouse liver cell extracts at 37°C for the indicated times (0-24 hours). Reaction products were separated by polyacrylamide gel electrophoresis (PAGE), stained with methylene blue, and visualized by transillumination. Samples are identified in Table 14. </p><p id="p0061" num="0061"> [0040] Figure 14 is a gel photograph that illustrates the levels of degradation of synthetic 2'OMe-RNA oligomers in cell extracts. A series of 22-mer single-stranded 2'OMe-RNA oligonucleotides were incubated in mouse liver cell extracts at 37°C for the indicated times (0-96 hours). Reaction products were separated by polyacrylamide gel electrophoresis 
<!-- EPO <DP n="13"/>-->
 (PAGE), stained with methylene blue, and visualized by transillumination. Samples are identified in Table 15. </p><p id="p0062" num="0062"> [0041] Figure 15 illustrates relative miR-21 suppression by various AMOs using a luciferase reporter assay. A reporter plasmid that expresses both Renilla luciferase and firefly luciferase was transfected into HeLa cells. Cell extracts were studied for relative activity of both enzymes and Renilla luciferase activity was normalized to firefly luciferase activity. The Renilla luciferase gene contains a miR-21 binding site and miR-21 is highly expressed in HeLa cells. Different anti-miR-21 oligonucleotides (X-axis) were transfected into the cells and the relative ability of different designs to suppress miR-21 activity directly relate to the increase in Renilla luciferase activity (Y-axis). Sequences are identified in Table 16. </p><p id="p0063" num="0063">[0042] Figure 16 illustrates relative miR-21 suppression by various AMOs using a luciferase reporter assay. A reporter plasmid that expresses both Renilla luciferase and firefly luciferase was transfected into HeLa cells. Cell extracts were studied for relative activity of both enzymes and Renilla luciferase activity was normalized to firefly luciferase activity. The Renilla luciferase gene contains a miR-21 binding site and miR-21 is highly expressed in HeLa cells. Different anti-miR-21 oligonucleotides (X-axis) having various 3 '-end structures were transfected into the cells and the relative ability of different designs to suppress miR-21 activity directly relate to the increase in Renilla luciferase activity (Y-axis). Sequences are identified in Table 18. The length of the AMO as synthesized is shown in the name under which is indicated the expected length of the AMO that survives incubation in serum or exposure to cellular nucleases. </p><p id="p0064" num="0064"> [0043] Figure 17 illustrates knockdown of HPRT expression by chimeric "gapmer" ASOs, with or without PS bonds in the 2'-modified flanking domains and without further modification, with the FQ modification placed internally near the ends between the last and penultimate base, or with the FQ modification based at the 5'- and 3 '-ends. ASOs were transfected into HeLa cells and RNA was prepared 24 hours post transfection. Relative HPRT levels were assessed by RT-qPCR and are reported on the Y-axis. </p><p id="p0065" num="0065">DETAILED DESCRIPTION OF THE INVENTION </p><p id="p0066" num="0066">[0044] The antisense oligonucleotides of the invention have modifications placed at the 3 '-end and/or 5 '-end, or placed between nucleotides, wherein the modifications increase affinity to the complementary target and provide nuclease resistance. In one embodiment of 
<!-- EPO <DP n="14"/>-->
 the invention, the compounds are the same as those described in U.S. Application No. </p><p id="p0067" num="0067">13/073,866, the disclosure of which is incorporated by reference herein in its entirety. </p><p id="p0068" num="0068">[0045] In another embodiment of the invention, the antisense oligonucleotide comprises at least one modification that has the structure: </p><p id="p0069" num="0069"><img id="imgf000014_0001" he="31" wi="68" file="imgf000014_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 wherein the linking groups Li and L2 positioning the modification at an internal position of the oligonucleotide are independently an alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, or alkoxy groups; R1-R5 are independently a hydrogen, alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, alkoxy, an electron withdrawing group, an electron donating group, or an attachment point for a ligand; and X is a nitrogen or carbon atom, wherein if X is a carbon atom, the fourth substituent attached to the carbon atom can be hydrogen or a C1-C8 alkyl group. In a further embodiment of the invention, the antisense oligonucleotide comprises at least one modification that has the structure: </p><p id="p0070" num="0070"><img id="imgf000014_0002" he="48" wi="119" file="imgf000014_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 wherein the linking groups Li and L2 positioning the modification at an internal position of the oligonucleotide are independently an alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, or alkoxy groups; Ri, R2, R4, R5 are independently a hydrogen, alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, 
<!-- EPO <DP n="15"/>-->
 heteroaryl, substituted aryl, cycloalkyl, alkylaryl, alkoxy, an electron withdrawing group, or an electron donating group; Re, R7, R9-R12 are independently a hydrogen, alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, alkoxy, an electron withdrawing group, or an electron donating group; Rs is a hydrogen, alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, alkoxy, or an electron withdrawing group; and X is a nitrogen or carbon atom, wherein if X is a carbon atom, the fourth substituent attached to the carbon atom can be hydrogen or a C1-C8 alkyl group. </p><p id="p0071" num="0071"> [0046] The compositions and methods of the invention involve modification of an oligonucleotide by placing non-base modifying group(s) as insertions at a terminal end or between bases while retaining the ability of that sequence to hybridize to a complementary sequence. Typically, insertion of non-base modifying groups between bases results in a significant loss of affinity of the modified sequence to its complement. The unique compositions of the invention, whether the non-base group is located at the 5'- or 3 '-end or internally, increase affinity of the modified sequence to its complement, increasing stability and increasing T<sub>m</sub>. Placement of such non-base modifying group(s) prevents nucleases from initiating degradation at the modified linkage(s). When placed terminally or between the first and second bases at both ends of the oligonucleotide, the sequence is protected from attack by both 5'-exonucleases and 3'-exonucleases. Placement at central position(s) within the sequence can additionally confer some resistance to endonucleases. In particular, compounds of the class of Formula 2 above impede nuclease attack for several flanking internucleotide phosphate bonds adjacent to the modified linkage, creating a protected "zone" where unmodified linkages are less susceptible to nuclease cleavage. The modifications also reduce the rate of cleavage or totally prevent cleavage of terminal bases. Thus the compositions and methods of the invention permit synthesis of ASOs having increased T<sub>m</sub> and increased nuclease resistance yet do not employ modified but instead employ a non-base modifying group inserted between residues. The non-base modifier can also be placed directly at the 5'-end and/or 3 '-end of the oligomer which will similarly protect the compound from exonuclease attack. </p><p id="p0072" num="0072"> [0047] The ability of the modifying groups of the present invention to increase binding affinity (T<sub>m</sub>) of duplexed nucleic acids is demonstrated in Example 1, where melting studies were conducted for a series of unmodified and modified 10-mer duplex DNA oligomers. 
<!-- EPO <DP n="16"/>-->
 Using compositions and methods of the present invention, an increase of +1 1 °C was achieved using only two modifying groups (between the two terminal bases on each end of the oligomer). Similar duplexes made with insertions of a propanediol group show significant destabilization, consistent with the expected results for non-base insertions. The ability of the modifying groups of the present invention to increase binding affinity (T<sub>m</sub>) of duplexed nucleic acids is further demonstrated in Examples 8 and 10, where melting studies were conducted for a series of unmodified and modified 22-mer 2'OMe-RNA oligomers duplexed with an RNA target. This experiment simulates binding of an anti-miRNA antisense oligomer (AMO) with a target miRNA (for Example 10, the target was a synthetic miR-21). In this context, an increase as high as of +4°C was seen for use of even a single modifier. The magnitude of the effect varies with sequence and in some base contexts was slightly destabilizing. </p><p id="p0073" num="0073"> [0048] The ability of the modifying groups of the present invention to improve nuclease stability is demonstrated in Example 2, where single-stranded DNA oligomers were incubated in serum (subjected to degradation by serum nucleases) and then examined for integrity by polyacrylamide gel electrophoresis (PAGE). Unmodified DNA oligomers are rapidly degraded in serum whereas a 10-mer DNA oligonucleotide with an insertion of the napthyl-azo modifier between the terminal bases on each end resulted in a compound that was not degraded after 4 hours incubation. Other modifying groups, such as a propanediol spacer, only slowed the rate of degradation slightly. T<sub>m</sub>-enhancing, nuclease blocking modifications (such as the napthyl-azo group) can be inserted into single-stranded oligomers to improve properties. </p><p id="p0074" num="0074"> [0049] Stabilized, increased binding affinity oligomers of this type can have a variety of uses, as is well appreciated by those with skill in the art. As examples (not meant to be limiting), such oligomers can be used as ASOs to promote reduction of mRNA or miRNA levels in a cell or animal. Such examples are demonstrated in Examples 3, 4, 5 and 10 below. The present invention can be equally well applied to ASOs intended to degrade a target mRNA or to inhibit function by tight binding (steric blocking). Examples of steric blocking acting ASOs are demonstrated in Examples 3, 4, and 10; in this case, the compounds are used as AMOs. Examples of degrading ASOs are demonstrated in Example 5 and 12; in these cases, the compounds are used as anti-mRNA oligonucleotides in an RNase H active design. 
<!-- EPO <DP n="17"/>-->
 [0050] In a further embodiment of the invention, the modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miR As (miR-mimics). Careful placement of the modifying group should lead to improvements in nuclease stability and could alter local thermal stability, which if employed asymmetrically in an RNA duplex, is well known to influence strand loading into RISC (Peek and Behlke, 2007, Curr. Opin. Mol. Ther. 9(2): 110-18), and therefore impact relative biological potency of the compound as a synthetic trigger of RNAi. Utility in RNAi applications is </p><p id="p0075" num="0075">demonstrated in Example 6. </p><p id="p0076" num="0076"> [0051] Oligonucleotides antisense in orientation to miRNAs will bind the miRNA and functionally remove that species from participation in the microRNA-Induced Silencing Complex (miRISC) (Krutzfeldt et al, 2007, Nucleic Acids Res. 35(9): 2885-92). Such AMOs are thought to function by a steric binding mechanism, and compounds with high stability and high affinity generally show improved functional performance compared with low affinity compounds (Lennox and Behlke, 2010, Pharm. Res. 27(9): 1788-99). The ASOs of the present invention can function as anti-miRNA oligonucleotides. This function is demonstrated in Examples 3, 4, 10 and 11. </p><p id="p0077" num="0077"> [0052] In the modifications of the present invention, a modifying group is inserted terminally or between adjacent bases, thereby generating an ASO with reduced toxicity and improved binding affinity and nuclease stability. The bases can be DNA, 2'OMe RNA, LNA, or other modified bases. However, modified bases do not need to be employed. Low toxicity for one of the modifying groups of the present invention, the napthyl-azo modifier, is demonstrated in Example 7. Because the modifications are inserted between the bases, they can be added as a phosphoramidite compound using standard phosphoramidite synthesis chemistry. The modifying group can also be placed at the 5 '-end, at the 3 '-end, or at both the 5'-end and 3'-end of the ASO. Modification at the 3 '-end can be introduced as a modified CPG support or made using a phosphoramidite with a universal support. It is possible to have a non-base modification at both terminal ends, but in many embodiments containing more than one non-base modifier it may be preferential to place one non-base modifier at the terminal end and the second non-base modifier internally, such as between the terminal and penultimate bases. This simplifies the manufacture of oligonucleotides by allowing for further attachment and the base end. 
<!-- EPO <DP n="18"/>-->
 [0053] In yet another application where ASOs are employed to alter or modify gene expression, the ASOs are designed to be complementary to a pre-mRNA species at sites at or near an intron/exon splice junction. Binding of the ASO at or near splice sites can alter processing at this intron/exon junction by the nuclear splicing machinery thereby changing splice patterns present in the final mature mRNA (i.e., can be used to alter the exons that are included or excluded in the final processed mRNA). Following mRNA maturation, the altered mRNA will direct synthesis of an altered protein species as a result of this ASO treatment. Methods to design splice-blocking oligonucleotides (SBOs) are well known to those with skill in the art (see, e.g., Aartsma-Rus et ah, 2009, Mol. Ther. 17(3): 548-53; and Mitrpant et ah, 2009, Mol. Ther. 17(8): 1418-26). Because SBOs are intended to alter the form of an mRNA but not destroy that mRNA, oligonucleotides of this class are made using chemistries which are compatible with steric blocking antisense mechanism of action and not with chemistries or designs that trigger RNA degradation. One example of the use of SBOs induces exon-skipping in the dystrophin gene in individuals having a mutant form of this gene which causes Duchenne muscular dystrophy (see Muntoni and Wood, 201 1, Nat. Rev. Drug Discov. 10(8): 621-37; and Goemans et ah, 2011, N. Engl. J. Med. 364(16): 1513-22). Synthetic oligonucleotides using the design and chemistries of the present invention can be employed as SBOs. This class of ASO has also been called "splice switching </p><p id="p0078" num="0078">oligonucleotides", or SSOs. </p><p id="p0079" num="0079"> [0054] In one embodiment, a synthetic oligonucleotide comprises a non-nucleotide modifier of the present invention positioned at or near one or both ends of the sequence. In another embodiment, a synthetic oligonucleotide comprises a non-nucleotide modifier of the present invention positioned at the 3' or 5 '-end. In a further embodiment, the oligonucleotide contains a first modification at a terminal end and a second modification between the terminal base and the penultimate base of the other end. In yet a further embodiment, the </p><p id="p0080" num="0080">oligonucleotide contains a modification between the terminal base and the penultimate base at the 5'-end, and a second modification at the 3 '-end. The relative increase of binding affinity contributed by the non-base modifier may vary with sequence context (Example 8) which can influence which of the various design options taught herein is most potent. </p><p id="p0081" num="0081">[0055] In one embodiment of the invention, the modification is a napthyl-azo compound. The oligonucleotide is made using modified bases such that the complex of the SBO with the target pre-mRNA does not form a substrate for RNase H, using chemically-modified residues 
<!-- EPO <DP n="19"/>-->
 that are well known to those with skill in the art, including, for example, 2'-0-methyl RNA, 2'-methyoxyethyl RNA (2'-MOE), 2'-F RNA, LNA, and the like. SBOs made using the non- nucleotide modifiers of the present invention have increased binding affinity compared to the cognate unmodified species. This can permit use of shorter sequences, which can show improved uptake into cells and improved biological activity. </p><p id="p0082" num="0082"> [0056] In another embodiment of the invention, the modification has the structure: </p><p id="p0083" num="0083"><img id="imgf000019_0001" he="81" wi="54" file="imgf000019_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 ormula 5 </p><p id="p0084" num="0084">In a further embodiment of the invention, the modification has the structure: 
<!-- EPO <DP n="20"/>-->
</p><p id="p0085" num="0085"><img id="imgf000020_0001" he="84" wi="79" file="imgf000020_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0086" num="0086">[0057] The antisense oligonucleotides of the invention may be conjugated to other ligands, which may aid in the delivery of the antisense oligonucleotide to a cell or organism. In one embodiment of the invention, the ligand is 5' cholesterol monoethyleneglycol (/5CholMEG/): </p><p id="p0087" num="0087"><img id="imgf000020_0002" he="55" wi="108" file="imgf000020_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0088" num="0088">In another embodiment of the invention, the ligand is 5' cholesterol triethyleneglycol (/5Chol- 
<!-- EPO <DP n="21"/>-->
</p><p id="p0089" num="0089"><img id="imgf000021_0001" he="52" wi="145" file="imgf000021_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0090" num="0090">In a further embodiment of the invention, the ligand is 3' cholesterol monoethyleneglycol (/3CholMEG/): </p><p id="p0091" num="0091"><img id="imgf000021_0002" he="38" wi="127" file="imgf000021_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0092" num="0092">In another embodiment of the invention, the ligand is 3' cholesterol triethyleneglycol (/3CholTEG/): </p><p id="p0093" num="0093"><img id="imgf000021_0003" he="32" wi="157" file="imgf000021_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0094" num="0094">The ligand may be conjugated to the antisense oligonucleotide with or without an additional S18 (hexaethyleneglycol) spacer. In a preferred embodiment, the antisense oligonucleotide is an AMO. In another preferred embodiment, the non-nucleotide modification is a FQ napthyl- azo compound (also referred to as iFQ or ZEN in this disclosure). </p><p id="p0095" num="0095"> [0058] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope. 
<!-- EPO <DP n="22"/>-->
 EXAMPLE 1 </p><p id="p0096" num="0096"> [0059] This example demonstrates the improved thermal stability of internal napthyl-azo- containing oligomers compared to other compounds. </p><p id="p0097" num="0097"> [0060] Oligonucleotide synthesis and preparation. DNA oligonucleotides were synthesized using solid phase phosphoramidite chemistry, deprotected and desalted on NAP- 5 columns (Amersham Pharmacia Biotech, Piscataway, NJ) according to routine techniques (Caruthers et ah, 1992, Methods Enzymoh 211 : 3-20). The oligomers were purified using reversed-phase high performance liquid chromatography (RP-HPLC). The purity of each oligomer was determined by capillary electrophoresis (CE) carried out on a Beckman P/ACE MDQ system (Beckman Coulter, Inc., Fullerton, CA). All single-strand oligomers were at least 90% pure. Electrospray-ionization liquid chromatography mass spectrometry (ESI- LCMS) of the oligonucleotides was conducted using an Oligo HTCS system ( ovatia, Princeton, NJ), which consisted of ThermoFinnigan TSQ7000, Xcalibur data system, ProMass data processing software, and Paradigm MS4™ HPLC (Michrom BioResources, Auburn, CA). Protocols recommended by the manufacturers were followed. Experimental molar masses for all single-strand oligomers were within 1.5 g/mol of expected molar mass. These results confirm identity of the oligomers. </p><p id="p0098" num="0098"> [0061] Preparation of DNA samples. Melting experiments were carried out in buffer containing 3.87 mM NaH<sub>2</sub>P0<sub>4</sub>, 6.13 mM Na<sub>2</sub>HP0<sub>4</sub>, 1 mM Na<sub>2</sub>EDTA, and 1 M NaCl. 1 M NaOH was used to titrate each solution to pH 7.0. Total sodium concentrations were estimated to be 1.02 M. The DNA samples were thoroughly dialyzed against melting buffer in a 28-well Microdialysis System (Life Technologies, Carlsbad, CA) following the manufacturer's recommended protocol. Concentrations of DNA oligomers were estimated from the samples' UV absorbance at 260 nm in a spectrophotometer (Beckman Coulter, Inc., Fullerton, CA), using extinction coefficients for each oligonucleotide that were estimated using the nearest neighbor model for calculating extinction coefficients (see Warshaw et ah, 1966, J. Moh Biol. 20(1): 29-38). </p><p id="p0099" num="0099"> [0062] Internal modifications studied. The FQ napthyl-azo compound (Formula 3, Integrated DNA Technologies, Inc., sometimes referred to as "iFQ" or "ZEN" in this disclosure), was introduced into oligonucleotides using phosphoramidite reagents at the time of synthesis. 
<!-- EPO <DP n="23"/>-->
</p><p id="p0100" num="0100"><img id="imgf000023_0001" he="57" wi="78" file="imgf000023_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 Formula 3 </p><p id="p0101" num="0101">In the first series of duplexes, the iFQ group was placed as an insertion between bases in the duplex so that a 10-base top strand annealed to a 10-base bottom strand and the iFQ group was not aligned to a base. Additionally, 10-mer oligonucleotides with C3 spacer insertions were also synthesized and studied. The C3 spacer represents the control wherein a linear insertion of a phosphate group plus propanediol is placed between bases, which is similar to the iFQ insertions without having the napthyl-azo ring structures present. Extinction coefficients at 260 nm of iFQ were estimated to be 13340; the C3 spacer does not contribute to UV absorbance. </p><p id="p0102" num="0102"> [0063] In a second series of duplexes, the iFQ group was placed as a substitution for a base in the duplex so that a 9-base top strand annealed to a 10-base bottom strand and the iFQ group was aligned to a base. Additionally, 10-mer oligonucleotides with C3 spacer substitutions were also synthesized and studied. </p><p id="p0103" num="0103"> [0064] Measurement of melting curves. Oligomer concentrations were measured at least twice for each sample. If the estimated concentrations for any sample differed more 
<!-- EPO <DP n="24"/>-->
 than 4%, the results were discarded and new absorbance measurements were performed. To prepare oligonucleotide duplexes, complementary DNA oligomers were mixed in 1 : 1 molar ratio, heated to 367 K (i.e., 94°C) and slowly cooled to an ambient temperature. Each solution of duplex DNA was diluted with melting buffer to a total DNA concentration (CT) of 2 μΜ. </p><p id="p0104" num="0104"> [0065] Melting experiments were conducted on a single beam Beckman DU 650 spectrophotometer (Beckman-Coulter) with a Micro T<sub>m</sub> Analysis accessory, a Beckman High Performance Peltier Controller (to regulate the temperature), and 1 cm path-length cuvettes. Melt data were recorded using a PC interfaced to the spectrophotometer. UV-absorbance values at 268 nm wavelength were measured at 0.1 degree increments in the temperature range from 383 to 368 K (i.e., 10 - 95°C). Both heating (i.e., "denaturation") and cooling (i.e., "renaturation") transition curves were recorded in each sample at a controlled rate of temperature change (24.9 ± 0.3°C per hour). Sample temperatures were collected from the internal probe located inside the Peltier holder, and recorded with each sample's UV- absorbance data. Melting profiles were also recorded for samples of buffer alone (no oligonucleotide), and these "blank" profiles were digitally subtracted from melting curves of the DNA samples. To minimize systematic errors, at least two melting curves were collected for each sample in different cuvettes and in different positions within the Peltier holder. </p><p id="p0105" num="0105">[0066] Determination of melting temperatures. To determine each sample's melting temperature, the melting profiles were analyzed using methods that have been previously described (see Doktycz et al, 1992, Biopolymers 32(7): 849-64; Owczarzy et ah, 1997 <sup>'</sup>, Biopolymers 44(3): 217-39; and Owczarzy, 2005, Biophys. Chem. 117(3): 207-15.). Briefly, the experimental data for each sample was smoothed, using a digital filter, to obtain a plot of the sample's UV-absorbance as a function of its temperature. The fraction of single-stranded oligonucleotide molecules, Θ, was then calculated from that plot. The "melting temperature" or "T<sub>m</sub>" of a sample was defined as the temperature where Θ = 0.5. Table 1 lists the melting temperatures of the oligonucleotides tested. </p><p id="p0106" num="0106">Table 1 : Melting temperatures for nucleic acids containing a single internal modifying group as an insertion 
<img id="imgf000024_0001" he="12" wi="127" file="imgf000024_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/>
 
<!-- EPO <DP n="25"/>-->
 1 5' ATCGTTGCTA </p><p id="p0107" num="0107"> 43.9 - 2 3 ' TAGCAACGAT </p><p id="p0108" num="0108"> 3 5' ATC / GTTGCTA iFQ "/" </p><p id="p0109" num="0109"> 48.0 4.1 </p><p id="p0110" num="0110"> 2 3' TAG CAACGAT </p><p id="p0111" num="0111"> 4 5' ATCG/ TTGCTA iFQ "/" </p><p id="p0112" num="0112"> 48.6 4.7 +3.7 </p><p id="p0113" num="0113"> 2 3' TAGC AACGAT </p><p id="p0114" num="0114"> 5 5' ATCGT / TGCTA iFQ "/" </p><p id="p0115" num="0115"> 46.3 2.4 </p><p id="p0116" num="0116"> 2 3' TAGCA AC GAT </p><p id="p0117" num="0117"> 6 5' A/ TCGTTGCTA iFQ "/" </p><p id="p0118" num="0118"> 51.75 7.9 </p><p id="p0119" num="0119"> 2 3' T AGC AACGAT </p><p id="p0120" num="0120"> +7.2 </p><p id="p0121" num="0121"> 7 5' ATCGTTGCT /A iFQ "/" </p><p id="p0122" num="0122"> 50.25 6.4 </p><p id="p0123" num="0123"> 2 3' TAGCAACGA T </p><p id="p0124" num="0124"> 8 5' ATC / GTTGCTA iSpC3 "/" </p><p id="p0125" num="0125"> 36.3 -7.6 </p><p id="p0126" num="0126"> 2 3' TAG CAACGAT </p><p id="p0127" num="0127"> 9 5' ATCG/ TTGCTA iSpC3 "/" </p><p id="p0128" num="0128"> 36.6 -7.3 -8.7 </p><p id="p0129" num="0129"> 2 3' TAGC AACGAT </p><p id="p0130" num="0130"> 10 5' ATCGT / TGCTA iSpC3 "/" </p><p id="p0131" num="0131"> 32.6 -11.3 </p><p id="p0132" num="0132"> 2 3' TAGCA AC GAT </p><p id="p0133" num="0133"> "/" signifies the site of insertion of a modifying group between bases as indicated. iFQ = internal FQ azo quencher (ZEN) </p><p id="p0134" num="0134"> iSpC3 = internal C3 spacer </p><p id="p0135" num="0135">[0067] When the iFQ (ZEN) modifier was inserted centrally within a 10-mer oligonucleotide (between bases 3/4, 4/5, or 5/6), T<sub>m</sub> was increased by an average of 3.7°C. When placed between terminal residues (between bases 1/2 or 9/10), T<sub>m</sub> was increased by an average of 7.2°C. In contrast, insertion of a small propanediol group (C3 spacer) had a significant negative impact on the T<sub>m</sub> of the duplex (average AT<sub>m</sub> of -8.7°C). </p><p id="p0136" num="0136">[0068] A subset of these sequences were studied using the internal modifications as base substitutions, such that now a 9-base top strand annealed to a 10-base bottom strand with the modification replacing a base and being aligned with a base on the opposing strand. Results are shown in Table 2. In this case, it is evident that the base substitution was significantly destabilizing whereas the insertions (Table 1) were stabilizing (ZEN) or were at least less destabilizing (C3). </p><p id="p0137" num="0137">Table 2: Melting temperatures for nucleic acids containing 
<!-- EPO <DP n="26"/>-->
 a single internal modifying group comparing substitution vs. insertion </p><p id="p0138" num="0138"><img id="imgf000026_0001" he="170" wi="139" file="imgf000026_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0139" num="0139">[0069] For this series of internal modifications, the average AT<sub>m</sub> for iFQ (ZEN) insertion was +3.7°C while the average AT<sub>m</sub> for iFQ (ZEN) substitution was -6°C. The average AT<sub>m</sub> for iC3 spacer insertion was -8.7°C while the average AT<sub>m</sub> for iC3 spacer substitution was more than -20°C (accurate measurements were not possible as the T<sub>m</sub> was below room temperature). Therefore insertion placement is preferred to substitution placement. 
<!-- EPO <DP n="27"/>-->
 [0070] The napthyl-azo modifier was introduced into the same 10-mer oligomer sequence at 2 or 3 sites, either adjacent to or separated by several bases. Duplexes were formed and T<sub>m</sub> values were measured as before. Results are shown in Table 3. Some of the singly modified duplexes from Table 1 are also included in Table 3 to improve clarity of comparisons between modification patterns. 
<!-- EPO <DP n="28"/>-->
</p><p id="p0140" num="0140">Table 3: Melting temperatures for nucleic acids containing </p><p id="p0141" num="0141"> multiple internal modifying groups as insertions </p><p id="p0142" num="0142"><img id="imgf000028_0001" he="158" wi="128" file="imgf000028_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0143" num="0143"> gnifies the site of insertion of a modifying group between bases as indicated. </p><p id="p0144" num="0144">[0071] Insertion of two adjacent napthyl-azo modifiers was destabilizing and T<sub>m</sub> was found to change by -4 to -8.9°C depending on sequence context. Placing two napthyl-azo modifying groups in the same sequence separated by 3 bases was slightly stabilizing (T<sub>m</sub> +2.9°C); however, this was less stabilizing than use of a single modifier alone (T<sub>m</sub> +4.7°C). Use of 3 modifier groups separated by 2 bases between groups was destabilizing. However, 
<!-- EPO <DP n="29"/>-->
 when two napthyl-azo modifier groups were placed at the ends (between both bases 1/2 and 9/10), T<sub>m</sub> was increased by 1 1°C. Thus, an additive effect can be obtained by placing multiple insertions of the modifying group into a sequence so long as a sufficient number of bases separate the groups. End effects are particularly potent. </p><p id="p0145" num="0145"> [0072] Therefore, internal incorporation of the napthyl-azo group within a DNA duplex stabilizes the duplex when placed as an insertion between bases. Certain anthraquinone groups can stabilize a duplex when placed on the ends (Patra et al., 2009, J. Am. Chem. Soc. 131(35): 12671-81); however, this effect has not been described for internal placement. Therefore, the use of napthyl-azo-class compounds would be preferred as an internal modifying group to increase duplex stability. </p><p id="p0146" num="0146">EXAMPLE 2 </p><p id="p0147" num="0147"> [0073] This example demonstrates the improved nuclease stability of internal napthyl- azo-containing oligomers compared to other compounds. </p><p id="p0148" num="0148"> [0074] Oligonucleotide synthesis and purification. DNA oligonucleotides were synthesized using solid phase phosphoramidite chemistry, deprotected and desalted on NAP- 5 columns (Amersham Pharmacia Biotech, Piscataway, NJ) according to routine techniques (Caruthers et al., 1992). The oligomers were purified using reversed-phase high performance liquid chromatography (RP-HPLC). The purity of each oligomer was determined by capillary electrophoresis (CE) carried out on a Beckman P/ACE MDQ system (Beckman Coulter, Inc., Fullerton, CA). All single-strand oligomers were at least 90% pure. </p><p id="p0149" num="0149">Electrospray-ionization liquid chromatography mass spectrometry (ESI-LCMS) of the oligonucleotides was conducted using an Oligo HTCS system (Novatia, Princeton, NJ), which consisted of ThermoFinnigan TSQ7000, Xcalibur data system, ProMass data processing software, and Paradigm MS4™ HPLC (Michrom BioResources, Auburn, CA). Protocols recommended by the manufacturers were followed. Experimental molar masses for all single-strand oligomers were within 1.5 g/mol of expected molar mass. These results confirm identity of the oligomers. The synthesized oligonucleotides are listed in Table 4. </p><p id="p0150" num="0150">Table 4: Synthetic oligomers employed in Example 2 </p><p id="p0151" num="0151">SEQ </p><p id="p0152" num="0152"> Name Sequence </p><p id="p0153" num="0153"> ID NO: 
<!-- EPO <DP n="30"/>-->
 1 DNA 5' ATCGTTGCTA 3' </p><p id="p0154" num="0154">26 5' iFQ 5' A (iFQ) CGTTGCTA 3' </p><p id="p0155" num="0155">27 3' iFQ 5' ATCGTTGC (iFQ) A 3' </p><p id="p0156" num="0156">28 5'+3' iFQ 5' A (iFQ) CGTTGC (iFQ) A 3' </p><p id="p0157" num="0157">29 5' iC3 5' A (iSpC3) CGTTGCTA 3' </p><p id="p0158" num="0158">30 3' iC3 5' ATCGTTGCT (iSpC3) A 3' </p><p id="p0159" num="0159">31 5'+3' iC3 5' A(iSpC3) TCGTTGCT(iSpC3) A 3' </p><p id="p0160" num="0160">[0075] Radiolabeling of oligomers. Single-stranded oligomers were radiolabeled at the 5'-end using polynucleotide kinase. Briefly, 5 pmoles of each oligonucleotide were incubated with 10 units of OptiKinase (USB, Cleveland, OH) and 10 pmoles of alpha <sup>32</sup>P γ-ΑΤΡ (3000 Ci/mmol) (Perkin Elmer, Waltham, MA) for 30 minutes at 37°C, followed by 65°C for 10 minutes. Excess radionucleotide was removed by gel filtration using two sequential passes through MicroSpin G-25 columns (GE Healthcare, Buckinghamshire, UK). Isotope incorporation was measured in a Perkin Elmer TriCarb 2800 TR scintillation counter (Perkin Elmer, Waltham, MA). </p><p id="p0161" num="0161"> [0076] Serum degradation of oligomers. As labeling efficiencies varied (lower specific activity was obtained for the oligomers with a modification near the 5 '-end), equivalent numbers of dpms of radiolabeled oligomers were mixed with unlabeled oligomers to a final concentration of 8 μΜ in the presence of 50% fetal bovine serum (not heat inactivated; </p><p id="p0162" num="0162">Invitrogen, Carlsbad, CA). Samples were incubated at 37°C for 0, 30, 60, or 240 minutes; aliquots were removed at the indicated time points, an equal volume of 90% formamide was added, and samples flash frozen on dry ice. Degradation products were separated by PAGE using a 20% polyacrylamide, 7 M Urea denaturing gel and visualized on a Cyclone phosphorimager (Perkin Elmer, Waltham, MA). Results are shown in Figure 1. </p><p id="p0163" num="0163">[0077] The unmodified DNA oligomer was rapidly degraded and no intact full-length material was present after 30 minutes incubation. The sample was fully degraded by 4 hours. A similar pattern of degradation was seen for the oligomer having a single internal C3 spacer positioned near the 5 '-end. In contrast, only incomplete degradation was observed for the 
<!-- EPO <DP n="31"/>-->
 oligomer bearing a single internal FQ modifier near the 5'-end. The degradation pattern observed is most consistent with processive 3'-exonuclease cleavage that stopped before the oligomer was fully degraded. This suggests the possibility that the iFQ modifier protects neighboring DNA residues from exonuclease degradation, providing a small zone of protection around the 5 '-end. </p><p id="p0164" num="0164"> [0078] The oligomer having a single internal C3 spacer near the 3 '-end shows prompt removal of what appears to be a single base and then was slowly degraded. Slightly greater protection was seen in the oligomer having an internal C3 spacer placed near both ends. In contrast, no evidence was seen for single base cleavage at the 3 '-end of the oligomer having a single internal FQ modifier near the 3 '-end, and no evidence for degradation was observed after 4 hours incubation in 50% serum for the oligomer having an internal FQ modifier placed near both ends. </p><p id="p0165" num="0165"> [0079] Therefore, the FQ modifier will block exonuclease attack from the enzymes present in fetal bovine serum, and can confer relative nuclease resistance to neighboring unmodified bases, creating a protected "zone" in its vicinity. </p><p id="p0166" num="0166">EXAMPLE 3 </p><p id="p0167" num="0167"> [0080] This example demonstrates improved functional activity of internal napthyl-azo- containing ASOs at reducing microRNA activity compared to other compounds. </p><p id="p0168" num="0168">[0081] Oligonucleotide synthesis and purification. DNA, 2'OMe RNA, and LNA containing oligonucleotides were synthesized using solid phase phosphoramidite chemistry, deprotected and desalted on NAP-5 columns (Amersham Pharmacia Biotech, Piscataway, NJ) according to routine techniques (Caruthers et ah, 1992). The oligomers were purified using reversed-phase high performance liquid chromatography (RP-HPLC). The purity of each oligomer was determined by capillary electrophoresis (CE) carried out on a Beckman P/ACE MDQ system (Beckman Coulter, Inc., Fullerton, CA). All single-strand oligomers were at least 85% pure. Electrospray-ionization liquid chromatography mass spectrometry (ESI- LCMS) of the oligonucleotides was conducted using an Oligo HTCS system (Novatia, Princeton, NJ), which consisted of ThermoFinnigan TSQ7000, Xcalibur data system, ProMass data processing software, and Paradigm MS4™ HPLC (Michrom BioResources, Auburn, CA). Protocols recommended by the manufacturers were followed. Experimental molar masses for all single-strand oligomers were within 1.5 g/mol of expected molar mass. 
<!-- EPO <DP n="32"/>-->
 These results confirm identity of the oligomers. Table 5 lists the synthetic oligomers used in this Example. </p><p id="p0169" num="0169">Table 5: Synthetic oligomers employed in Example 3 (miR-21 AMOs) </p><p id="p0170" num="0170"><img id="imgf000032_0001" he="133" wi="150" file="imgf000032_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0171" num="0171"> Uppercase = 2'OMe R A </p><p id="p0172" num="0172"> Lowercase = DNA </p><p id="p0173" num="0173"> Uppercase with underscore = LNA </p><p id="p0174" num="0174"> " * " = phosphorothioate linkage </p><p id="p0175" num="0175"> "z" = napthyl-azo modifier (iFQ) </p><p id="p0176" num="0176">[0082] Plasmid preparation. The psiCHECK™-2 vector (Promega, Madison, WI) was restriction enzyme digested sequentially with Xhol and Notl (New England Biolabs, Ipswitch, MA) and purified with a Qiaquick PCR purification column (Qiagen, Valencia, CA). A perfect complement hsa-miR-21 binding site was created by annealing two synthetic 
<!-- EPO <DP n="33"/>-->
 duplexed oligonucleotides (Integrated DNA Technologies, Coralville, IA) and was cloned into the Xhol/Notl sites in the 3'UTR οΐ Renilla luciferase. This miR-21 reporter construct was sequence verified on a 3130 Genetic Analyzer (AB, Foster City, CA). Plasmids were purified using a Plasmid Midiprep Kit (Bio-Rad, Hercules, CA) and treated twice for endotoxin removal with the MiraCLEAN Endotoxin Removal Kit (Minis Corporation, Madison, WI). Plasmids were filtered through a 0.2 μ filter and quantified by measurement of the absorbance at 260 nm using UV spectrophotometry. This reporter plasmid having a perfect match miRNA binding site is denoted as psiCHECK™-2-miR21. </p><p id="p0177" num="0177">[0083] Cell culture, transfections, and luciferase assays. HeLa cells were plated in a 100 mm dish in DMEM containing 10% FBS to achieve 90% confluency the next day. The following morning, 5 μg of the psiCHECK™-2-miR21 plasmid was transfected with </p><p id="p0178" num="0178">Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA). After 6 hours, cells were washed with IX PBS, trypsinized, counted, and replated in DMEM with 10% FBS in 48-well plates to achieve -70% confluency the next day. The following morning, the miR-21 AMOs were transfected at various concentrations in triplicate with 1 μΐ TriFECTin<sup>®</sup> (Integrated DNA Technologies) per well in DMEM without serum. After 6 hours, the transfection media was removed and replenished with DMEM containing 10% FBS. The following morning, (48 hours after plasmid transfection, 24 hours after miRNA AMO transfection) the cells were analyzed for luciferase luminescence using the Dual-Luciferase<sup>®</sup> Reporter Assay System (Promega, Madison, WI) per the manufacturer's instructions. Renilla luciferase was measured as a fold increase in expression compared to the TriFECTin<sup>®</sup> reagent-only negative controls. Values for Renilla luciferase luminescence were normalized to levels concurrently measured for firefly luciferase, which is present as a separate expression unit on the same plasmids as an internal control (RLuc/FLuc ratio). </p><p id="p0179" num="0179"> [0084] Results. The RLuc/FLuc ratios obtained from transfections done with the various AMOs are shown in Figure 2. In the untreated state, HeLa cells contain large amounts of miRNA 21 that suppress expression of the RLuc reporter. Any treatment that decreases miR- 21 levels leads to an increase in RLuc expression and thus increases the relative RLuc/FLuc ratio (with FLuc serving as an internal normalization control for transfection efficiency). </p><p id="p0180" num="0180">[0085] The unmodified 2'OMe RNA AMO showed essentially no inhibition of miR-21 activity, probably due to rapid nuclease degradation of this unprotected oligomer during transfection or in the intracellular environment. The addition of 3 PS linkages on each end of 
<!-- EPO <DP n="34"/>-->
 the AMO blocks exonuclease attack and the "2'OMe-PSends" AMO showed good potency for functional knockdown of miR-21. When this AMO is changed to be fully PS modified ("2'OMe-PS"), potency drops, which is probably due to having lower binding affinity (lower T<sub>m</sub>) that accompanies extensive PS modification. Each substitution of a PS bond for a standard phosphodiester bond reduces T<sub>m</sub>, and there are 21 PS bonds in this oligomer compared with only 6 PS bonds in the "2'OMe PSends" version. </p><p id="p0181" num="0181">[0086] A desirable modification chemistry or modification pattern is one that both increases nuclease stability and increases T<sub>m</sub>. The internal napthyl-azo modifier meets these criteria. The 2'OMe oligomer having an internal napthyl-azo modifier placed between the terminal and adjacent bases on each end (2'OMe 5'+3'iFQ) showed markedly improved anti- miR21 activity and was more potent than any of the PS modified 2'OMe AMOs tested. </p><p id="p0182" num="0182">Adding PS modification to this design (2'OMePS 5'+3'iFQ) reduced potency, likely due to the lower binding affinity caused by the addition of 19 PS linkages. This compound was nevertheless still significantly more potent than the 2'OMe-PS version without the 2 iFQ modifications. </p><p id="p0183" num="0183"> [0087] Protecting only one end of the anti-miR-21 AMO with an internal napthyl-azo modifier showed improved potency when compared with the unmodified 2'OMe AMO; however, the performance was much reduced compared with the dual-modified version. Interestingly, modification at the 5 '-terminal linkage had more effect than modification at the 3 '-terminal linkage, the exact opposite of the results anticipated from the relative serum stability profiles demonstrated in Example 2. This result is explained by measured effects of T<sub>m</sub> (see Table 6). </p><p id="p0184" num="0184"> [0088] Addition of a third iFQ modification into the end-blocked version (2'OMe 5'+I+3'iFQ) showed reduced potency compared with the original end-blocked version (2'OMe 5'+3'iFQ), which is likely due to a reduction of T<sub>m</sub> seen with placing this many iFQ modifying groups in a single, short 22-mer sequence. </p><p id="p0185" num="0185"> [0089] The "DNA/LNA-PS" AMO is a design employed by Exiqon as its preferred anti- miRNA agent and is widely accepted as the "gold standard" for miRNA knockdown studies performed today. The DNA/LNA compound showed the same potency as the dual-modified "2'OMe 5'+3'iFQ" AMO. The "2'OMe/LNA-PS" AMO showed highest potency within the set studied. The LNA modification confers nuclease resistance and gives very large increases in T<sub>m</sub>, resulting in AMOs with higher potency but also having lower specificity than AMOs 
<!-- EPO <DP n="35"/>-->
 without LNA bases with lower binding affinity. The relative specificity of the different AMOs is presented in Example 4 below. Of note, the LNA-PS modified AMOs show some toxicity and cell cultures transfected with the highest doses (50 nM) had dysmorphic, unhealthy appearing cells at the time of harvest. The "2'OMe 5'+3'iFQ" AMO did not show any visual evidence for toxicity at any of the doses tested. In subsequent experimentation, toxicity effects were evaluated at high doses by measuring cell viability, cytotoxicity, and induction of apoptosis (see Example 7). The "2'OMe 5'+3'iFQ" chemistry showed no cellular toxicity, compared to the substantial cellular toxicity that occurred upon transfection of single-stranded oligonucleotides containing LNA bases, extensive PS modification (all 21 linkages), or both LNA and PS modifications (the "gold standard" AMO). Thus, the "2'OMe 5'+3'iFQ" may be a new class of AMO that achieves high potency yet maintains low toxicity. </p><p id="p0186" num="0186"> [0090] The melting temperatures, T<sub>m</sub>, of the AMOs described above were measured using the same methods described in Example 1. Synthetic AMO oligonucleotides were annealed to a synthetic RNA complement (mature miR21 sequence). Measurements were done at 2 μΜ duplex concentration in 150 mM NaCl to approximate intracellular ion concentration. </p><p id="p0187" num="0187">Table 6: T<sub>m</sub> of synthetic miR-21 AMOs in 150 mM NaCl </p><p id="p0188" num="0188"><img id="imgf000035_0001" he="93" wi="155" file="imgf000035_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/><!-- EPO <DP n="36"/>--></p><p id="p0189" num="0189"><img id="imgf000036_0001" he="52" wi="156" file="imgf000036_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0190" num="0190"> Uppercase = 2'OMe RNA </p><p id="p0191" num="0191"> Lowercase = DNA </p><p id="p0192" num="0192"> Uppercase with underscore = LNA </p><p id="p0193" num="0193"> " * " = phosphorothioate linkage </p><p id="p0194" num="0194"> "z" = insertion of napthyl-azo modifier (iFQ) </p><p id="p0195" num="0195">[0091] The 22-mer 2'OMe miR21 AMO showed a T<sub>m</sub> of 72.1°C when hybridized to an RNA perfect complement in 150 mM NaCl. Substitution of 6 PS bonds for native PO linkages lowered T<sub>m</sub> by 1.2°C ("2'OMe PSends") and complete PS modified lowered T<sub>m</sub> by 5.0°C ("2'OMe PS"), a change of -0.20 to -0.25°C per modified internucleotide linkage. In contrast, insertion of an iFQ group at the 3'-terminal linkage ("2'OMe 3'iFQ") resulted in a T<sub>m</sub> increase of +0.3°C and at the 5'-terminal linkage ("2'OMe 5'iFQ") resulted in a T<sub>m</sub> increase of +2.2°C. Combining these two designs, addition of two iFQ modifications (one at each terminal linkage, "2'OMe 5'+3'iFQ") increased T<sub>m</sub> to 75.4°C, which is a change of +3.3°C compared with the unmodified sequence or +4.5°C relative to the PS-end blocked sequence (which is the most relevant comparison). This dual-end-modification pattern results in good nuclease resistance (Figure 1) and when employed in a 2'OMe AMO shows increased T<sub>m</sub> (Table 6) and is a very potent anti-miR21 agent (Figure 2). Interestingly, addition of a third iFQ group centrally placed ("2'OMe 5'+I+3' iFQ") resulted in a T<sub>m</sub> decrease of 0.8°C relative to the unmodified compound, or a decrease of 4.1°C relative to the two-end insertion version ("2'OMe 5'+3'iFQ"). Thus while inserting the iFQ modifier between terminal bases increases T<sub>m</sub>, adding a third modification in the center of the sequence leads to a decrease in T<sub>m</sub>, even though these modifications are fully 10 bases distant from each other. This loss of T<sub>m</sub> results in a loss of functional potency (Figure 2). Therefore the dual-modified end-insertion pattern is preferred. 
<!-- EPO <DP n="37"/>-->
 [0092] As a general rule, the relative potency of the various miR21 AMOs correlated with increased binding affinity (T<sub>m</sub>). All variations in potency observed between compounds could be explained by relative contributions of improvements in binding affinity and nuclease stability between the different modification patterns studied. The AMO having 2'OMe bases with an iFQ modification placed near each end ("2'OMe 5'+3'iFQ") provided an excellent balance of nuclease stability with increased T<sub>m</sub> and the only AMO showing higher potency was the "2'OMe/LNA-PS" compound. The "2'OMe/LNA-PS" compound, however, showed reduced specificity due to its extreme elevation in binding affinity (see Example 4) and increased cellular toxicity (see Example 7). Therefore, the novel "2'OMe 5'+3'iFQ" design of the present invention is superior. 
<!-- EPO <DP n="38"/>-->
</p><p id="p0196" num="0196">EXAMPLE 4 </p><p id="p0197" num="0197"> [0093] This example demonstrates improved specificity of internal napthyl-azo- containing oligomers when reducing microR A activity compared to other compounds containing modifications that increase binding affinity. </p><p id="p0198" num="0198"> [0094] Three of the more potent AMO designs from the functional study performed in Example 3 were examined in greater detail to assess their relative ability to discriminate mismatches between the synthetic anti-miRNA oligonucleotide and their target. In general, high affinity oligonucleotides show high potency but usually show reduced specificity as the high affinity permits hybridization even in the presence of one or more mismatches in complementarity. The designs "2'OMe 5'+3'iFQ", "DNA/LNA-PS", and "2'OMe/LNA-PS" were synthesized as variants having 1, 2, or 3 mismatches to the miR-21 target sequence. Sequences are shown in Table 7. Studies were performed as described in Example 3. </p><p id="p0199" num="0199">Table 7 </p><p id="p0200" num="0200"><img id="imgf000038_0001" he="124" wi="155" file="imgf000038_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/><!-- EPO <DP n="39"/>-->
 DNA/ L A PS </p><p id="p0201" num="0201"> 47 t*C*a*a* G*a*t*C*a*g*T*c*t* C*a*t*A*a*g* G*t*a </p><p id="p0202" num="0202"> 3MUT </p><p id="p0203" num="0203">41 2'OMe/ LNA PS U*C*A*A*C*A*U*C*A*G*T*C*U*G*A*U*A*A*G*C*U*A </p><p id="p0204" num="0204">2'OMe/ LNA PS </p><p id="p0205" num="0205"> 48 U*C*A*A*C*A*U*C*A*G*T*C*U* C*A*U*A*A*G*C*U*A </p><p id="p0206" num="0206"> 1MUT </p><p id="p0207" num="0207">2'OMe/ LNA PS </p><p id="p0208" num="0208"> 49 U*C*A*A* G*A*U*C*A*G*T*C*U* C*A*U*A*A*G*C*U*A </p><p id="p0209" num="0209"> 2MUT </p><p id="p0210" num="0210">2'OMe/ LNA PS </p><p id="p0211" num="0211"> 50 U*C*A*A* G*A*U*C*A*G*T*C*U* C*A*U*A*A*G* G*U*A </p><p id="p0212" num="0212"> 3MUT </p><p id="p0213" num="0213"> Uppercase = 2'OMe RNA </p><p id="p0214" num="0214"> Lowercase = DNA </p><p id="p0215" num="0215"> Uppercase with underscore = LNA </p><p id="p0216" num="0216"> " * " = phosphorothioate linkage </p><p id="p0217" num="0217"> "z" = napthyl-azo modifier (iFQ) </p><p id="p0218" num="0218"> Mutations are identified with bold italic font </p><p id="p0219" num="0219">[0095] Results. The RLuc/FLuc ratios obtained from transfections done with the various AMOs are shown in Figure 3. In the untreated state, HeLa cells contain large amounts of miRNA 21 that suppress expression of the RLuc reporter. Any treatment that decreases miR- 21 levels leads to an increase in RLuc expression and thus increases the relative RLuc/FLuc ratio (with FLuc serving as an internal normalization control for transfection efficiency). For each of the chemistries studied, the parent wild-type sequence is followed by variants having 1, 2, or 3 mutations. </p><p id="p0220" num="0220"> [0096] In all cases, the perfect match AMO showed significant suppression of miR-21 activity as evidenced by increases in luciferase levels (increase in the RLuc to FLuc ratio indicating de-repression of the RLuc mRNA). As in Example 3 (Figure 3), the </p><p id="p0221" num="0221">"2'OMe/LNA-PS" compound showed the highest potency as evidenced by suppression of miR-21 at low dose (1 nM and 5 nM data points). The "2'OMe 5'+3'iFQ" and "DNA/LNA- PS" AMOs showed relatively similar performance both in wild-type (perfect match) and mutant (mismatch) versions. In both cases, a single mismatch showed a partial reduction of anti-miR-21 activity, the double mismatch showed almost complete elimination of anti-miR- 
<!-- EPO <DP n="40"/>-->
 21 activity, and the triple mismatch did not show any anti-miR-21 activity. In contrast, the higher affinity "2'OMe/LNA-PS" compound showed significant anti-miR-21 activity for both the single and double mismatch compounds and even showed some activity at high dose (50 nM) for the triple mismatch compound. Thus, while the "2'OMe/LNA-PS" compound is most potent, it is also the least specific of the reagents studied. </p><p id="p0222" num="0222"> [0097] Of note, the above experiments were performed using AMOs that placed the mismatches at positions that are LNA modified (in the LNA containing AMOs). This design may influence the likelihood that a mismatch will affect activity as it disrupts a high affinity LNA:RNA base pair. Thus, these results represent the best case scenario for specificity of the LNA-modified AMOs. The experiment was repeated using a new set of reagents where the mismatches were all positioned at non-LNA bases. This new series of AMO reagents is shown in Table 8. </p><p id="p0223" num="0223">Table 8: Synthetic oligomers employed in Example 4 (miR-21 AMOs) </p><p id="p0224" num="0224"><img id="imgf000040_0001" he="124" wi="155" file="imgf000040_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/><!-- EPO <DP n="41"/>-->
 DNA/ L A PS </p><p id="p0225" num="0225"> 56 t*C*a*a*C*c*t*C*a*g*T*c*a*G*a*t*A*a*c*C*t*a </p><p id="p0226" num="0226"> 3MUT v2 </p><p id="p0227" num="0227">41 2'OMe/ LNA PS U*C*A*A*C*A*U*C*A*G*T*C*U*G*A*U*A*A*G*C*U*A </p><p id="p0228" num="0228">2'OMe/ LNA PS </p><p id="p0229" num="0229"> 57 U*C*A*A*C*A*U*C*A*G*T*C*A*G*A*U*A*A*G*C*U*A </p><p id="p0230" num="0230"> 1MUT v2 </p><p id="p0231" num="0231">2'OMe/ LNA PS </p><p id="p0232" num="0232"> 58 U*C*A*A*C*C*U*C*A*G*T*C*A*G*A*U*A*A*G*C*U*A </p><p id="p0233" num="0233"> 2MUT v2 </p><p id="p0234" num="0234">2'OMe/ LNA PS </p><p id="p0235" num="0235"> 59 U*C*A*A*C*C*U*C*A*G*T*C*-¾*G*A*U*A*A*C*C*U*A </p><p id="p0236" num="0236"> 3MUT v2 </p><p id="p0237" num="0237"> Uppercase = 2'OMe RNA </p><p id="p0238" num="0238"> Lowercase = DNA </p><p id="p0239" num="0239"> Uppercase with underscore = LNA </p><p id="p0240" num="0240"> " * " = phosphorothioate linkage </p><p id="p0241" num="0241"> "z" = napthyl-azo modifier (iFQ) </p><p id="p0242" num="0242"> Mutations are identified with bold italic font </p><p id="p0243" num="0243">[0098] Results. The RLuc/FLuc ratios obtained from transfections done with the various AMOs are shown in Figure 4. In the untreated state, HeLa cells contain large amounts of miRNA 21 that suppress expression of the RLuc reporter. Any treatment that decreases miR- 21 levels leads to an increase in RLuc expression and thus increases the relative RLuc/FLuc ratio (with FLuc serving as an internal normalization control for transfection efficiency). For each of the chemistries studied, the parent wild-type sequence is followed by variants having 1, 2, or 3 mutations. </p><p id="p0244" num="0244"> [0099] The results were nearly identical to those obtained with the original mutation mismatch placement (Figure 3). In all cases, the perfect match AMO showed significant suppression of miR-21 activity as evidenced by increases in luciferase levels (increase in the RLuc to FLuc ratio indicating de-repression of the RLuc mRNA). As in Example 3 (Figure 3), the "2'OMe/LNA-PS" compound showed the highest potency as evidenced by suppression of miR-21 at low dose (1 nM and 5 nM data points). The "2'OMe 5'+3'iFQ" and </p><p id="p0245" num="0245">"DNA/LNA-PS" AMOs showed relatively similar performance both in wild-type (perfect match) and mutant (mismatch) versions. In both cases, a single mismatch showed a partial 
<!-- EPO <DP n="42"/>-->
 reduction of anti-miR-21 activity, the double mismatch showed almost complete elimination of anti-miR-21 activity, and the triple mismatch did not show any anti-miR-21 activity. In contrast, the higher affinity "2'OMe/LNA-PS" compound showed significant anti-miR-21 activity for both the single and double mismatch compounds and even showed some activity at high dose (50 nM) for the triple mismatch compound. Thus, while the "2'OMe/LNA-PS" compound is most potent, it is also the least specific of the reagents studied. </p><p id="p0246" num="0246">EXAMPLE 5 </p><p id="p0247" num="0247"> [00100] This example demonstrates improved functional activity of internal napthyl-azo- containing oligomers at reducing cellular mRNA levels when incorporated into RNase H active ASOs as compared to other related compounds. </p><p id="p0248" num="0248"> [00101] Oligonucleotides antisense in orientation to cellular messenger RNAs (mRNAs) will hybridize to the mRNA and form an RNA/DNA heteroduplex, which is a substrate for cellular RNase H. Degradation by RNase H leads to a cut site in the mRNA and </p><p id="p0249" num="0249">subsequently to total degradation of that RNA species, thereby functionally lowering effective expression of the targeted transcript and the protein it encodes. ASOs of this type require a domain containing at least 4 bases of DNA to be a substrate for RNase H, and maximal activity is not seen until 8-10 DNA bases are present. ASOs must be chemically modified to resist degradation by serum and cellular nucleases. Phosphorothioate (PS) modification of the internucleotide linkages is compatible with RNase H activation, however most other nuclease resistant modifications prevent RNase H activity, including all 2'- modifications, such as 2'OMe RNA, LNA, MOE, etc. The PS modification lowers binding affinity (T<sub>m</sub>). In general, modifications that lower T<sub>m</sub> decrease potency while modifications that increase T<sub>m</sub> improve potency. One strategy to improve potency of ASOs is to employ a chimeric design where a low T<sub>m</sub>, RNase H activating domain made of PS-modified DNA is flanked by end domains that contain 2'-modified sugars which confer high binding affinity but are not RNase H activating ("gapmer" design). One commonly employed strategy is to place five 2'-modified bases at the 5'-end, ten PS-modified DNA bases in the middle, and five 2'-modified bases at the 3'-end of the ASO (so called "5-10-5" design). A modification that confers nuclease resistance, increases binding affinity, and does not impair the reagent's ability to activate RNase H would be ideal. The present example demonstrates the utility of 
<!-- EPO <DP n="43"/>-->
 the internal napthyl-azo modifier to improve the nuclease stability and increase binding affinity of ASOs, enhancing their function as gene knockdown reagents. </p><p id="p0250" num="0250">[00102] Oligonucleotide synthesis and purification. DNA, 2'OMe RNA, and LNA containing oligonucleotides were synthesized using solid phase phosphoramidite chemistry, deprotected and desalted on NAP-5 columns (Amersham Pharmacia Biotech, Piscataway, NJ) according to routine techniques (Caruthers et ah, 1992). The oligomers were purified using reversed-phase high performance liquid chromatography (RP-HPLC). The purity of each oligomer was determined by capillary electrophoresis (CE) carried out on a Beckman P/ACE MDQ system (Beckman Coulter, Inc., Fullerton, CA). All single-strand oligomers were at least 85% pure. Electrospray-ionization liquid chromatography mass spectrometry (ESI- LCMS) of the oligonucleotides was conducted using an Oligo HTCS system (Novatia, Princeton, NJ), which consisted of ThermoFinnigan TSQ7000, Xcalibur data system, ProMass data processing software, and Paradigm MS4™ HPLC (Michrom BioResources, Auburn, CA). Protocols recommended by the manufacturers were followed. Experimental molar masses for all single-strand oligomers were within 1.5 g/mol of expected molar mass. These results confirm identity of the oligomers. 
<!-- EPO <DP n="44"/>-->
</p><p id="p0251" num="0251">Table 9: Synthetic oligomers employed in Example 5 (anti-HPRT ASOs) </p><p id="p0252" num="0252"><img id="imgf000044_0001" he="204" wi="155" file="imgf000044_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/><!-- EPO <DP n="45"/>-->
 HPRT#1 5-10-5 PS 2x </p><p id="p0253" num="0253"> 74 A<sub>z</sub>U*A*G*G*a*c*t*c*c*a*g*a*t*g*U*U*U*C<sub>z</sub>C iFQ </p><p id="p0254" num="0254">75 HPRT#1 5-10-5 gapPS A U A G G a*c*t*c*c*a*g*a*t*g*U U U C C </p><p id="p0255" num="0255">HPRT#1 5-10-5 gapPS </p><p id="p0256" num="0256"> 76 A<sub>Z</sub>U A G G a*c*t*c*c*a*g*a*t*g*U U U C<sub>Z</sub>C </p><p id="p0257" num="0257"> 2x iFQ </p><p id="p0258" num="0258">77 HPRT#1 5-10-5 gapPS </p><p id="p0259" num="0259"> A<sub>Z</sub>U A G G a*c*t*c*c<sub>z</sub>a*g*a*t*g*U U U C<sub>Z</sub>C 3x iFQ </p><p id="p0260" num="0260">78 </p><p id="p0261" num="0261"> HPRT#1 5-10-5 LNA PS A*T*A*G*G*a*c*t*c*c*a*g*a*t*g*T*T*T*C*C</p><p id="p0262" num="0262">Uppercase = 2'0Me RNA </p><p id="p0263" num="0263"> Lowercase = DNA </p><p id="p0264" num="0264"> Uppercase with underscore = LNA </p><p id="p0265" num="0265"> " * " = phosphorothioate linkage </p><p id="p0266" num="0266"> "z" = insertion of napthyl-azo modifier (iFQ) </p><p id="p0267" num="0267">[00103] HeLa cell culture, transfections, and RT-qPCR methods. HeLa cells were split into 48-well plates and were transfected the next day at -60% confluency in serum-free Dulbecco's Modified Eagle Medium (Invitrogen, Carlsbad, CA) using TriFECTin<sup>®</sup> </p><p id="p0268" num="0268">(Integrated DNA Technologies, Coralville, IA) at a concentration of 2% (1 per 50 μϊ<sub>^</sub> OptiMEM<sup>®</sup> I) (Invitrogen, Carlsbad, CA) with ASOs at the indicated concentrations. All transfections were performed in triplicate. After 6 hours, media was exchanged with </p><p id="p0269" num="0269">Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum. RNA was prepared 24 hours after transfection using the SV96 Total RNA Isolation Kit (Promega, Madison, WI). cDNA was synthesized using 150 ng total RNA with SuperScript™-II Reverse Transcriptase (Invitrogen, Carlsbad, CA) per the manufacturer's instructions using both random hexamer and oligo-dT priming. Transfection experiments were all performed a minimum of three times. </p><p id="p0270" num="0270"> [00104] Quantitative real-time PCR was performed using 10 ng cDNA per 10 μϊ<sub>^</sub> reaction with Immolase™ DNA Polymerase (Bioline, Randolph, MA), 200 nM primers, and 200 nM probe. Hypoxanthine phosphoribosyltransferase 1 (HPRT1) (GenBank Acc. No. </p><p id="p0271" num="0271">NM_000194) specific primers were: </p><p id="p0272" num="0272"> HPRT-For 5' GACTTTGCTTTCCTTGGTCAGGCA (SEQ ID NO: 79), </p><p id="p0273" num="0273">HPRT-Rev 5' GGCTTATATCCAACACTTCGTGGG (SEQ ID NO: 80), and probe 
<!-- EPO <DP n="46"/>-->
 HPRT-P 5' MAX- ATGGTCAAGGTCGCAAGCTTGCTGGT-IowaBlackFQ (IBFQ) (SEQ ID NO: 81) </p><p id="p0274" num="0274">and were normalized to levels of an internal control gene, human acidic ribosomal phosphoprotein P0 (RPLPO) (GenBank Acc. No. NM_001002), which was measured in a multiplexed reaction using primers: </p><p id="p0275" num="0275"> RPLPO-For 5' GGCGACCTGGAAGTCCAACT (SEQ ID NO: 82), </p><p id="p0276" num="0276">RPLPO-Rev 5' CCATCAGCACCACAGCCTTC (SEQ ID NO: 83), and probe </p><p id="p0277" num="0277">RPLPO-P 5' FAM-ATCTGCTGCATCTGCTTGGAGCCCA-IBFQ (SEQ ID NO: 84) (Bieche et ah, 2000, Clin. Cancer Res. 6(2): 452-59). Cycling conditions employed were: 95°C for 10 minutes followed by 40 cycles of 2-step PCR with 95°C for 15 seconds and 60°C for 1 minute. PCR and fluorescence measurements were done using an ABI Prism™ 7900 Sequence Detector (Applied Biosystems Inc., Foster City, CA). All reactions were performed in triplicate. Expression data were normalized. Copy number standards were multiplexed using linearized cloned amplicons for both the HPRT and RPLPO assays. </p><p id="p0278" num="0278">Unknowns were extrapolated against standards to establish absolute quantitative </p><p id="p0279" num="0279">measurements. </p><p id="p0280" num="0280"> [00105] Results. ASOs were transfected into HeLa cells at 1 nM, 5 nM, and 20 nM concentrations. RNA was prepared 24 hours post transfection, converted to cDNA, and HPRT expression levels were measured using qPCR. Results are shown in Figure 5 for the set of anti-HPRT ASOs made from DNA bases. Unmodified single-stranded DNA oligos are rapidly degraded by exonucleases and endonucleases. No knockdown of HPRT was observed using this design (HPRT DNA), presumably due to rapid degradation of the unprotected compound. ASOs with a single iFQ modification near the 3'-end (HPRT DNA 3'iFQ), a single iFQ modification near the 5'-end (HPRT DNA 5'iFQ), two iFQ modifications inserted near both ends (HPRT DNA 5 '+3 'iFQ), and three iFQ modifications inserted in the center and near both ends (HPRT DNA 5'+I+3'iFQ) were also tested and similarly showed no functional gene knockdown at the doses examined. Therefore, the addition of even up to three iFQ modifications does not provide sufficient nuclease stabilization to permit otherwise unmodified DNA oligos to function as antisense gene-knockdown agents. </p><p id="p0281" num="0281">[00106] The same series of oligonucleotides was synthesized having phosphorothioate (PS) internucleotide bonds throughout the sequence (except where the phosphate connects to an iFQ modifier). Historically, DNA-PS oligos were among the first effective antisense 
<!-- EPO <DP n="47"/>-->
 compounds studied. This modification increases nuclease stability; however, it also lowers binding affinity (T<sub>m</sub>) and as a result this so-called "first generation" antisense chemistry usually shows relatively low potency. The "DNA-PS" ASO reduced HPRT levels by 50% at 20 nM concentration; however, no reduction in HPRT levels was observed at lower doses. Addition of the iFQ modification, which increases binding affinity and blocks exonuclease action, improved function of the DNA-PS ASOs. The "DNA-PS 5'+I+3'iFQ" compound showed the best results within this series, with HPRT knockdown of 70% at 20 nM and 40% at 5 nM observed (Figure 5). </p><p id="p0282" num="0282"> [00107] A second set of ASOs was synthesized using a chimeric "5- 10-5 gapmer" design where five base end domains were made of 2'OMe RNA and a central ten base RNase H active domain were made of DNA. Oligonucleotides had zero, one, two, or three iFQ modifiers inserted at the same positions as the DNA ASOs in Figure 5. These </p><p id="p0283" num="0283">oligonucleotides were transfected into HeLa cells as before and HPRT mRNA levels were examined 24 hours post-transfection. Results are shown in Figure 6. The three gapmer ASOs with a phosphodiester DNA central domain showed no activity in reducing HPRT mRNA levels, regardless of whether the sequence was modified with the iFQ group or not ("5- 10-5", 5-10-5 2x iFQ" and "5- 10-5 3x iFQ"). The same sequence fully PS modified ("5- 10-5-PS") showed good potency with 75% knockdown of HPRT at 20 nM concentration. The addition of two iFQ groups near the ends of this design ("5-10-5-PS 2xiFQ") showed the best potency of this set, with &gt;90% knockdown of HPRT at 20 nM and &gt;70% knockdown at 5 nM concentration. </p><p id="p0284" num="0284"> [00108] Although 2'OMe RNA is somewhat resistant to endonuclease attack, gapmer ASOs of this design are usually made with full PS modification to prevent exonuclease degradation. Consistent with this idea, an ASO with the DNA domain protected by PS internucleotide linkages but having phosphodiester bonds in the 2'OMe flanking domains showed no gene knockdown activity ("5- 10-5 gapPS"). Use of the iFQ modification at the ends, however, permits use of this new design by providing protection from exonuclease attack; this new design should also increase binding affinity and lower toxicity by reducing PS content. This strategy was effective and the ASO ("5-10-5 gapPS 2xiFQ") showed knockdown of HPRT levels by &gt;90%&gt; at 20 nM and by &gt;70%&gt; at 5 nM. Potency was very similar to the full PS modified ASO. This design is expected to have reduced toxicity; however, toxicity is not easily tested in this system as HeLa cells are tolerant to fairly high 
<!-- EPO <DP n="48"/>-->
 doses of PS modified oligonucleotides. Benefit from reduced PS content will be better appreciated in vivo. </p><p id="p0285" num="0285"> [00109] Although it did not increase functional potency, addition of a third centrally placed iFQ group ("5-10-5 gapPS-3x-iFQ") was compatible with gene knockdown in this RNase H active antisense design. It is generally accepted that maximal activity of RNase H active ASOs requires a DNA domain having at least 8 uninterrupted DNA residues. It was unexpected that the 3xiFQ design (where the 10 base DNA domain is interrupted by a central iFQ group) would work without reducing potency compared with the 2xiFQ design (where the 10 base DNA domain is continuous). It is possible that unique properties of the iFQ group allow its insertion to remain compatible with RNase H activity, possibly due to the same postulated base stacking interactions that result in increased T<sub>m</sub> in these compounds. </p><p id="p0286" num="0286">[00110] The most potent antisense design in current use are LNA-modified gapmers, where very strong T<sub>m</sub> enhancing LNA modifications are used in the flanking domains in place of the 2'OMe RNA bases used in the present example. While potent, this design is expensive and can show significant toxicity in certain contexts. The same anti-HPRT sequence was made as an LNA 5-10-5 gapmer (fully PS modified). As expected, this compound showed the highest relative potency of any of the ASOs tested ("5-10-5 LNA PS") but the observed potency was only marginally higher than the best of the iFQ compositions ("5-10-5-PS 2xiFQ"). The very high binding affinity LNA reagents usually result in decreased specificity, so use of the iFQ designs of the present invention may show improved specificity at a small cost in potency. </p><p id="p0287" num="0287">EXAMPLE 6 </p><p id="p0288" num="0288"> [00111] This example demonstrates use of the iFQ modification in RNA duplexes with application in suppressing gene expression via an RNAi mechanism of action. </p><p id="p0289" num="0289">[00112] The use of double-stranded RNA (dsRNA) to trigger gene suppression via RNA interference (RNAi) is a well-described technique. Synthetic dsRNAs that mimic natural cellular products (small interfering RNAs, or siRNAs) are usually 21 bases long with a central 19 base duplex domain with 2-base 3'-overhangs. Alternatively, slightly larger synthetic oligonucleotides can be used that are substrates for the cytoplasmic nuclease Dicer, which processes these species into 21-mer siRNAs. Typically these reagents are asymmetric and have a 25 base top (Sense strand, "S") and a 27 base bottom strand (Antisense strand, 
<!-- EPO <DP n="49"/>-->
 "AS") with a single 2-base 3 '-overhang on the AS strand. These longer siRNAs are called Dicer-substrate siRNAs, or DsiRNAs. Although dsRNA is far more stable to nuclease attack than single-stranded RNA (ssRNA), degradation of the synthetic siRNAs can significantly limit potency of the compounds, especially when used in vivo. Incorporation of chemical modifications, such as 2'OMe RNA, 2'F RNA, or LNA bases, improves nuclease stability and can improve function of the siRNA. Selective placement of nuclease-resistant </p><p id="p0290" num="0290">phosphorothioate bonds (PS) can also help stabilize the siRNA, especially when used near the terminal 3'-internucleotide linkages. Unfortunately, careful placement of modified groups is essential as extensive chemical modification usually lowers functional potency of the compound even though nuclease stabilization has been achieved, probably through disrupting interaction of the RNA duplex with key protein mediators of RNAi, like Dicer or Ago2. </p><p id="p0291" num="0291">[00113] The present example demonstrates that the iFQ modifier can be introduced into DsiRNAs. Like other chemical modifiers, iFQ insertion can lead to increased potency, decreased potency, or no change in potency depending upon placement. </p><p id="p0292" num="0292">[00114] Oligonucleotide synthesis and purification. RNA and modified RNA oligonucleotides were synthesized using solid phase phosphoramidite chemistry, deprotected and desalted according to routine techniques (Caruthers et ah, 1992). The oligomers were purified using ion-exchange high performance liquid chromatography (IE-HP LC) and were handled under RNase-free conditions. All RNA oligonucleotides were prepared as a sodium salt. The purity of each oligomer was determined by capillary electrophoresis (CE) carried out on a Beckman P/ACE MDQ system (Beckman Coulter, Inc., Fullerton, CA). All single- strand oligomers were at least 85% pure. Electrospray-ionization liquid chromatography mass spectrometry (ESI-LCMS) of the oligonucleotides was conducted using an Oligo HTCS system (Novatia, Princeton, NJ), which consisted of ThermoFinnigan TSQ7000, Xcalibur data system, ProMass data processing software, and Paradigm MS4™ HPLC (Michrom BioResources, Auburn, CA). Protocols recommended by the manufacturers were followed. Experimental molar masses for all single-strand oligomers were within 1.5 g/mol of expected molar mass. These results confirm identity of the oligomers. </p><p id="p0293" num="0293"> [00115] Duplexes were formed by mixing equal molar amounts of the top and bottom strands in 30 mM Hepes, pH 7.5, 100 mM potassium acetate, heating at 95°C for 2 minutes, then cooling to room temperature. Table 10 lists the duplexes synthesized for Example 6. 
<!-- EPO <DP n="50"/>-->
 Table 10: Synthetic RNA duplexes employed in Example 6 (anti-HPRT DsiRNAs) </p><p id="p0294" num="0294"><img id="imgf000050_0001" he="125" wi="149" file="imgf000050_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0295" num="0295"> Uppercase = RNA </p><p id="p0296" num="0296"> Lowercase = DNA </p><p id="p0297" num="0297"> "z" = insertion of napthyl-azo modifier (iFQ) </p><p id="p0298" num="0298"> Note: gaps have been introduced in sequences for the purpose of alignment only and do not represent any modification to sequence. </p><p id="p0299" num="0299">[00116] HeLa cell culture, transfections, and RT-qPCR methods. HeLa cells were transfected in "reverse format" at -60% confluency (Invitrogen, Carlsbad, CA) using 1 μΐ, Lipofectamine™ RNAiMAX per 50 μΐ. OptiMEM™ I (Invitrogen, Carlsbad, CA) with RNA duplexes at the indicated concentrations. All transfections were performed in triplicate. RNA was prepared 24 hours after transfection using the SV96 Total RNA Isolation Kit (Promega, Madison, WI); cDNA was synthesized using 150 ng total RNA with </p><p id="p0300" num="0300">SuperScript™-II Reverse Transcriptase (Invitrogen, Carlsbad, CA) per the manufacturer's instructions using both random hexamer and oligo-dT priming. 
<!-- EPO <DP n="51"/>-->
 [00117] Quantitative real-time PCR reactions were done using 10 ng cDNA per 10 μΐ<sub>^</sub> reaction, Immolase™ DNA Polymerase (Bioline, Randolph, MA), 500 nM primers, and 250 nM probe. Hypoxanthine phosphoribosyltransferase 1 (HPRT1) (GenBank Acc, No. </p><p id="p0301" num="0301">NM_000194) specific primers were: </p><p id="p0302" num="0302"> HPRT-For 5' GACTTTGCTTTCCTTGGTCAGGCA (SEQ ID NO: 79), </p><p id="p0303" num="0303">HPRT -Rev 5' GGCTTATATCCAACACTTCGTGGG (SEQ ID NO: 80), and probe </p><p id="p0304" num="0304">HPRT-P 5' FAM- ATGGTCAAGGTCGCAAGCTTGCTGGT-IowaBlackFQ (IBFQ) (SEQ ID NO: 81). </p><p id="p0305" num="0305"> Cycling conditions employed were: 95°C for 10 minutes followed by 40 cycles of 2-step PCR with 95°C for 15 seconds and 60°C for 1 minute. PCR and fluorescence measurements were done using an ABI Prism™ 7900 Sequence Detector (Applied Biosystems Inc., Foster City, CA). All data points were performed in triplicate. Expression data were normalized to levels of an internal control gene, human splicing factor, arginine/serine-rich 9 (SFRS9) (GenBank Acc. No. NM_003769), which was measured in a multiplexed reaction using primers: </p><p id="p0306" num="0306"> SFRS9-For 5' TGTGCAGAAGGATGGAGT (SEQ ID NO: 103), </p><p id="p0307" num="0307">SFRS9-Rev 5' CTGGTGCTTCTCTCAGGATA (SEQ ID NO: 104), and probe </p><p id="p0308" num="0308">SFRS9-P 5' MAX-TGGAATATGCCCTGCGTAAACTGGA-IBFQ (SEQ ID NO: 105), setting the baseline to cells transfected with a scrambled negative control RNA duplex (NCI). Copy number standards were run in parallel using linearized cloned amplicons for both the HPRT and SFRS9 assays. Unknowns were extrapolated against standards to establish absolute quantitative measurements. </p><p id="p0309" num="0309"> [00118] Results. The anti-HPRT DsiRNA employed in the present study is extremely potent and typically shows detectable knockdown of target mRNA at low picomolar levels. Consistent with this expectation, the unmodified duplex reduced HPRT levels by -40% at a 10 pM dose at 24 hours post-transfection in HeLa cells. A series of modified duplexes containing the iFQ group positioned at various locations in the S strand, AS strand, or both were similarly transfected into HeLa cells and HPRT mRNA levels were measured 24 hour post-transfection. Results are shown in Figure 7. </p><p id="p0310" num="0310"> [00119] Placing the iFQ group near the 3 '-end of the AS strand was well tolerated; </p><p id="p0311" num="0311">insertion between bases 1 and 2 from the 3 '-end (in the single-stranded 3 '-overhang domain) (duplex HPRT iFQ vl) or between bases 3 and 4 from the 3'-end (at the start of the duplex 
<!-- EPO <DP n="52"/>-->
 domain) (duplex HPRT iFQ v4) showed similar potency to the unmodified duplex. Placing the iFQ group near the 5 '-end of the S strand was similarly well tolerated (duplex HPRT iFQ v2) as was placing the iFQ group near both ends of the S strand (duplex HPRT iFQ v3). In contrast, duplexes having an iFQ group near the 5'-end of the AS strand showed reduced potency (duplexes HPRT iFQ v5 and v7), so modification at this position should be avoided. </p><p id="p0312" num="0312">[00120] Within the error of the system studied, the iFQ modified and unmodified duplexes showed similar potency (except for those duplexes modified at the 5'-end of the AS strand, as noted above). Benefit from the iFQ group is most likely to be evident in settings where nuclease stabilization is needed, which is not appreciated in the present in vitro system, but based on the results of Examples 1 and 2, greater benefit would be expected from use of this modification when used in vivo where exposure to serum nucleases is more problematic. 
<!-- EPO <DP n="53"/>-->
</p><p id="p0313" num="0313">EXAMPLE 7 </p><p id="p0314" num="0314"> [00121] This example demonstrates decreased cellular toxicity from lipid transfected internal napthyl-azo-containing oligomers compared with other compounds. </p><p id="p0315" num="0315">[00122] Toxicity from chemical modification of synthetic oligomers can be problematic as it can give unwanted side effects, cause unreliable results, and limit therapeutic utility of the oligomer. Cellular death can result from toxic chemical modifications by inducing necrosis or apoptosis. Toxicity was ascertained with oligomers containing a non-targeting, negative control ("NCI ") sequence using chemical modification patterns employed in the AMOs examined in Examples 3 and 4 (see Table 1 1). Generalized cytotoxicity (from necrosis and/or apoptosis) was measured by quantifying the relative number of live and dead cells after treatment with the chemically modified oligomers, while cytotoxicity resulting from the induction of the apoptotic pathway was determined by measuring the levels of caspase-3 and -7 after oligomer treatment. </p><p id="p0316" num="0316"> [00123] Oligonucleotide synthesis and preparation. DNA oligonucleotides were synthesized using solid phase phosphoramidite chemistry, deprotected and desalted on NAP- 5 columns (Amersham Pharmacia Biotech, Piscataway, NJ) according to routine techniques (Caruthers et al., 1992). The oligomers were purified using reversed-phase high performance liquid chromatography (RP-HPLC). The purity of each oligomer was determined by capillary electrophoresis (CE) carried out on a Beckman P/ACE MDQ system (Beckman Coulter, Inc., Fullerton, CA). All single-strand oligomers were at least 90% pure. </p><p id="p0317" num="0317">Electrospray-ionization liquid chromatography mass spectrometry (ESI-LCMS) of the oligonucleotides was conducted using an Oligo HTCS system (Novatia, Princeton, NJ), which consisted of ThermoFinnigan TSQ7000, Xcalibur data system, ProMass data processing software, and Paradigm MS4™ HPLC (Michrom BioResources, Auburn, CA). Protocols recommended by the manufacturers were followed. Experimental molar masses for all single-strand oligomers were within 1.5 g/mol of expected molar mass. These results confirm identity of the oligomers. </p><p id="p0318" num="0318">Table 11: Synthetic oligomers employed in Example 7 (NCI AMOs) 
<img id="imgf000053_0001" he="15" wi="150" file="imgf000053_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/>
 
<!-- EPO <DP n="54"/>-->
 106 2'OMe 5'+3' iFQ G<sub>Z</sub>C G U A U U A U A G C C G A U U A A C G<sub>Z</sub>A</p><p id="p0319" num="0319">107 2'OMe PSends G*C*G*U A U U A U A G C C G A U U A A*C*G*A</p><p id="p0320" num="0320">108 DNA/PS g*c*g*t*a*t*t*a*t*a*g*c*c*g*a*t*t*a*a*c*g*a</p><p id="p0321" num="0321">109 DNA/LNA PO g C g t A t t A t a G c c G a t T a a C g a</p><p id="p0322" num="0322">110 DNA/LNA PS g*C*g*t*A*t*t*A*t*a*G*c*c*G*a*t*T*a*a*C*g*a</p><p id="p0323" num="0323">111 2'OMe/LNA PO G C G T A T T A T A G C C G A T T A A C G A</p><p id="p0324" num="0324">112 2'OMe/LNA PS Q- -
<img id="imgf000054_0001" he="4" wi="39" file="imgf000054_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 Q-k </p><p id="p0325" num="0325">Uppercase = 2'OMe RNA </p><p id="p0326" num="0326"> Lowercase = DNA </p><p id="p0327" num="0327"> Uppercase with underscore = LNA </p><p id="p0328" num="0328"> " * " = phosphorothioate linkage </p><p id="p0329" num="0329"> "z" = napthyl-azo modifier (iFQ) </p><p id="p0330" num="0330">[00124] Cell culture, transfections, and luciferase assays. HeLa cells were plated in 48- well plates in DMEM containing 10% FBS to achieve 90% confluency the next day. The following morning, NCI AMOs were transfected at 100 nM or 50 nM concentrations in triplicate wells in two sets (one for measuring general cytotoxicity, one for measuring apoptosis induction) with 1 μΐ TriFECTin<sup>®</sup> (Integrated DNA Technologies) per well in DMEM containing 10% FBS. An apoptosis-inducing agent, Staurosporine (1 mM in DMSO), was incubated at 1 μΜ on the cells for 24 hours as a positive control. After 24 hours of NCI AMO treatment, the first set of cells was analyzed for viability using the MultiTox-Glo Multiplex Cytotoxicity Assay (Promega, Madison, WI) with the peptide- substrate GF-AFC (glycyl-phenylalanylaminofluoiOCOumarin), which generates a fluorescence signal upon cleavage by a "live-cell" specific protease, measured at </p><p id="p0331" num="0331">405nmEx/505nmEm in &amp; SpectraFiuor Microplate Reader (Tecan Group Ltd, Mannedorf, Switzerland). Continuing to use the MultiTox-Glo Multiplex Cytotoxicity Assay, the same cells were subsequently analyzed for cytotoxicity by detecting a "dead-cell" protease activity in a luciferase-based assay measured on a GloMax® 96 Microplate Luminometer (Promega) 
<!-- EPO <DP n="55"/>-->
 per the manufacturer's recommendations. To assess cytotoxicity derived from induction of the apoptosis pathway, the Caspase-Glo® 3/7 Assay (Promega) was performed with the second set of cells to measure caspase-3 and -7 levels according to the manufacturer's recommendations on a GloMax® 96 Microplate Luminometer (Promega). </p><p id="p0332" num="0332">[00125] Results. For the cytotoxicity analysis graphed in Figure 8, data is presented as a ratio of live/ dead cells as calculated from the abundance of "live-cell" and "dead-cell" proteases described above. The ratio of five/dead cells serves as an internal normalizing control providing data independent of ceil number, and a reduction of live/dead ceils correlates with cytotoxicity. The "2'OMe 5'+3' iFQ" and "2'OMe PSends" compounds are the least toxic oligomers and there is minimal toxicity even at the high 100 nM dose. The "DNA/PS" oligomer, which is entirely comprised of PS linkages, shows substantial cell death at both doses suggesting that PS modification is toxic to the cells. When LNA bases are incorporated into the NCI AMO, such as in the "DNA/LNA PO" oligomer, cell death is seen at the high 100 nM dose suggesting that LNA modification is toxic to the cells. Importantly, additive ceil death is seen after combining these two chemistries in the "DNA/LNA PS" oligomer, demonstrating toxicity which also correlates with the dysmorphic, unhealthy cells seen during the visual analysis at the time the assay was performed. Substituting DNA with 2'OMe bases in the "2'OMe/LNA PO" and "2'OMe/LNA PS" NCI AMOs reduces toxicity compared with their DNA counterparts; however, ceil death is still seen at the 100 nM dose. </p><p id="p0333" num="0333">[00126] In parallel, HeLa ceils treated with the NCI AMOs were assessed for apoptosis induction by evaluating the levels of caspase-3 and -7 in a luciferase-based assay (Figure 9). Luminescence is proportional to the abundance of the apoptosis effectors and an increase in RLUs correlates with an increase in apoptosis. The data in Figure 9 mirrors the cytotoxicity profiles from the NCI AMOs assayed in Figure 8. The NCI AMOs that do not trigger apoptosis are the "2'OMe 5'+3' iFQ" and "2'OMe PSends" compounds. Both extensive PS modification ("DNA/PS") and incorporation of LNA bases ("DNA/LNA PO") induce apoptosis, while an additive effect is seen when these two chemistries are combined </p><p id="p0334" num="0334">("DNA/LNA PS"). Again, substitution of DNA bases for 2'OMe bases ("2'OMe/LNA PO" and "2'OMe/LNA PS") reduces apoptosis induction. However, the "2'OMe/LNA PS" still demonstrates apoptosis induction at the 100 nM dose. </p><p id="p0335" num="0335"> [00127] This cytotoxicity profiling analysis clearly exemplifies that certain chemical modification strategies can be detrimental to cell viability. The "2'OMe 5'+3' iFQ" AMO and 
<!-- EPO <DP n="56"/>-->
 the "DNA/LNA PS" AMOs, which demonstrated similar high potency in Example 3, have significantly different toxicity profiles. The "2'OMe 5 '+3' iFQ" oligomer was non-toxic in this system, and the "DNA/LNA PS" oligomer caused substantial cell death in Figure 8 and was shown to induce apoptosis in Figure 9. These data confirm the superiority of the "2OMe 5'-ί-3' iFQ" AMO when compared to other standard AMOs with comparable potency </p><p id="p0336" num="0336">(Example 3), increased specificity (Example 4), and reduced toxicity. </p><p id="p0337" num="0337">EXAMPLE 8 </p><p id="p0338" num="0338"> [00128] This example demonstrates that the magnitude of T<sub>m</sub> enhancement (i.e., stability) derived from use of the internal napthyl-azo modification varies with the nearest-neighbor base context. </p><p id="p0339" num="0339"> [00129] It is well established that the binding affinity (or T<sub>m</sub>) of a nucleic acid duplex varies with base composition. Further, the identity of the flanking bases (i.e., "nearest neighbors") directly influences T<sub>m</sub> (Santa Lucia Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 1460-1465, 1998). Example 1 demonstrated positive T<sub>m</sub> effects when the napthyl-azo modifier was incorporated in a short lOmer DNA oligomer duplexed with a DNA </p><p id="p0340" num="0340">complement. The present example demonstrates the T<sub>m</sub> effects of the napthyl-azo modifier when incorporated in 22-mer 2'OMe oligomers duplexed with RNA complements. </p><p id="p0341" num="0341">[00130] Specifically, this study examines the T<sub>m</sub> effects caused by insertion of the napthyl- azo modifier between 5'- or 3 '-terminal 2'OMe residues of 22mer 2'OMe oligomers when duplexed with a perfect match complementary RNA target. This artificial system mimics behavior of a steric blocking ASO binding a miRNA target (e.g., an AMO). Nearest neighbor base effects were studied for all 16 possible dinucleotide pairs. The effects of the napthyl-azo modifier placed externally at the 5 '-end or 3 '-end of the 2'OMe oligomer were also studied. </p><p id="p0342" num="0342"> [00131] Oligonucleotide synthesis and preparation. 2'OMe and RNA oligonucleotides were synthesized using solid phase phosphoramidite chemistry, deprotected and desalted on NAP-5 columns (Amersham Pharmacia Biotech, Piscataway, NJ) according to routine techniques (Caruthers et ah, 1992, Methods Enzymol. 211 : 3-20). The oligomers were purified using reversed-phase high performance liquid chromatography (RP-HPLC). The purity of each oligomer was determined by capillary electrophoresis (CE) carried out on a Beckman P/ACE MDQ system (Beckman Coulter, Inc., Fullerton, CA). All single-strand 
<!-- EPO <DP n="57"/>-->
 oligomers were at least 90% pure. Electrospray-ionization liquid chromatography mass spectrometry (ESI-LCMS) of the oligonucleotides was conducted using an Oligo HTCS system (Novatia, Princeton, NJ), which consisted of ThermoFinnigan TSQ7000, Xcalibur data system, ProMass data processing software, and Paradigm MS4™ HPLC (Michrom BioResources, Auburn, CA). Protocols recommended by the manufacturers were followed. Experimental molar masses for all single-strand oligomers were within 1.5 g/mol of expected molar mass. These results confirm identity of the oligomers. </p><p id="p0343" num="0343"> [00132] Preparation of samples. Melting experiments were carried out in buffer containing 3.87 mM NaH<sub>2</sub>P0<sub>4</sub>, 6.13 mM Na<sub>2</sub>HP0<sub>4</sub>, 1 mM Na<sub>2</sub>EDTA, and 130 mM NaCl, i.e., close to physiologic saline. 1 M NaOH was used to titrate each solution to pH 7.0. Total sodium concentrations were estimated to be 150 mM. The DNA samples were thoroughly dialyzed against melting buffer in a 28-well Microdialysis System (Life Technologies, Carlsbad, CA) following the manufacturer's recommended protocol. Concentrations of oligomers were estimated from the samples' UV absorbance at 260 nm in a </p><p id="p0344" num="0344">spectrophotometer (Beckman Coulter, Inc., Fullerton, CA), using extinction coefficients for each oligonucleotide that were estimated using the nearest neighbor model for calculating extinction coefficients (see Warshaw et ah, 1966, J. Mol. Biol. 20(1): 29-38). </p><p id="p0345" num="0345">[00133] Internal modifications studied. The napthyl-azo compound (Formula 3, Integrated DNA Technologies, Inc., sometimes referred to as "iFQ" or "ZEN" in this disclosure), was introduced into 2'OMe oligonucleotides using phosphoramidite reagents at the time of synthesis. 
<!-- EPO <DP n="58"/>-->
</p><p id="p0346" num="0346"><img id="imgf000058_0001" he="50" wi="68" file="imgf000058_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 Formula 3 </p><p id="p0347" num="0347">In some of the oligomers, the group was placed as an insertion between the 5'- or 3 '-terminal bases (iFQ); in other cases, the group was placed at the 5'- or 3 '-end and was not inserted between bases (FQ). Extinction coefficients at 260 nm of iFQ were estimated to be 13340. </p><p id="p0348" num="0348">[00134] Measurement of melting curves. Oligomer concentrations were measured at least twice for each sample. If the estimated concentrations for any sample differed more than 4%, the results were discarded and new absorbance measurements were performed. To prepare oligonucleotide duplexes, complementary 2'OMe:RNA oligomers were mixed in 1 : 1 molar ratio, heated to 367 K (i.e., 94°C) and slowly cooled to an ambient temperature. Each solution of duplex was diluted with melting buffer to a total concentration (d) of 2 μΜ. </p><p id="p0349" num="0349">[00135] Melting experiments were conducted on a single beam Beckman DU 650 spectrophotometer (Beckman-Coulter) with a Micro T<sub>m</sub> Analysis accessory, a Beckman High Performance Peltier Controller (to regulate the temperature), and 1 cm path-length cuvettes. Melt data were recorded using a PC interfaced to the spectrophotometer. UV-absorbance values at 268 nm wavelength were measured at 0.1 degree increments in the temperature range from 383 to 368 K (i.e., 10 - 95°C). Both heating (i.e., "denaturation") and cooling (i.e., "renaturation") transition curves were recorded in each sample at a controlled rate of temperature change (24.9 ± 0.3°C per hour). Sample temperatures were collected from the internal probe located inside the Peltier holder, and recorded with each sample's UV- absorbance data. Melting profiles were also recorded for samples of buffer alone (no oligonucleotide), and these "blank" profiles were digitally subtracted from melting curves of the DNA samples. To minimize systematic errors, at least two melting curves were collected for each sample in different cuvettes and in different positions within the Peltier holder. 
<!-- EPO <DP n="59"/>-->
 [00136] Determination of melting temperatures. To determine each sample's melting temperature, the melting profiles were analyzed using methods that have been described (see Doktycz et al, 1992, Biopofymers 32(7): 849-64; Owczarzy et al, 1997, Biopofymers 44(3): 217-39; and Owczarzy, 2005, Biophys. Chem. 1 17(3): 207-15.). Briefly, the experimental data for each sample was smoothed, using a digital filter, to obtain a plot of the sample's UV- absorbance as a function of its temperature. The fraction of single-stranded oligonucleotide molecules, Θ, was then calculated from that plot. The "melting temperature" or "T<sub>m</sub>" of a sample was defined as the temperature where Θ = 0.5. </p><p id="p0350" num="0350"> [00137] Results. 2'OMe oligomers modified with an internal napthyl-azo modifier placed between the terminal 5 '-end residues or the terminal 3 '-end residues were duplexed with RNA targets to mimic complexation between an AMO and a target miRNA. Control duplexes without the napthyl-azo modifier were studied in parallel. UV melt profiles were collected as described above under physiologic conditions. T<sub>m</sub> values were collected for the forward and reverse melt curves for three independent samples. The average T<sub>m</sub> values for the set are shown in Table 12. The T<sub>m</sub> value of the control duplex was subtracted from the T<sub>m</sub> value of the modified duplex to yield a AT<sub>m</sub> value, which represents the change in stability seen with modification. </p><p id="p0351" num="0351">Table 12. T<sub>m</sub> of napthyl-azo internally-modified 2'OMe AMOs duplexed with RNA </p><p id="p0352" num="0352"> SEQ ID Dinucleotide pair rp </p><p id="p0353" num="0353"> Sequence -* m 0 </p><p id="p0354" num="0354"> No. studied c °c</p><p id="p0355" num="0355">113 5' U z CAAC AUCAGUCUGAUAAGCUA 3' </p><p id="p0356" num="0356"> 11 0 </p><p id="p0357" num="0357"> 114 3' A GUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0358" num="0358"> 5' UzC ... 3' +4. 0</p><p id="p0359" num="0359">115 5' UCAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0360" num="0360"> 73 0 </p><p id="p0361" num="0361"> 114 3' AGUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0362" num="0362"> 116 5' U z GAAC AUCAGUCUGAUAAGCUA 3' </p><p id="p0363" num="0363"> 76 </p><p id="p0364" num="0364"> 117 3' A CUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0365" num="0365"> 5' UzG ... 3' +2. 2</p><p id="p0366" num="0366">118 5' UGAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0367" num="0367"> 74 3 </p><p id="p0368" num="0368"> 117 3' ACUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0369" num="0369"> 119 5' U z AAAC AUCAGUCUGAUAAGCUA 3' </p><p id="p0370" num="0370"> 73 5 </p><p id="p0371" num="0371"> 120 3' A UUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0372" num="0372"> 5' UzA ... 3' +0. 4</p><p id="p0373" num="0373">121 5' UAAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0374" num="0374"> 73 1 </p><p id="p0375" num="0375"> 120 3' AUUUGUAGUCAGACUAUUCGAU 5' 
<!-- EPO <DP n="60"/>-->
122 5' UzUAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0376" num="0376"> 73 5 </p><p id="p0377" num="0377">123 3' A AUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0378" num="0378"> 5' UzU . . 3' +1 3</p><p id="p0379" num="0379">124 5' UUAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0380" num="0380"> 72 2 </p><p id="p0381" num="0381">123 3' AAUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0382" num="0382"> 125 5' CzCAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0383" num="0383"> 76 ± </p><p id="p0384" num="0384"> 126 3' G GUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0385" num="0385"> 5' CzC . . 3' +1 3</p><p id="p0386" num="0386">127 5' CCAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0387" num="0387"> 74 O Q </p><p id="p0388" num="0388"> 126 3' GGUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0389" num="0389"> 128 5' CzGAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0390" num="0390"> 76 7 </p><p id="p0391" num="0391"> 129 3' G CUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0392" num="0392"> 5' CzG . . 3' +2 3</p><p id="p0393" num="0393">130 5' CGAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0394" num="0394"> 74 4 </p><p id="p0395" num="0395">129 3' GCUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0396" num="0396"> 131 5' CzAAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0397" num="0397"> 73 5 </p><p id="p0398" num="0398">132 3' G UUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0399" num="0399"> 5' CzA . . 3' +0 6</p><p id="p0400" num="0400">133 5' CAAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0401" num="0401"> 72 Q </p><p id="p0402" num="0402"> 132 3' GUUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0403" num="0403"> 134 5' CzUAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0404" num="0404"> 75 O </p><p id="p0405" num="0405"> 135 3' G AUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0406" num="0406"> 5' CzU . . 3' +3 3</p><p id="p0407" num="0407">136 5' CUAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0408" num="0408"> 72 2 </p><p id="p0409" num="0409">135 3' GAUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0410" num="0410"> 137 5' GzCAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0411" num="0411"> 75 7 </p><p id="p0412" num="0412"> 138 3' C GUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0413" num="0413"> 5' GzC . . 3' +0 2</p><p id="p0414" num="0414">139 5' GCAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0415" num="0415"> 75 5 </p><p id="p0416" num="0416">138 3' CGUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0417" num="0417"> 140 5' GzGAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0418" num="0418"> 75 6 </p><p id="p0419" num="0419">141 3' C CUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0420" num="0420"> 5' GzG . . 3' +0 7</p><p id="p0421" num="0421">142 5' GGAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0422" num="0422"> 74 9 </p><p id="p0423" num="0423">141 3' CCUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0424" num="0424"> 143 5' GzAAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0425" num="0425"> 73 2 </p><p id="p0426" num="0426">144 3' C UUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0427" num="0427"> 5' GzA . . 3' +0 1</p><p id="p0428" num="0428">145 5' GAAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0429" num="0429"> 73 1 </p><p id="p0430" num="0430">144 3' CUUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0431" num="0431"> 146 5' GzUAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0432" num="0432"> 73 Q </p><p id="p0433" num="0433"> 147 3' C AUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0434" num="0434"> 5' GzU . . 3' +1 7</p><p id="p0435" num="0435">148 5' GUAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0436" num="0436"> 72 2 </p><p id="p0437" num="0437">147 3' CAUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0438" num="0438"> 149 5' AzCAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0439" num="0439"> 76 5 </p><p id="p0440" num="0440">150 3' U GUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0441" num="0441"> 5' AzC . . 3' +3 4</p><p id="p0442" num="0442">151 5' ACAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0443" num="0443"> 73 1 </p><p id="p0444" num="0444">150 3' UGUUGUAGUCAGACUAUUCGAU 5' 
<!-- EPO <DP n="61"/>-->
152 5' AzGAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0445" num="0445"> 75 7 </p><p id="p0446" num="0446">153 3' U CUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0447" num="0447"> 5' AzG ... 3' +1 .3</p><p id="p0448" num="0448">154 5' AGAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0449" num="0449"> 74 4 </p><p id="p0450" num="0450">153 3' UCUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0451" num="0451"> 155 5' AzAAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0452" num="0452"> 73 3 </p><p id="p0453" num="0453"> 156 3' U UUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0454" num="0454"> 5' AzA ... 3' +0 .2</p><p id="p0455" num="0455">157 5' AAAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0456" num="0456"> 73 ± </p><p id="p0457" num="0457"> 156 3' UUUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0458" num="0458"> 158 5' AzUAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0459" num="0459"> 73 O Q </p><p id="p0460" num="0460"> 159 3' U AUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0461" num="0461"> 5' AzU ... 3' +1 .1</p><p id="p0462" num="0462">160 5' AUAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0463" num="0463"> 72 7 </p><p id="p0464" num="0464"> 159 3' UAUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0465" num="0465"> 161 5' UCAACAUCAGUCUGAUAAGCUzC 3' </p><p id="p0466" num="0466"> 74 1 </p><p id="p0467" num="0467">162 3' AGUUGUAGUCAGACUAUUCGA G 5' </p><p id="p0468" num="0468"> 5' ... UzC 3' -0 .3</p><p id="p0469" num="0469">163 5' UCAACAUCAGUCUGAUAAGCUC 3' </p><p id="p0470" num="0470"> 74 4 </p><p id="p0471" num="0471">162 3' AGUUGUAGUCAGACUAUUCGAG 5' </p><p id="p0472" num="0472"> 164 5' UCAACAUCAGUCUGAUAAGCUzG 3' </p><p id="p0473" num="0473"> 73 Ό </p><p id="p0474" num="0474"> 165 3' AGUUGUAGUCAGACUAUUCGA C 5' </p><p id="p0475" num="0475"> 5' ... UzG 3' -0 .7</p><p id="p0476" num="0476">166 5' UCAACAUCAGUCUGAUAAGCUG 3' </p><p id="p0477" num="0477"> 74 3 </p><p id="p0478" num="0478"> 165 3' AGUUGUAGUCAGACUAUUCGAC 5' </p><p id="p0479" num="0479"> 167 5' UCAACAUCAGUCUGAUAAGCUzA 3' </p><p id="p0480" num="0480"> 73 O Q </p><p id="p0481" num="0481"> 168 3' AGUUGUAGUCAGACUAUUCGA U 5' </p><p id="p0482" num="0482"> 5' ... UzA 3' +0 .6</p><p id="p0483" num="0483">169 5' UCAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0484" num="0484"> 73 2 </p><p id="p0485" num="0485">168 3' AGUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0486" num="0486"> 170 5' UCAACAUCAGUCUGAUAAGCUzU 3' </p><p id="p0487" num="0487"> 74 4 </p><p id="p0488" num="0488">171 3' AGUUGUAGUCAGACUAUUCGA A 5' </p><p id="p0489" num="0489"> 5' ... UzU 3' +0 .4</p><p id="p0490" num="0490">172 5' UCAACAUCAGUCUGAUAAGCUU 3' </p><p id="p0491" num="0491"> 74 0 </p><p id="p0492" num="0492">171 3' AGUUGUAGUCAGACUAUUCGAA 5' </p><p id="p0493" num="0493"> 173 5' UCAACAUCAGUCUGAUAAGCCzC 3' </p><p id="p0494" num="0494"> 75 0 </p><p id="p0495" num="0495"> 174 3' AGUUGUAGUCAGACUAUUCGG G 5' </p><p id="p0496" num="0496"> 5' ... CzC 3' -1 .7</p><p id="p0497" num="0497">175 5' UCAACAUCAGUCUGAUAAGCCC 3' </p><p id="p0498" num="0498"> 76 7 </p><p id="p0499" num="0499">174 3' AGUUGUAGUCAGACUAUUCGGG 5' </p><p id="p0500" num="0500"> 176 5' UCAACAUCAGUCUGAUAAGCCzG 3' </p><p id="p0501" num="0501"> 74 4 </p><p id="p0502" num="0502">177 3' AGUUGUAGUCAGACUAUUCGG C 5' </p><p id="p0503" num="0503"> 5' ... CzG 3' -1 .6</p><p id="p0504" num="0504">178 5' UCAACAUCAGUCUGAUAAGCCG 3' </p><p id="p0505" num="0505"> 76 0 </p><p id="p0506" num="0506"> 177 3' AGUUGUAGUCAGACUAUUCGGC 5' </p><p id="p0507" num="0507"> 179 5' UCAACAUCAGUCUGAUAAGCCzA 3' </p><p id="p0508" num="0508"> 74 6 </p><p id="p0509" num="0509">180 3' AGUUGUAGUCAGACUAUUCGG U 5' </p><p id="p0510" num="0510"> 5' ... CzA 3' 0. 0</p><p id="p0511" num="0511">181 5' UCAACAUCAGUCUGAUAAGCCA 3' </p><p id="p0512" num="0512"> 74 6 </p><p id="p0513" num="0513">180 3' AGUUGUAGUCAGACUAUUCGGU 5' 
<!-- EPO <DP n="62"/>-->
 182 5' UCAACAUCAGUCUGAUAAGCCzU 3' </p><p id="p0514" num="0514"> 75 0 </p><p id="p0515" num="0515"> 183 3' AGUUGUAGUCAGACUAUUCGG A 5' </p><p id="p0516" num="0516"> 5' .. CzU 3' +0 5</p><p id="p0517" num="0517">184 5' UCAACAUCAGUCUGAUAAGCCU 3' </p><p id="p0518" num="0518"> 74 5 </p><p id="p0519" num="0519"> 183 3' AGUUGUAGUCAGACUAUUCGGA 5' </p><p id="p0520" num="0520"> 185 5' UCAACAUCAGUCUGAUAAGCGzC 3' </p><p id="p0521" num="0521"> 76 O Q </p><p id="p0522" num="0522"> 186 3' AGUUGUAGUCAGACUAUUCGC G 5' </p><p id="p0523" num="0523"> 5' .. GzC 3' +0 2</p><p id="p0524" num="0524">187 5' UCAACAUCAGUCUGAUAAGCGC 3' </p><p id="p0525" num="0525"> 76 Ό </p><p id="p0526" num="0526"> 186 3' AGUUGUAGUCAGACUAUUCGCG 5' </p><p id="p0527" num="0527"> 188 5' UCAACAUCAGUCUGAUAAGCGzG 3' </p><p id="p0528" num="0528"> 77 0 </p><p id="p0529" num="0529"> 189 3' AGUUGUAGUCAGACUAUUCGC C 5' </p><p id="p0530" num="0530"> 5' .. GzG 3' +0 1</p><p id="p0531" num="0531">190 5' UCAACAUCAGUCUGAUAAGCGG 3' </p><p id="p0532" num="0532"> 76 Q z&gt; </p><p id="p0533" num="0533"> 189 3' AGUUGUAGUCAGACUAUUCGCC 5' </p><p id="p0534" num="0534"> 191 5' UCAACAUCAGUCUGAUAAGCGzA 3' </p><p id="p0535" num="0535"> 76 1 </p><p id="p0536" num="0536"> 192 3' AGUUGUAGUCAGACUAUUCGC U 5' </p><p id="p0537" num="0537"> 5' .. GzA 3' -0 2</p><p id="p0538" num="0538">193 5' UCAACAUCAGUCUGAUAAGCGA 3' </p><p id="p0539" num="0539"> 76 3 </p><p id="p0540" num="0540"> 192 3' AGUUGUAGUCAGACUAUUCGCU 5' </p><p id="p0541" num="0541"> 194 5' UCAACAUCAGUCUGAUAAGCGzU 3' </p><p id="p0542" num="0542"> 76 3 </p><p id="p0543" num="0543"> 195 3' AGUUGUAGUCAGACUAUUCGC A 5' </p><p id="p0544" num="0544"> 5' .. GzU 3' +0 9</p><p id="p0545" num="0545">196 5' UCAACAUCAGUCUGAUAAGCGU 3' </p><p id="p0546" num="0546"> 75 </p><p id="p0547" num="0547"> 195 3' AGUUGUAGUCAGACUAUUCGCA 5' </p><p id="p0548" num="0548"> 197 5' UCAACAUCAGUCUGAUAAGCAzC 3' </p><p id="p0549" num="0549"> 73 7 </p><p id="p0550" num="0550"> 198 3' AGUUGUAGUCAGACUAUUCGU G 5' </p><p id="p0551" num="0551"> 5' .. AzC 3' -0 4</p><p id="p0552" num="0552">199 5' UCAACAUCAGUCUGAUAAGCAC 3' </p><p id="p0553" num="0553"> 74 1 </p><p id="p0554" num="0554"> 198 3' AGUUGUAGUCAGACUAUUCGUG 5' </p><p id="p0555" num="0555"> 200 5' UCAACAUCAGUCUGAUAAGCAzG 3' </p><p id="p0556" num="0556"> 72 Q z&gt; </p><p id="p0557" num="0557"> 201 3' AGUUGUAGUCAGACUAUUCGU C 5' </p><p id="p0558" num="0558"> 5' .. AzG 3' -0 9</p><p id="p0559" num="0559">202 5' UCAACAUCAGUCUGAUAAGCAG 3' </p><p id="p0560" num="0560"> 73 0 Q </p><p id="p0561" num="0561"> 201 3' AGUUGUAGUCAGACUAUUCGUC 5' </p><p id="p0562" num="0562"> 203 5' UCAACAUCAGUCUGAUAAGCAzA 3' </p><p id="p0563" num="0563"> 73 Ό </p><p id="p0564" num="0564"> 204 3' AGUUGUAGUCAGACUAUUCGU U 5' </p><p id="p0565" num="0565"> 5' .. AzA 3' +0 1</p><p id="p0566" num="0566">205 5' UCAACAUCAGUCUGAUAAGCAA 3' </p><p id="p0567" num="0567"> 73 O </p><p id="p0568" num="0568"> 204 3' AGUUGUAGUCAGACUAUUCGUU 5' </p><p id="p0569" num="0569"> 206 5' UCAACAUCAGUCUGAUAAGCAzU 3' </p><p id="p0570" num="0570"> 73 ± </p><p id="p0571" num="0571"> 207 3' AGUUGUAGUCAGACUAUUCGU A 5' </p><p id="p0572" num="0572"> 5' .. AzU 3' -0 2</p><p id="p0573" num="0573">208 5' UCAACAUCAGUCUGAUAAGCAU 3' </p><p id="p0574" num="0574"> 73 3 </p><p id="p0575" num="0575"> 207 3' AGUUGUAGUCAGACUAUUCGUA 5' </p><p id="p0576" num="0576"> Top strands are 2'OMe RNA (bold font) and are shown in 5 '-3 ' orientation. </p><p id="p0577" num="0577">Bottom strands are RNA (standard font) and are shown in 3 '-5' orientation, </p><p id="p0578" num="0578">"z" indicates the iFQ napthyl-azo modifier. 
<!-- EPO <DP n="63"/>-->
 [00138] For all 16 dinucleotide pairs, insertion of the napthyl-azo modifier between the 5'- most and adjacent base increased stability of the 2'0Me:R A duplex. Values range from +4.0°C to +0.1°C, varying with nearest neighbor pairs. The average T<sub>m</sub> value was increased by +1.5°C with iFQ modification. Modification of the 3'-most and adjacent base altered T<sub>m</sub>. Effects range from T<sub>m</sub> stabilizing at +0.9°C to T<sub>m</sub> destabilizing at -1.7°C, with an average effect of -0.2°C. Thus the precise T<sub>m</sub> effects of insertion of the napthyl-azo modifier varied with sequence context and whether the modification was at the 5 '-end or 3 '-end of the oligomer. </p><p id="p0579" num="0579"> [00139] The effects of terminal modification were studied next, where the napthyl-azo modifier was placed at either the 5 '-end or 3 '-end of the 2'OMe oligomer (not between terminal residues as before). The stability of 2'OMe:R A duplexes was studied in an identical fashion for each of the 4 possible bases on each end of the modified strand. Results are shown in Table 13. </p><p id="p0580" num="0580">Table 13. T<sub>m</sub> of napthyl-azo end-modified 2'OMe AMOs duplexed with RNA </p><p id="p0581" num="0581"> SEQ ID End-base </p><p id="p0582" num="0582"> Sequence -* m 0 c °c No. studied </p><p id="p0583" num="0583"> 209 5' z UCAAC AUCAGUCUGAUAAGCUA 3' </p><p id="p0584" num="0584"> 76 1 </p><p id="p0585" num="0585"> 114 3' AGUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0586" num="0586"> 5' zU ... 3' +2. 9</p><p id="p0587" num="0587">115 5' UCAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0588" num="0588"> 73 2 </p><p id="p0589" num="0589"> 114 3' AGUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0590" num="0590"> 210 5' z CCAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0591" num="0591"> 78 </p><p id="p0592" num="0592"> 126 3' GGUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0593" num="0593"> 5' zC ... 3' +3. 4</p><p id="p0594" num="0594">127 5' CCAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0595" num="0595"> 75 0 </p><p id="p0596" num="0596"> 126 3' GGUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0597" num="0597"> 211 5' z GCAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0598" num="0598"> 78 3 </p><p id="p0599" num="0599"> 138 3' CGUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0600" num="0600"> 5' zG ... 3' +3. 3</p><p id="p0601" num="0601">139 5' GCAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0602" num="0602"> 75 0 </p><p id="p0603" num="0603"> 138 3' CGUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0604" num="0604"> 212 5' z ACAAC AUCAGUCUGAUAAGCUA 3' </p><p id="p0605" num="0605"> 75 1 </p><p id="p0606" num="0606"> 150 3' UGUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0607" num="0607"> 5' zA ... 3' +1. 9</p><p id="p0608" num="0608">151 5' ACAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0609" num="0609"> 73 2 </p><p id="p0610" num="0610"> 150 3' UGUUGUAGUCAGACUAUUCGAU 5' 
<!-- EPO <DP n="64"/>-->
 213 5' UCAACAUCAGUCUGAUAAGCUC z 3' </p><p id="p0611" num="0611"> 73 5 </p><p id="p0612" num="0612"> 162 3' AGUUGUAGUCAGACUAUUCGAG 5' </p><p id="p0613" num="0613"> 5' .. Cz 3' -1 2</p><p id="p0614" num="0614">163 5' UCAACAUCAGUCUGAUAAGCUC 3' </p><p id="p0615" num="0615"> 74 7 </p><p id="p0616" num="0616"> 162 3' AGUUGUAGUCAGACUAUUCGAG 5' </p><p id="p0617" num="0617"> 214 5' UC AACAUC AGUCUGAUAAGCUG z 3' </p><p id="p0618" num="0618"> 74 1 </p><p id="p0619" num="0619"> 165 3' AGUUGUAGUCAGACUAUUCGAC 5' </p><p id="p0620" num="0620"> 5' .. Gz 3' -1 0</p><p id="p0621" num="0621">166 5' UCAACAUCAGUCUGAUAAGCUG 3' </p><p id="p0622" num="0622"> 75 ± </p><p id="p0623" num="0623"> 165 3' AGUUGUAGUCAGACUAUUCGAC 5' </p><p id="p0624" num="0624"> 215 5' UCAACAUCAGUCUGAUAAGCUAz 3' </p><p id="p0625" num="0625"> 74 4 </p><p id="p0626" num="0626"> 168 3' AGUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0627" num="0627"> 5' .. Az 3' +1 2</p><p id="p0628" num="0628">169 5' UCAACAUCAGUCUGAUAAGCUA 3' </p><p id="p0629" num="0629"> 73 2 </p><p id="p0630" num="0630"> 168 3' AGUUGUAGUCAGACUAUUCGAU 5' </p><p id="p0631" num="0631"> 216 5' UC AACAUC AGUCUGAUAAGCUU z 3' </p><p id="p0632" num="0632"> 74 7 </p><p id="p0633" num="0633"> 171 3' AGUUGUAGUCAGACUAUUCGAA 5' </p><p id="p0634" num="0634"> 5' .. Uz 3' +1 7</p><p id="p0635" num="0635">172 5' UCAACAUCAGUCUGAUAAGCUU 3' </p><p id="p0636" num="0636"> 73 0 </p><p id="p0637" num="0637"> 171 3' AGUUGUAGUCAGACUAUUCGAA 5' </p><p id="p0638" num="0638"> Top strands are 2'OMe RNA (bold font) and are shown in 5 '-3 ' orientation. </p><p id="p0639" num="0639">Bottom strands are RNA (standard font) and are shown in 3 '-5' orientation, </p><p id="p0640" num="0640">"z" indicates the terminal FQ napthyl-azo modifier. </p><p id="p0641" num="0641">[00140] The effect of modification with the napthyl-azo group at the 5'-end of a 2'OMe oligomer duplexed to RNA varied from +3.4°C to +1.9°C, averaging +2.9°C for the 4 bases. The effect of modification with the napthyl-azo group at the 3 '-end of a 2'OMe oligomer duplexed to RNA varied from +1.7°C to -1.2°C, averaging +0.2°C for the 4 bases. Thus terminal addition of the napthyl-azo modifier affects duplex stability in a similar fashion to internal modification. The magnitude of the T<sub>m</sub> effect varies with sequence. It is possible that functional potency of a modified antisense oligomer may vary slightly with placement of the napthyl-azo modifier depending on sequence context. </p><p id="p0642" num="0642">EXAMPLE 9 </p><p id="p0643" num="0643"> [00141] This example demonstrates improved nuclease stability of napthyl-azo-modified 2'OMe oligomers. Stability of internal napthyl-azo-modified DNA oligomers was demonstrated in Example 2. The present example extends this study to examine the effects of this modification on 2'OMe oligomers in serum and in cell extracts. The 2'OMe RNA backbone shows higher binding affinity to RNA targets than DNA and shows some intrinsic 
<!-- EPO <DP n="65"/>-->
 resistance to nuclease degradation which is significantly improved through use of the napthyl-azo modifier. </p><p id="p0644" num="0644">[00142] Oligonucleotide synthesis and purification. Oligonucleotides were synthesized using solid phase phosphoramidite chemistry, deprotected and desalted on NAP-5 columns (Amersham Pharmacia Biotech, Piscataway, NJ) according to routine techniques (Caruthers et ah, 1992). The oligomers were purified using reversed-phase high performance liquid chromatography (RP-HPLC). The purity of each oligomer was determined by capillary electrophoresis (CE) carried out on a Beckman P/ACE MDQ system (Beckman Coulter, Inc., Fullerton, CA). All single-strand oligomers were at least 90% pure. Electrospray-ionization liquid chromatography mass spectrometry (ESI-LCMS) of the oligonucleotides was conducted using an Oligo HTCS system ( ovatia, Princeton, NJ), which consisted of ThermoFinnigan TSQ7000, Xcalibur data system, ProMass data processing software, and Paradigm MS4™ HPLC (Michrom BioResources, Auburn, CA). Protocols recommended by the manufacturers were followed. Experimental molar masses for all single-strand oligomers were within 1.5 g/mol of expected molar mass. These results confirm identity of the oligomers. The synthesized oligonucleotides are listed in Table 14. </p><p id="p0645" num="0645">[00143] Nuclease stability assay methods. A male mouse was sacrificed via cervical dislocation. One gram of liver tissue was placed into 10 ml of T-PER tissue protein extraction reagent (Pierce, Rockford, IL) containing a 1/100 volume cocktail of protease inhibitors comprising 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), pepstatin-A, E-64, bestatin, leupeptin, and aprotinin (Sigma-Aldrich, St. Louis, MO). The liver-extraction reagent mixture was immediately homogenized at 35,000 RPMs for 1 minute using a 10 mm stainless steel probe on an Omni TH homogenizer (Omni International, Kennesaw, GA), followed by centrifugation at 10,000x g for 5 min. The supernatant was stored at -80°C. </p><p id="p0646" num="0646">[00144] In a 70 μΐ total reaction volume, the oligomers (AMOs) were diluted to 15 μΜ in PBS and incubated in 10% and 50% non-heat- inactivated fetal bovine serum (FBS), or 20% and 50% mouse liver protein extract at 37°C for 0, 2, 6 or 24 hrs. Degradation reactions were stopped at each time point by adding an equal volume of 2X formamide gel loading buffer (90% formamide, IX TBE, 0.025% w/v bromophenol blue and 0.025% w/v xylene cyanol) and immediately flash freezing on dry ice with subsequent storage at -80°C. 200 pmoles 
<!-- EPO <DP n="66"/>-->
 (13.33μ1) of each reaction was heated to 95°C for 5 minutes and placed on ice for 2 min, loaded on 7M urea 20% polyacrylamide gels and electrophoresed at 30 mAs. Gels were stained for 30 minutes in a methylene blue solution (0.02% w/v methylene blue in 0.1X TBE), destained in several washes of H20 for 2 hrs and images were generated with an HP Scanjet 4850 Photo Scanner (Hewlett-Packard Company, Palo Alto, CA). </p><p id="p0647" num="0647"> [00145] A 15 μΐ (225 pmoles) aliquot of each degradation reaction in both 10% FBS and 20% mouse liver protein extract at the 24 hr time point was analyzed by electrospray ionization liquid chromatography mass spectrometry (ESI-LC-MS) for evaluation of degradation products. The 20% mouse liver protein extract reactions were incubated with 200 μg/ml of Proteinase K (Sigma-Aldrich) at 37°C for 1 hour prior to mass spectometry. The 10% FBS and Proteinase K-digested 20% mouse liver protein extract treated oligomers were extracted with an equal volume of phenol:chloroform:isoamyl alcohol 25:24: 1 (Sigma- Aldrich) and ethanol precipitated (3 μΐ of 10 μg/μl glycogen, 1/10 vol 3M Na+ Acetate pH 5.2, 2.5 vol cold EtOH). Pellets were re-suspended in 60 μΐ H20 and the entire sample was analyzed by ESI-LC-MS. </p><p id="p0648" num="0648"> [00146] Results. Oligomers employed in the nuclease stability studies are listed in Table 14. The sequences are complementary to miR-21 and represent chemical variants of miR-21 AMOs. The 2'OMe oligomers were incubated in 10% FBS for periods of 0, 2, 6, or 24 hours, separated by PAGE, stained with methylene blue, and visualized by transillumination as outlined above. Results are shown in Figures 10 and 11. </p><p id="p0649" num="0649">Table 14: Synthetic oligomers employed in Figures </p><p id="p0650" num="0650"><img id="imgf000066_0001" he="52" wi="155" file="imgf000066_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/><!-- EPO <DP n="67"/>-->
 38 2'OMe 5'iFQ UzC A A C A U C A G U C U G A U A A G C U A</p><p id="p0651" num="0651">35 2'OMe 5'+3'iFQ UzC A A C A U C A G U C U G A U A A G C UzA</p><p id="p0652" num="0652">218 2'OMe 3'FQ U C A A C A U C A G U C U G A U A A G C U Az </p><p id="p0653" num="0653">2'OMe </p><p id="p0654" num="0654"> 219 UzC A A C A U C A G U C U G A U A A G C U Az </p><p id="p0655" num="0655"> 5'iFQ+3'FQ </p><p id="p0656" num="0656"> Uppercase = 2'OMe R] </p><p id="p0657" num="0657"> " * " = phosphorothioate linkage </p><p id="p0658" num="0658"> "x" = internal C3 spacer (propanediol) </p><p id="p0659" num="0659"> "z" = napthyl-azo modifier (FQ) </p><p id="p0660" num="0660">[00147] Degradation of the unmodified 2'OMe RNA oligomer (SEQ ID No.32) proceeded rapidly with little full length product present after 2 hours and no full length product present after 6 hours incubation. The addition of 3 PS bonds between terminal residues on both the 5'- and 3 '-ends (SEQ ID No.33) significantly slowed but did not entirely stop degradation. By 6 hours, an (n-l)mer species appeared which comprised around half of the remaining oligomer by 24 hours. The degradation product was identified by mass spectrometry to represent removal of the 3 '-terminal base, reducing the starting 22-mer oligomer to a 21-mer species. The oligomer with a C3 spacer (propanediol) placed between the terminal bases on both the 5'- and 3'-ends (SEQ ID No.217) also showed rapid loss of one base such that 100% of the starting mass was reduced to (n-l)mer by 2 hours incubation; however, no further degradation was seen at 24 hours, indicating that the C3 spacer element blocked further degradation. The degradation product was identified by mass spectrometry to represent removal of the 3 '-terminal base, reducing the starting 22-mer oligomer to a 21-mer species. Inserting a single napthyl-azo (iFQ) group between the terminal 5 '-residues of the oligomer (SEQ ID No.38) did not significantly affect degradation in serum, and this compound was degraded at around the same rate as the unmodified version (SEQ ID No.32). Inserting two napthyl-azo (iFQ) groups, one between the terminal 5 '-residues and one between the terminal 3'-residues of the oligomer (SEQ ID No.35) showed loss of one base such that 100% of the starting mass was reduced to (n-l)mer by 6 hours incubation (slower rate of degradation than was seen using the internal C3 spacer) and no further change was seen at 24 hours, indicating that the iFQ modifier blocked further degradation. The 
<!-- EPO <DP n="68"/>-->
 degradation product was identified by mass spectrometry to represent removal of the 3 '- terminal base, reducing the starting 22-mer oligomer to a 21-mer species. The oligomer with a single napthyl-azo (FQ) modifier placed at the 3 '-end (not between residues, but instead as a modification of the 3 '-hydroxyl of the 3 '-terminal base) (SEQ ID No. 218) showed no degradation over 24 hours, fully protecting the oligomer from attack by the 3'-exonuclease activity present in serum. The oligomer with two napthyl-azo (FQ) modifiers, one placed between the 5'-terminal residues and the second placed at the 3 '-end (SEQ ID No. 219) also showed no degradation over 24 hours. </p><p id="p0661" num="0661"> [00148] The degradation studies were next extended to include incubation of the same set of oligomers in liver cell extracts. While the primary nuclease activity in serum is a 3 '- exonuclease, cell extracts contain 5'-exonuclease, 3'-exonuclease, and endonuclease activities. To function in live cells or animals, a synthetic antisense oligomer must survive the nucleases present in both serum (during the delivery phase) and the intracellular environment (during effector phase), and stability in this environment will influence both the magnitude of effect as well as the duration of effect achieved. The 2'OMe oligomers (Table 14) were incubated in 20% liver cell extracts for periods of 0, 2, 6, or 24 hours, separated by PAGE, stained with methylene blue, and visualized by transillumination as outlined above. Results are shown in Figures 12 and 13. </p><p id="p0662" num="0662"> [00149] The unmodified 2'OMe RNA oligomer (SEQ ID No. 32) showed evidence for degradation after 2 hours and little full-length product was present after 24 hours incubation. The addition of 3 PS bonds between terminal residues on both the 5'- and 3'-ends (SEQ ID No. 33) significantly slowed but did not entirely stop degradation. By 24 hours, an (n-l)mer species appeared which was identified by mass spectrometry to represent removal of the 3 '- terminal base, reducing the starting 22-mer oligomer to a 21-mer species. The rate and magnitude of 3 '-degradation was lower in cell extracts than in serum (compare Figures 10 and 12). The oligomer with a C3 spacer (propanediol) placed between the terminal bases on both the 5'- and 3 '-ends (SEQ ID No. 217) also showed loss of one base and 100% of the starting mass was reduced to (n-l)mer by 24 hours incubation. The degradation product was identified by mass spectrometry to represent removal of the 3 '-terminal base, reducing the starting 22-mer oligomer to a 21-mer species. Inserting a single napthyl-azo (iFQ) group between the terminal 5 '-residues of the oligomer (SEQ ID No. 38) did not significantly affect degradation in liver cell extracts, and this compound was degraded at around the same rate as 
<!-- EPO <DP n="69"/>-->
 the unmodified version (SEQ ID No. 32). Inserting two napthyl-azo (iFQ) groups, one between the terminal 5'-residues and one between the terminal 3 '-residues of the oligomer (SEQ ID No. 35) showed loss of one base such that most of the starting mass has been reduced to (n-l)mer by 24 hours incubation (again, slower than was seen with incubation in serum). The degradation product was identified by mass spectrometry to represent removal of the 3 '-terminal base, reducing the starting 22-mer oligomer to a 21-mer species. The oligomer with a single napthyl-azo (FQ) modifier placed at the 3 '-end (not between residues, but as a modification of the 3'-hydroxyl of the 3 '-terminal base) (SEQ ID No. 218) showed some degradation, but &gt;50% of the starting mass remained intact after 24 hours incubation. This result differs from that seen when this same oligomer was incubated in serum where no degradation was observed; this oligomer has no 5 '-modification and is thus susceptible to attack by 5'-exonucleases present in cell extracts which are absent in serum. The oligomer with two napthyl-azo (FQ) modifiers, one placed between the 5 '-terminal residues and the second placed at the 3 '-end (SEQ ID No. 219) showed no degradation over 24 hours. </p><p id="p0663" num="0663">[00150] Non-base modifiers such as a C3 spacer or iFQ block degradation by exonucleases when placed between bases, however loss of the external base can occur. Exonuclease attack is fully blocked when the modifier is positioned after the terminal base. 2'OMe RNA oligomers were stable in serum with only 3'-end modification; however, both 5'-end and 3 '- end modifications were needed to achieve full protection in cell extracts. Thus incorporation of modifying groups that confer nuclease resistance on both ends of the oligomer is preferred. </p><p id="p0664" num="0664">[00151] When synthetic oligonucleotides are delivered to cells in tissue culture or to animals via IV injection, the compounds are exposed to serum in culture medium or blood for periods lasting from several minutes to many hours. The serum stability testing shown in Figures 10 and 11 show incubation for periods as long as 24 hours, which meets this need. In contrast, once the synthetic oligonucleotide exits the serum environment and enters living cells, it will ideally remain intact for many days, during which time the oligomer is active as an anti-miRNA agent, as a splice-switching agent, or as an anti-mRNA ASO. Stability of oligomers in cell extracts for up to 24 hours was demonstrated in Figures 12 and 13. </p><p id="p0665" num="0665">[00152] The degradation studies were next extended to include incubation of the set of oligomers shown in Table 15 in mouse liver cell extracts for 4 days. Oligomers were incubated in 20% liver cell extracts for either 0 or 96 hours, separated by PAGE, stained with 
<!-- EPO <DP n="70"/>-->
 methylene blue, and visualized by transillumination as outlined above. Results are shown in Figure 14. </p><p id="p0666" num="0666">Table 15: Synthetic oligomers employed in Figure 14 </p><p id="p0667" num="0667"><img id="imgf000070_0001" he="69" wi="155" file="imgf000070_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0668" num="0668"> Lowercase = DNA </p><p id="p0669" num="0669"> "z" = napthyl-azo modifier (FQ) </p><p id="p0670" num="0670">[00153] A DNA oligomer with the napthyl-azo modifier placed between bases at the 5'- end and following the terminal base at the 3 '-end (SEQ ID No. 220) was completely degraded in cell extracts. In spite of protection from both 5'- and 3'-exonuclease attack by the terminal FQ modifying groups, this oligomer remained sensitive to endonucleases present in the cell extract. In contrast, a 2'OMe oligomer with similar end modification remained fully intact after 4 days incubation in cell extract at 37°C (SEQ ID No. 219), indicating that, unlike DNA, the 2'OMe modified sugar backbone protects the compound from endonuclease attack. As expected, a 2'OMe oligomer with the napthyl-azo modifier placed between bases at the 5'-end and between bases at the 3'-end (SEQ ID No. 35) had the terminal 3'-residue removed but was otherwise intact after 4 days incubation in cell extract. A 2'OMe oligomer modified only at the 3 '-end with the napthyl-azo group (SEQ ID No. 218) had -50% of the input mass survive incubation for 4 days in cell extract. This finding demonstrates that 3 '- end modification alone is insufficient to fully protect a 2'OMe oligomer from degradation, presumably from 5'-exonuclease activity present in the cell extract. 
<!-- EPO <DP n="71"/>-->
 [00154] Thus incorporation of modifying groups that confer exonuclease resistance on both ends of the oligomer is preferred, and 2'OMe R A is preferred over DNA due to its increased resistance to endonuclease attack. It is anticipated that other 2 '-modifications, such as LNA, 2'-MOE (2'-0-methoxyethyl), and other 2 '-modified sugars, as are well known to those with skill in the art, would show similar improved stability in serum or in cell extracts, and can similarly be used with the napthyl-azo modifier as taught herein. </p><p id="p0671" num="0671">EXAMPLE 10 </p><p id="p0672" num="0672"> [00155] Extending the results from Example 3, this example compares functional activity of additional design variants of modified ASOs at reducing microRNA activity. </p><p id="p0673" num="0673">[00156] Oligonucleotide synthesis and purification. Oligomers were synthesized using solid phase phosphoramidite chemistry, deprotected and desalted on NAP-5 columns (Amersham Pharmacia Biotech, Piscataway, NJ) according to routine techniques (Caruthers et ah, 1992). The oligomers were purified using reversed-phase high performance liquid chromatography (RP-HPLC). The purity of each oligomer was determined by capillary electrophoresis (CE) on a Beckman P/ACE MDQ system (Beckman Coulter, Inc., Fullerton, CA). All single-strand oligomers were at least 85% pure. Electrospray-ionization liquid chromatography mass spectrometry (ESI-LCMS) of the oligonucleotides was conducted using an Oligo HTCS system (Novatia, Princeton, NJ), which consisted of ThermoFinnigan TSQ7000, Xcalibur data system, ProMass data processing software, and Paradigm MS4™ HPLC (Michrom BioResources, Auburn, CA). Protocols recommended by the manufacturers were followed. Experimental molar masses for all single-strand oligomers were within 1.5 g/mol of expected molar mass. These results confirm identity of the oligomers. Table 16 lists the synthetic oligomers used in this Example, all of which were designed to be perfectly complementary to miR-21. </p><p id="p0674" num="0674">Table 16: Synthetic oligomers employed in Example 10 (miR-21 AMOs) 
<img id="imgf000071_0001" he="15" wi="155" file="imgf000071_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/>
 
<!-- EPO <DP n="72"/>-->
 32 2'OMe U C A A C A U C A G U C U G A U A A G C U A </p><p id="p0675" num="0675">37 2'OMe 3'iFQ U C A A C A U C A G U C U G A U A A G C UzA </p><p id="p0676" num="0676">218 2'OMe 3'FQ U C A A C A U C A G U C U G A U A A G C U Az </p><p id="p0677" num="0677">221 2'OMe 3'iC3 U C A A C A U C A G U C U G A U A A G C UxA </p><p id="p0678" num="0678">38 2'OMe 5'iFQ UzC A A C A U C A G U C U G A U A A G C U A </p><p id="p0679" num="0679">222 2'OMe 5'iC3 UxC A A C A U C A G U C U G A U A A G C U A </p><p id="p0680" num="0680">2'OMe </p><p id="p0681" num="0681"> 35 UzC A A C A U C A G U C U G A U A A G C UzA </p><p id="p0682" num="0682"> 5'iFQ+3'iFQ </p><p id="p0683" num="0683"> 2'OMe </p><p id="p0684" num="0684"> 217 UxC A A C A U C A G U C U G A U A A G C UxA </p><p id="p0685" num="0685"> 5'iC3+3'iC3 </p><p id="p0686" num="0686">219 2'OMe 5'iFQ+3'FQ UzC A A C A U C A G U C U G A U A A G C U Az </p><p id="p0687" num="0687">223 2'OMe 5'iC3+3'C3 UxC A A C A U C A G U C U G A U A A G C U Ax</p><p id="p0688" num="0688">Uppercase = 2'OMe RNA </p><p id="p0689" num="0689"> "x" = C3 spacer (propanediol) </p><p id="p0690" num="0690"> "z" = napthyl-azo modifier (FQ) </p><p id="p0691" num="0691">[00157] Plasmid preparation. The psiCHECK™-2 vector (Promega, Madison, WI) was restriction enzyme digested sequentially with Xhol and Notl (New England Biolabs, Ipswitch, MA) and purified with a Qiaquick PCR purification column (Qiagen, Valencia, CA). A perfect complement hsa-miR-21 binding site was created by annealing two synthetic duplexed oligonucleotides (Integrated DNA Technologies, Coralville, IA) and was cloned into the Xhol/Notl sites in the 3'UTR of Renilla luciferase. This miR-21 reporter construct was sequence verified on a 3130 Genetic Analyzer (AB, Foster City, CA). Plasmids were purified using a Plasmid Midiprep Kit (Bio-Rad, Hercules, CA) and treated twice for endotoxin removal with the MiraCLEAN Endotoxin Removal Kit (Minis Corporation, Madison, WI). Plasmids were filtered through a 0.2 μ filter and quantified by measurement 
<!-- EPO <DP n="73"/>-->
 of the absorbance at 260 nm using UV spectrophotometry. This reporter plasmid having a perfect match miRNA binding site is denoted as psiCHECK™-2-miR21. </p><p id="p0692" num="0692">[00158] Cell culture, transfections, and luciferase assays. HeLa cells were plated in a 100 mm dish in DMEM containing 10% FBS to achieve 90% confluency the next day. The following morning, 5 μg of the psiCHECK™-2-miR21 plasmid was transfected with </p><p id="p0693" num="0693">Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA). After 6 hours, cells were washed with PBS, trypsinized, counted, and replated in DMEM with 10% FBS in 48-well plates to achieve -70% confluency the next day. The following morning, the miR-21 AMOs were transfected at various concentrations in triplicate with 1 μΐ TriFECTin<sup>®</sup> (Integrated DNA Technologies) per well in DMEM without serum. After 6 hours, the transfection media was removed and replenished with DMEM containing 10% FBS. The following morning, (48 hours after plasmid transfection, 24 hours after miRNA AMO transfection) the cells were analyzed for luciferase luminescence using the Dual-Luciferase<sup>®</sup> Reporter Assay System (Promega, Madison, WI) per the manufacturer's instructions. Renilla luciferase was measured as a fold increase in expression compared to the TriFECTin<sup>®</sup> reagent-only negative controls. Values for Renilla luciferase luminescence were normalized to levels concurrently measured for firefly luciferase, which is present as a separate expression unit on the same plasmids as an internal control (RLuc/FLuc ratio). </p><p id="p0694" num="0694"> [00159] Results. The RLuc/FLuc ratios obtained from transfections done with the various AMOs are shown in Figure 15. In the untreated state, HeLa cells contain large amounts of miRNA 21 that suppress expression of the RLuc reporter. Any treatment that decreases miR- 21 levels leads to an increase in RLuc expression and thus increases the relative RLuc/FLuc ratio (with FLuc serving as an internal normalization control for transfection efficiency). </p><p id="p0695" num="0695">[00160] The unmodified 2'OMe RNA AMO (SEQ ID No. 32) showed essentially no inhibition of miR-21 activity, probably due to rapid nuclease degradation of this unprotected oligomer during transfection or in the intracellular environment. Protecting either end of the anti-miR-21 AMO from exonuclease attack with an internal napthyl-azo modifier improved potency when compared with the unmodified 2'OMe AMO. The 2'0Me-3'iFQ (SEQ ID No. 37, with an internal napthyl-azo modifier between the terminal 3 '-residues) show some improvement over the unmodified oligomer. Similar results were obtained whether the modifier was positioned between the terminal bases (SEQ ID No. 37) or at the 3 '-end (SEQ ID No. 218, 2'0Me-3 'FQ). If an internal C3 (propanediol) spacer group is positioned 
<!-- EPO <DP n="74"/>-->
 between the 3' residues (2'0Me-3'iC3, SEQ ID No. 221), no functional benefit is observed. Interestingly, this modification blocks 3'-exonuclease attack, providing significant protection of the oligomer in both serum and the intracellular environment (Example 9), yet does not increase functional potency of the oligomer as an anti-miRNA reagent against this target. 5'- modification with the napthyl-azo group placed between terminal residues significantly increased potency of miR-21 knockdown (SEQ ID No. 38) whereas a C3 spacer placed at this same position provides no benefit (SEQ ID No. 222). The 2'OMe AMO modified with two napthyl-azo groups where one group is placed near the 5 '-end between terminal residues and the other group is placed near the 3 '-end between terminal residues (SEQ ID No. 35) or where one group is placed near the 5 '-end between terminal residues and the other group is placed at the 3 '-end (SEQ ID No. 219) both showed very potent inhibition of miR-21 activity and were the most potent reagents tested in this survey. In spite of providing equal protection of the oligomer from degradation (Example 9), the same oligomers modified with C3 spacers (SEQ ID No. 35 and SEQ ID no. 223) showed no anti-miR-21 activity. Thus nuclease stabilization alone does not account for the large improvement in AMO activity seen with use of the napthyl-azo modifier. Increased binding affinity likely is a second key element to the benefit obtained from use of this modification strategy. </p><p id="p0696" num="0696"> [00161] The melting temperatures, T<sub>m</sub>, of the AMOs described above were measured using the same methods described in Example 8 and are shown in Table 17 below. Synthetic AMO oligonucleotides were annealed to a synthetic RNA complement (mature miR-21 RNA sequence, SEQ ID No. 114, 5' phos-UAGCUUAUCAGACUGAUGUUGA 3 '). </p><p id="p0697" num="0697"> Measurements were done at 2 μΜ duplex concentration in 150 mM NaCl to approximate intracellular ion concentration. Measurements were made on both the melt and re-anneal phase and repeated 3 times, so the values shown represent the average of 6 T<sub>m</sub> measurements. The AT<sub>m</sub> is calculated as the difference between the modified AMO variant and the unmodified version (SEQ ID No. 32). Note that the accuracy of T<sub>m</sub> measurement is around +/- 0.5°C so that the T<sub>m</sub> values for a given duplex reported in this experiment may vary slightly from that reported in earlier examples for the same duplex. </p><p id="p0698" num="0698">Table 17: T<sub>m</sub> of synthetic miR-21 AMOs in 150 mM NaCl 
<img id="imgf000074_0001" he="11" wi="165" file="imgf000074_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/>
 
<!-- EPO <DP n="75"/>-->
O: 2 2'OMe U C A A C A U C A G U C U G A U A A G C U A 72.0 - 7 2'OMe 3'iFQ U C A A C A U C A G U C U G A U A A G C UzA 72.4 +0.4 18 2'OMe 3'FQ U C A A C A U C A G U C U G A U A A G C U Az 72.6 +0.6 21 2'OMe 3'iC3 U C A A C A U C A G U C U G A U A A G C UxA 72.1 +0.1 8 2'OMe 5'iFQ UzC A A C A U C A G U C U G A U A A G C U A 75.4 +3.4 22 2'OMe 5'iC3 UxC A A C A U C A G U C U G A U A A G C U A 71.6 -0.4 </p><p id="p0699" num="0699">2'OMe</p><p id="p0700" num="0700"> 5 UzC A A C A U C A G U C U G A U A A G C UzA </p><p id="p0701" num="0701"> 5'iFQ+3'iFQ 75.6 +3.6 </p><p id="p0702" num="0702">2'OMe</p><p id="p0703" num="0703">17 UxC A A C A U C A G U C U G A U A A G C UxA </p><p id="p0704" num="0704"> 5'iC3+3'iC3 71.1 -0.9 </p><p id="p0705" num="0705">2'OMe</p><p id="p0706" num="0706">19 UzC A A C A U C A G U C U G A U A A G C U Az </p><p id="p0707" num="0707"> 5'iFQ+3'FQ 76.0 +4.0 </p><p id="p0708" num="0708">2'OMe</p><p id="p0709" num="0709">23 UxC A A C A U C A G U C U G A U A A G C U Ax </p><p id="p0710" num="0710"> 5'iC3+3'C3 72.6 +0.6</p><p id="p0711" num="0711">Uppercase = 2'OMe RNA </p><p id="p0712" num="0712"> "x" = C3 spacer (propanediol) </p><p id="p0713" num="0713"> "z" = napthyl-azo modifier (FQ) </p><p id="p0714" num="0714">[00162] As a general rule, the effects of the C3 spacer on T<sub>m</sub> was neutral or slightly destabilizing (greatest drop seen was -0.9°C for the dual-modified SEQ ID No.217) while the napthyl-azo modifier was slightly to significantly stabilizing (greatest gain seen was +4.0°C for SEQ ID No.219). The relative potency of the various miR-21 AMOs correlated with binding affinity (T<sub>m</sub>). All variations in potency observed between compounds could be explained by relative contributions of improvements in binding affinity and nuclease stability between the different modification patterns studied. The AMO having 2'OMe bases with an FQ modification placed near each end ("2'OMe 5'iFQ+3'iFQ", SEQ ID No.35) and that with an FQ modification placed near the 5'-end and at the 3'-end ("2'OMe 5'iFQ+3'FQ", SEQ ID No.219) both showed an excellent balance of nuclease stability with increased T<sub>m</sub>. The 
<!-- EPO <DP n="76"/>-->
 variant with the napthyl-azo modifier located between terminal bases at the 3 '-end (SEQ ID No. 35), however, is at risk for loss of the terminal residue by exonuclease attack whereas the having the modifier at the 3 '-end protects the terminal residue (SEQ ID No. 219) (see Example 9) and therefore use of this design may be preferred in some settings. </p><p id="p0715" num="0715">EXAMPLE 11 </p><p id="p0716" num="0716"> [00163] Extending the results from Example 10, this example compares functional activity of additional design variants of modified ASOs at reducing microRNA activity by optimizing 3 '-end structure. </p><p id="p0717" num="0717">[00164] Oligonucleotide synthesis and purification. Oligomers were synthesized using solid phase phosphoramidite chemistry, deprotected and desalted on NAP-5 columns (Amersham Pharmacia Biotech, Piscataway, NJ) according to routine techniques (Caruthers et ah, 1992). The oligomers were purified using reversed-phase high performance liquid chromatography (RP-HPLC). The purity of each oligomer was determined by capillary electrophoresis (CE) on a Beckman P/ACE MDQ system (Beckman Coulter, Inc., Fullerton, CA). All single-strand oligomers were at least 85% pure. Electrospray-ionization liquid chromatography mass spectrometry (ESI-LCMS) of the oligonucleotides was conducted using an Oligo HTCS system (Novatia, Princeton, NJ), which consisted of ThermoFinnigan TSQ7000, Xcalibur data system, ProMass data processing software, and Paradigm MS4™ HPLC (Michrom BioResources, Auburn, CA). Protocols recommended by the manufacturers were followed. Experimental molar masses for all single-strand oligomers were within 1.5 g/mol of expected molar mass. These results confirm identity of the oligomers. Table 18 lists the synthetic oligomers used in this Example, all of which were designed to be perfectly complementary to miR-21. </p><p id="p0718" num="0718">Table 18: Synthetic oligomers employed in Example 11 (miR-21 AMOs) </p><p id="p0719" num="0719"><img id="imgf000076_0001" he="23" wi="150" file="imgf000076_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/><!-- EPO <DP n="77"/>-->
 225 2'OMe 223'FQ U C A A C A U C A G U C U G A U A A G C U Az </p><p id="p0720" num="0720">226 2'OMe 223'iFQ U C A A C A U C A G U C U G A U A A G C UzA </p><p id="p0721" num="0721">227 2'OMe 213'FQ U C A A C A U C A G U C U G A U A A G C Uz </p><p id="p0722" num="0722">228 2'OMe 213'iFQ U C A A C A U C A G U C U G A U A A G CzU </p><p id="p0723" num="0723">229 2'OMe 203'FQ U C A A C A U C A G U C U G A U A A G Cz </p><p id="p0724" num="0724">230 2'OMe 203'iFQ U C A A C A U C A G U C U G A U A A GzC </p><p id="p0725" num="0725">231 2'OMe 193'FQ U C A A C A U C A G U C U G A U A A Gz </p><p id="p0726" num="0726"> Uppercase = 2'OMe RNA </p><p id="p0727" num="0727"> "x" = C3 spacer (propanediol) </p><p id="p0728" num="0728"> "z" = napthyl-azo modifier (FQ) </p><p id="p0729" num="0729">[00165] Plasmid preparation. The psiCHECK™-2 vector (Promega, Madison, WI) was restriction enzyme digested sequentially with Xhol and Notl (New England Biolabs, Ipswitch, MA) and purified with a Qiaquick PCR purification column (Qiagen, Valencia, CA). A perfect complement hsa-miR-21 binding site was created by annealing two synthetic duplexed oligonucleotides (Integrated DNA Technologies, Coralville, IA) and was cloned into the Xhol/Notl sites in the 3'UTR of Renilla luciferase. This miR-21 reporter construct was sequence verified on a 3130 Genetic Analyzer (AB, Foster City, CA). Plasmids were purified using a Plasmid Midiprep Kit (Bio-Rad, Hercules, CA) and treated twice for endotoxin removal with the MiraCLEAN Endotoxin Removal Kit (Minis Corporation, Madison, WI). Plasmids were filtered through a 0.2 μ filter and quantified by measurement of the absorbance at 260 nm using UV spectrophotometry. This reporter plasmid having a perfect match miRNA binding site is denoted as psiCHECK™-2-miR21. </p><p id="p0730" num="0730">[00166] Cell culture, transfections, and luciferase assays. HeLa cells were plated in a 100 mm dish in DMEM containing 10% FBS to achieve 90% confluency the next day. The following morning, 5 μg of the psiCHECK™-2-miR21 plasmid was transfected with Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA). After 6 hours, cells were washed with 
<!-- EPO <DP n="78"/>-->
 PBS, trypsinized, counted, and replated in DMEM with 10% FBS in 48-well plates to achieve -70% confluency the next day. The following morning, the miR-21 AMOs were transfected at various concentrations in triplicate with 1 μΐ TriFECTin<sup>®</sup> (Integrated DNA Technologies) per well in DMEM without serum. After 6 hours, the transfection media was removed and replenished with DMEM containing 10% FBS. The following morning, (48 hours after plasmid transfection, 24 hours after miRNA AMO transfection) the cells were analyzed for luciferase luminescence using the Dual-Luciferase<sup>®</sup> Reporter Assay System (Promega, Madison, WI) per the manufacturer's instructions. Renilla luciferase was measured as a fold increase in expression compared to the TriFECTin<sup>®</sup> reagent-only negative controls. Values for Renilla luciferase luminescence were normalized to levels concurrently measured for firefly luciferase, which is present as a separate expression unit on the same plasmids as an internal control (RLuc/FLuc ratio). </p><p id="p0731" num="0731"> [00167] Results. The RLuc/FLuc ratios obtained from transfections done with the various AMOs are shown in Figure 16. In the untreated state, HeLa cells contain large amounts of miRNA 21 that suppress expression of the RLuc reporter. Any treatment that decreases miR- 21 levels leads to an increase in RLuc expression and thus increases the relative RLuc/FLuc ratio (with FLuc serving as an internal normalization control for transfection efficiency). </p><p id="p0732" num="0732">[00168] This study examines the effects that shortening the 3 '-end of the anti-miRNA ASO (AMO) has on potency and on the precise placement of the napthyl-azo modifier. The 3 '-end of the AMO hybridizes to the 5 '-end of the miRNA, which is known as the "seed region" and is critical for miRNA activity. All AMOs in the present example had an unmodified 5 '-end. The 3 '-end was protected with a 3 '-modifier (such as an iFQ napthyl-azo group or an iC3 spacer), which blocks attack of the 3 '-end by exonuclease activity (see Example 9). Alternatively an iFQ modifier was placed between the 3 '-terminal base and the next base. This placement permits removal of the 3 '-terminal base by exonuclease activity, shortening the AMO by one base during transfection via exposure to serum and/or cellular nucleases, however thermodynamic benefit and therefore potency increases will still be imparted by the iFQ group. </p><p id="p0733" num="0733"> [00169] The 2'OMe 22 3'C3 (SEQ ID No. 224) serves as a control for the potency of the full length 22mer AMO without any group to enhance thermodynamic stability and uses a 3'- C3 end block to prevent exonuclease attack. This species will remain 22mer after incubation in serum and cell extract (see Example 9). The 2'OMe 22 3'FQ AMO (SEQ ID No. 225) 
<!-- EPO <DP n="79"/>-->
 shows the increase in potency gained by using the napthyl-azo modifier instead of the C3 spacer. It also remains 22mer length after incubation in serum or cell extract. Interestingly, the most potent designs were those which survive within cells as an (n-l)mer species with a single base truncation from the 3'-end (for miR-21, this is a 21mer species). The 2'OMe 22 3'iFQ (SEQ ID No. 226) will degrade to a 21mer in serum or cell extracts while the 2'OMe 21 3 'FQ (SEQ ID No. 227) is protected from loss of the terminal base; it was synthesized as a 21mer and remains a 21mer. Both of these designs showed the highest potency, indicating that this 3 '-end design for the AMO may be preferred, at least in certain sequence contexts. Further shortening of the AMO to 20mer length, 2'OMe 21 3 'iFQ (SEQ ID No. 228) or 2'OMe 20 3'FQ (SEQ ID No. 229) showed reduced activity and yet additional shortening of the AMO to 19mer length, 2'OMe 20 3 'iFQ (SEQ ID No. 230) or 2'OMe 19 3'FQ (SEQ ID No. 231) had no detectable anti-miR-21 activity in this assay system. </p><p id="p0734" num="0734">EXAMPLE 12 </p><p id="p0735" num="0735"> [00170] This example demonstrates improved functional activity of terminal napthyl-azo- modified oligomers at reducing cellular mRNA levels when incorporated into RNase H active ASOs as compared to other related compounds. </p><p id="p0736" num="0736"> [00171] Example 5 demonstrates improved function of ASOs containing internal modification with a T<sub>m</sub>-enhancing modification placed near the ends of the oligonucleotide at the penultimate position, between the last and next to last nucleotide. The present example demonstrates even more improved function when the T<sub>m</sub>-enhancing modifier is placed at the 5'- and 3 '-ends of the oligonucleotide. </p><p id="p0737" num="0737"> [00172] Oligonucleotides antisense in orientation to cellular messenger RNAs (mRNAs) will hybridize to the mRNA and form an RNA/DNA heteroduplex, which is a substrate for cellular RNase H. Degradation by RNase H leads to a cut site in the mRNA and </p><p id="p0738" num="0738">subsequently to total degradation of that RNA species, thereby functionally lowering effective expression of the targeted transcript and the protein it encodes. ASOs of this type require a domain containing at least 4 bases of DNA to be a substrate for RNase H, and maximal activity is not seen until 8-10 DNA bases are present. ASOs must be chemically modified to resist degradation by serum and cellular nucleases. Phosphorothioate (PS) modification of the internucleotide linkages is compatible with RNase H activation, however most other nuclease resistant modifications prevent RNase H activity, including all 2'- 
<!-- EPO <DP n="80"/>-->
 modifications, such as 2'OMe RNA, LNA, MOE, etc. The PS modification lowers binding affinity (T<sub>m</sub>). In general, modifications that lower T<sub>m</sub> decrease potency while modifications that increase T<sub>m</sub> improve potency. One strategy to improve potency of ASOs is to employ a chimeric design where a low T<sub>m</sub>, RNase H activating domain made of PS-modified DNA is flanked by end domains that contain 2'-modified sugars which confer high binding affinity but are not RNase H activating ("gapmer" design). One commonly employed strategy is to place five 2'-modified residues at the 5'-end, ten PS-modified DNA residues in the middle, and five 2'-modified residues at the 3'-end of the ASO (so called "5-10-5" gapmer design). Shorter ASOs, such as those that contain three 2'-modified residues at the 5'-end, ten PS- modified DNA residues in the middle, and three 2'-modified residues at the 3'-end ("3-10-3" gapmer design) will have lower T<sub>m</sub> than the longer "5-10-5" design and will have lower potency when using facilitated delivery methods (such as cationic lipid mediated </p><p id="p0739" num="0739">transfection) than the "5-10-5" ASOs but can show higher potency when administered in vivo using naked IV injection. In general, short oligonucleotides (around 16 residues, or preferable 12-14 residues, or less) enter mammalian cells better when administered without the aid of a delivery tool than longer oligonucleotides (Straarup et ah, 2010, Nucleic Acids Res. 38(20):7100-711 1. A modification that confers nuclease resistance, increases binding affinity, and does not impair the reagent's ability to activate RNase H may increase the potency of the shorter ASOs to compare with longer ASOs yet might retain the improved unassisted delivery characteristics of the shorter compounds. The present example demonstrates the utility of placing a T<sub>m</sub>-enhancing modification, in this case the napthyl-azo modifier (N,N-diethyl-4-(4-nitronaphthalen-l-ylazo)-phenylamine) at the 3 '- and 5 '-ends of ASOs to improve the nuclease stability, increase binding affinity and enhance potency as gene knockdown reagents. </p><p id="p0740" num="0740"> [00173] Oligonucleotide synthesis and purification. DNA, 2'OMe RNA, and LNA containing oligonucleotides were synthesized using solid phase phosphoramidite chemistry, deprotected and desalted on NAP-5 columns (Amersham Pharmacia Biotech, Piscataway, NJ) according to routine techniques (Caruthers et ah, 1992). Electrospray-ionization liquid chromatography mass spectrometry (ESI-LCMS) of the oligonucleotides was conducted using an Oligo HTCS system (Novatia, Princeton, NJ), which consisted of ThermoFinnigan TSQ7000, Xcalibur data system, ProMass data processing software, and Paradigm MS4™ HPLC (Michrom BioResources, Auburn, CA). Protocols recommended by the manufacturers 
<!-- EPO <DP n="81"/>-->
 were followed. Experimental molar masses for all single-strand oligomers were within 1.5 g/mol of expected molar mass. These results confirm identity of the oligomers. </p><p id="p0741" num="0741">Table 19: Synthetic oligomers employed in Example 12 (anti-HPRT ASOs) </p><p id="p0742" num="0742"><img id="imgf000081_0001" he="119" wi="143" file="imgf000081_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0743" num="0743"> Uppercase = 2'OMe RNA </p><p id="p0744" num="0744"> Lowercase = DNA </p><p id="p0745" num="0745"> Uppercase with underscore = LNA </p><p id="p0746" num="0746"> " * " = phosphorothioate linkage </p><p id="p0747" num="0747"> "z" = napthyl-azo modifier (iFQ, FQ) </p><p id="p0748" num="0748">[00174] HeLa cell culture, transfections, and RT-qPCR methods. HeLa cells were reverse transfected into 96-well plates in Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum (ATCC, Manassas, VA) using RNAiMAX<sup>®</sup> (Life Technologies, Carlsbad, CA) at a concentration of 2% (1 per 50 OptiMEM<sup>®</sup> I) (Life Technologies) with ASOs at the indicated concentrations. All transfections were performed in triplicate. RNA was prepared 24 hours after transfection using the SV96 Total RNA Isolation Kit (Promega, 
<!-- EPO <DP n="82"/>-->
 Madison, WI). cDNA was synthesized using 150 ng total RNA with Superscript -II</p><p id="p0749" num="0749">Reverse Transcriptase (Life Technologies) per the manufacturer's instructions using both random hexamer and oligo-dT priming. Quantitative real-time PCR was performed using 10 ng cDNA per 10 μΐ<sub>^</sub> reaction with Immolase™ DNA Polymerase (Bioline, Randolph, MA),</p><p id="p0750" num="0750">500 nM primers, and 250 nM probe. Hypoxanthine phosphoribosyltransferase 1 (HPRT1)</p><p id="p0751" num="0751">(GenBank Acc. No. NM_000194) specific primers and probe were: </p><p id="p0752" num="0752"> HPRT-For 5' GACTTTGCTTTCCTTGGTCAGGCA (SEQ ID NO: 79), </p><p id="p0753" num="0753"> HPRT-Rev 5' GGCTTATATCCAACACTTCGTGGG (SEQ ID NO: 80), </p><p id="p0754" num="0754"> HPRT-P 5' FAM-ATGGTCAAG/ZEN/GTCGCAAGCTTGCTGGT-IBFQ (SEQ ID NO:</p><p id="p0755" num="0755">240). </p><p id="p0756" num="0756"> Samples were normalized to levels of an internal control gene, human splicing factor, arginine/serine-rich 9 (SFRS9) (GenBank Acc. No. NM_003769), in a multiplexed reaction using primers and probe: </p><p id="p0757" num="0757"> SFRS9-For 5' TGTGCAGAAGGATGGAGT (SEQ ID NO: 241), </p><p id="p0758" num="0758">SFRS9-Rev 5' CTGGTGCTTCTCTCAGGATA (SEQ ID NO: 242), </p><p id="p0759" num="0759"> SFRS9-P 5' HEX-TGGAATATG/ZEN/CCCTGCGTAAACTGGA-IBFQ (SEQ ID NO: 243). Cycling conditions employed were: 95°C for 10 minutes followed by 40 cycles of 2-step PCR with 95°C for 15 seconds and 60°C for 1 minute. PCR and fluorescence measurements were done using an ABI Prism™ 7900 Sequence Detector (Life Technologies). All reactions were performed in triplicate. Copy number standards were multiplexed using linearized cloned amplicons for both the HPRT and SFRS9 assays. Unknowns were extrapolated against standards to establish absolute quantitative measurements. </p><p id="p0760" num="0760"> [00175] Results. ASOs were transfected into HeLa cells at 3 nM, 10 nM, and 30 nM concentrations. RNA was prepared 24 hours post transfection, converted to cDNA, and HPRT expression levels were measured using qPCR. Results are shown in Figure 17. The LNA-PS gapmer ("HPRT1 3-10-3 LNA PS", SEQ ID No. 232) was able to suppress HPRT expression by 85% when used at 30 nM and 65% at 10 nM concentrations. With the addition of the r<sub>m</sub>-enhancing modifications placed near the ends of the oligonucleotide at the penultimate position, between the last and next to last nucleotide, the LNA-PS gapmer ("HPRT1 3-10-3 LNA PS 2x iFQ", SEQ ID No. 233) showed improved potency with 95% knockdown of HPRT achieved when used at 30 nM and 90% knockdown at 10 nM concentrations. With addition of the r<sub>m</sub>-enhancing modification at the 5'- and 3 '-ends of the 
<!-- EPO <DP n="83"/>-->
 oligonucleotide, the LNA-PS gapmer ("HPRT1 3-10-3 LNA PS 2x FQ", SEQ ID No. 234) showed further increases in potency with over 95% knockdown of HPRT when used at 30 nM and over 90% knockdown when used at 10 nM concentrations. This demonstrates the utility of the r<sub>m</sub>-enhancing modifier when used either near or at the 3 '- and 5 '-ends of the ASO. </p><p id="p0761" num="0761"> [00176] For the 2'OMe versions of the short 3-10-3 design ASOs studied in the present example, the parent 2'OMe-PS gapmer ("HPRT1 3-10-3 PS", SEQ ID No. 236) was unable to reduce HPRT mRNA levels at the doses studied. This negative result was expected, as the 2'OMe modification does not confer a sufficient increase in binding affinity for this chemical composition to function as a short 3-10-3 design whereas the LNA modification provides a sufficient increase in binding affinity to be effective. In longer 5-10-5 designs, the 2'OMe gapmers can suppress HPRT mRNA levels (see Example 5, Figures 5 and 6). However, addition of the new non-nucleotide modifier to the 2'OMe 3-10-3 gapmer ASOs increases potency and a significant reduction in HPRT mRNA levels was observed using this new class of reagents. The 2'OMe gapmer with addition of the r<sub>m</sub>-enhancing modifications placed near the ends of the oligonucleotide at the penultimate position, between the last and next to last nucleotide ("HPRT1 3-10-3 PS 2x iFQ", SEQ ID No. 237), showed improved potency with 85% knockdown of HPRT achieved when used at 30 nM and 65% knockdown at 10 nM concentrations. This efficacy was similar to that seen using the LNA-PS 3-10-3 gapmer (SEQ ID No. 232) With addition of the r<sub>m</sub>-enhancing modification at the 5'- and 3 '-ends of the oligonucleotide, the 2'OMe-PS gapmer ("HPRT1 3-10-3 PS 2x FQ", SEQ ID No. 238) showed further increases in potency with over 90% knockdown of HPRT when used at 30 nM and almost 80% knockdown when used at 10 nM concentrations. These data further demonstrate the utility of the T<sub>m</sub>-enhancing modifier when used either near or at the 3'- and 5 '-ends of the ASO. </p><p id="p0762" num="0762"> [00177] The PS modification confers nuclease resistance but also lowers binding affinity. The variant of the LNA-PS gapmer having a terminal T<sub>m</sub>-enhancing modifier but with phosphodiester linkages between the 2 '-modified LNA residues ("HPRT1 3-10-3 LNA gapPS 2x FQ", SEQ ID No. 235) showed even greater increases in potency, with 90% knockdown of HPRT mRNA seen using a 3 nM dose. Therefore use of the terminal T<sub>m</sub>- enhancing modifier, which both increases binding affinity and blocks exonuclease attack, permits reduction in the amount of PS modification needed in the ASO, limited to the DNA 
<!-- EPO <DP n="84"/>-->
 segment in the middle domain of the gapmer. Reduction in PS content can lead to increases in potency and decreases in toxicity. </p><p id="p0763" num="0763"> [00178] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein. </p><p id="p0764" num="0764"> [00179] The use of the terms "a" and "an" and "the" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising," "having," "including," and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to") unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention. </p><p id="p0765" num="0765"> [00180] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context. 
</p></description><claims mxw-id="PCLM70076523" ref-ucid="WO-2014130945-A1" lang="EN" load-source="patent-office"><claim id="clm-0001" num="0001"><!-- EPO <DP n="85"/>--><claim-text> WHAT IS CLAIMED IS: </claim-text><claim-text>Claim 1 : An antisense oligonucleotide comprising at least one modification that is incorporated at the terminal end or between two nucleotides of the antisense oligonucleotide, wherein the modification increases binding affinity and nuclease resistance of the antisense oligonucleotide. </claim-text><claim-text>Claim 2: The antisense oligonucleotide of claim 1, wherein the modification is located at the 5 '-end of the antisense oligonucleotide. </claim-text><claim-text>Claim 3 : The antisense oligonucleotide of claim 1 , wherein the modification is located at the 3 '-end of the antisense oligonucleotide. </claim-text><claim-text>Claim 4: The antisense oligonucleotide of claim 1, wherein modifications are located at both the 5'- and 3 '-ends of the antisense oligonucleotide. </claim-text><claim-text>Claim 5: The antisense oligonucleotide of claim 1, wherein the modification is inserted between nucleotides and is located near the 3 '-end of the antisense oligonucleotide. </claim-text><claim-text>Claim 6: The antisense oligonucleotide of claim 1, wherein the modification is inserted between nucleotides and is located near the 5'-end of the antisense oligonucleotide. </claim-text><claim-text>Claim 7: The antisense oligonucleotide of claim 1, wherein modifications are inserted between nucleotides and are located near the 3 '-end and the 5 '-end of the antisense oligonucleotide. </claim-text><claim-text>Claim 8: The antisense oligonucleotide of claim 1, wherein a modification is located at the 5 '-end and a modification is inserted between nucleotides near the 3 '-end of the antisense oligonucleotide. 
<!-- EPO <DP n="86"/>-->
 Claim 9: The antisense oligonucleotide of claim 1 , wherein a modification is located at the 3 '-end and a modification is inserted between nucleotides near the 5 '-end of the antisense oligonucleotide. </claim-text><claim-text>Claim 10: The antisense oligonucleotide of claim 1, wherein the modification is a napthyl-azo compound. </claim-text><claim-text>The antisense oligonucleotide of claim 1 wherein the modification has the </claim-text><claim-text><img id="imgf000086_0001" he="30" wi="52" file="imgf000086_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 wherein the linking groups Li and L2 positioning the modification at an internal position of the oligonucleotide are independently an alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, or alkoxy groups; R -R5 are independently a hydrogen, alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, alkoxy, an electron withdrawing group, an electron donating group, or an attachment point for a ligand; and X is a nitrogen or carbon atom, wherein if X is a carbon atom, the fourth substituent attached to the carbon atom can be hydrogen or a C1-C8 alkyl group. 
<!-- EPO <DP n="87"/>-->
</claim-text><claim-text>The antisense oligonucleotide of claim 1 , wherein the modification has the </claim-text><claim-text><img id="imgf000087_0001" he="47" wi="102" file="imgf000087_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 wherein the linking groups Li and L2 positioning the modification at an internal position of the oligonucleotide are independently an alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, or alkoxy groups; Ri, R2, R4, R5 are independently a hydrogen, alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, alkoxy, an electron withdrawing group, or an electron donating group; R6, R7, R9-R12 are independently a hydrogen, alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, alkoxy, an electron withdrawing group, or an electron donating group; Rs is a hydrogen, alkyl, alkynyl, alkenyl, heteroalkyl, substituted alkyl, aryl, heteroaryl, substituted aryl, cycloalkyl, alkylaryl, alkoxy, or an electron withdrawing group; and X is a nitrogen or carbon atom, wherein if X is a carbon atom, the fourth substituent attached to the carbon atom can be hydrogen or a C1-C8 alkyl group. </claim-text><claim-text>Claim 13 : The antisense oligonucleotide of claim 6, wherein R<sub>8</sub> is O2. </claim-text><claim-text>Claim 14: The antisense oligonucleotide of claim 1, wherein the modification has the structure: 
<!-- EPO <DP n="88"/>-->
 
<img id="imgf000088_0001" he="47" wi="65" file="imgf000088_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 claim 15: The antisense oligonucleotide of claim 1, wherein the antisense </claim-text><claim-text>oligonucleotide further comprises at least one 2'-0-methyl RNA residue. </claim-text><claim-text>Claim 16: The antisense oligonucleotide of claim 15, further comprising at least one napthyl-azo compound modification that is incorporated at the terminal end of the antisense oligonucleotide, wherein the antisense oligonucleotide targets miRNA. </claim-text><claim-text>Claim 17: The antisense oligonucleotide of claim 16, wherein the antisense </claim-text><claim-text>oligonucleotide is the same length as the miRNA target. </claim-text><claim-text>Claim 18: The antisense oligonucleotide of claim 16, wherein the antisense </claim-text><claim-text>oligonucleotide is one base shorter than the miRNA target. </claim-text><claim-text>Claim 19: The antisense oligonucleotide of claim 1, wherein the antisense </claim-text><claim-text>oligonucleotide further comprises one or more phosphorothioate internucleotide linkages. </claim-text><claim-text>Claim 20: The antisense oligonucleotide of claim 1, wherein the each nucleotide of the antisense oligonucleotide is phosphorothioate modified, comprising at least one modification that is incorporated at the terminal end or between two bases of the antisense oligonucleotide. </claim-text><claim-text>Claim 21 : The antisense oligonucleotide claim 20, further comprising a chemical modification, wherein the chemical modification comprises 2'OMe RNA, 2'F RNA, or LNA bases. 
<!-- EPO <DP n="89"/>-->
 Claim 22: The antisense oligonucleotide of claim 20, wherein the at least one modification is a napthyl-azo compound. </claim-text><claim-text>Claim 23 : The antisense oligonucleotide of claim 1, wherein the antisense </claim-text><claim-text>oligonucleotide comprises a region of bases linked through phosphodiester bonds, wherein the region is flanked at one or both ends by regions containing phosphorothioate linkages. </claim-text><claim-text>Claim 24: The antisense oligonucleotide of claim 1, wherein the antisense </claim-text><claim-text>oligonucleotide comprises a region of bases linked through phosphorothioate bonds, wherein the region is flanked at one or both ends by regions containing phosphodiester linkages. </claim-text><claim-text>Claim 25: An oligonucleotide having the structure: </claim-text><claim-text>5'- Χι-Ζ<sub>η</sub>-Χ2-Χ3-Χ<sub>4</sub>-Ζη-Χ5-3' wherein Xi and X5 are independently 0-3 nucleotides wherein the internucleotide linkages are optionally phosphorothioate; Z is a napthyl-azo compound; n is 0 or 1 ; X2 and X<sub>4</sub> are independently 1 -5 nucleotides wherein the internucleotide linkages are optionally phosphorothioate; and X3 is 10-25 nucleotides, wherein the linkages are optionally phosphorothiaote. </claim-text><claim-text>Claim 26: A method of reducing a level of a target mRNA in a cell, said method comprising contacting the cell with an oligonucleotide, wherein said oligonucleotide is at least partially complementary to the target mRNA and wherein said oligonucleotide comprises at least one modification that is incorporated at the terminal end or between two bases of the oligonucleotide and wherein the modification increases binding affinity and nuclease resistance of the antisense oligonucleotide, in an amount sufficient to reduce the target mRNA. </claim-text><claim-text>Claim 27: A method of reducing a level of a target miRNA in a cell, said method comprising contacting the cell with an oligonucleotide, wherein said oligonucleotide is at least partially complementary to the target miRNA and wherein said oligonucleotide comprises at least one modification that is incorporated at the terminal end or between two 
<!-- EPO <DP n="90"/>-->
 bases of the oligonucleotide and wherein the modification increases binding affinity and nuclease resistance of the antisense oligonucleotide, in an amount sufficient to reduce the target miRNA. </claim-text><claim-text>Claim 28: The method of claim 14 where the oligonucleotide is the same length as the target miRNA. </claim-text><claim-text>Claim 29: The method of claim 14 wherein the oligonucleotide is one base shorter than the target miRNA, leaving a 1-base overhang on the 5 '-end of the target miRNA. </claim-text><claim-text>Claim 30: An oligonucleotide complementary to a target mRNA comprising: </claim-text><claim-text> (a) a modified 3 '-terminal internucleotide phosphodiester linkage, which </claim-text><claim-text> modified 3 '-terminal internucleotide phosphodiester linkage is resistant to 3' to 5' exonuclease degradation; </claim-text><claim-text> (b) modifications on the 3 '-terminus and the 5 '-terminus of the </claim-text><claim-text> oligonucleotide, wherein the modifications increase binding affinity of the oligonucleotide to the target mRNA; </claim-text><claim-text> (c) one or more additional modifications, which additional modification(s) facilitate(s) intracellular transport of said oligodeoxynucleotide; and</claim-text><claim-text>(d) a continuous stretch of at least five nucleotide residues having four </claim-text><claim-text> internucleotide phosphodiester linkages which are unmodified, wherein said oligodeoxynucleotide, when mixed with an RNA molecule for which it has complementarity under conditions in which an RNaseH is active, hybridizes to the RNA and forms a substrate that can be cleaved by the RNase H. </claim-text><claim-text>Claim 31 : The antisense oligonucleotide of claim 15, wherein the antisense </claim-text><claim-text>oligonucleotide contains one or more DNA molecules and wherein each 2'OMe and nucleotide is connected by a phosphorothioate group. </claim-text><claim-text>Claim 32: The antisense oligonucleotide of claim 31, additionally comprising at least one napthyl-azo compound modification that is incorporated at the terminal end of the antisense oligonucleotide, wherein the modification increases stability of the antisense oligonucleotide. 
<!-- EPO <DP n="91"/>-->
 Claim 33: The antisense oligonucleotide of claim 31, wherein the length of each 2'OMe portion is 2-5 nucleotides. </claim-text><claim-text>Claim 34: The antisense oligonucleotide of claim 33, wherein the length of each 2'OMe portion is 5 nucleotides. </claim-text><claim-text>Claim 35: The antisense oligonucleotide of claim 34 having the formula: </claim-text><claim-text><sub>Z</sub>M*M*M*M*M*D*D*D*D*D*D*D*D*D*D*M*M*M*M*Mz </claim-text><claim-text>wherein z is a napthyl-azo compound, M is 2Ό methyl RNA, D is DNA and * is a phosphorothioate linkage. </claim-text><claim-text>Claim 36: The antisense oligonucleotide of claim 15 having the formula: </claim-text><claim-text> zM M M M M*D*D*D*D*D*D*D*D*D*D*M M M M Mz </claim-text><claim-text>wherein z is a napthyl-azo compound, M is 2Ό methyl RNA, D is DNA and * is a phosphorothioate linkage. </claim-text><claim-text>Claim 37: The antisense oligonucleotide of claim 1, wherein the antisense </claim-text><claim-text>oligonucleotide contains one or more LNA molecules and wherein the LNA molecules are optionally contain phosphorothioate linkage groups. </claim-text><claim-text>Claim 38: The antisense oligonucleotide of claim 38, wherein the modification is a napthyl-azo compound that is incorporated at the terminal end of the antisense </claim-text><claim-text>oligonucleotide, wherein the modification increases stability of the antisense oligonucleotide. </claim-text><claim-text>Claim 39: The antisense oligonucleotide of claim 38, wherein the length of each LNA portion is 2-5 nucleotides. </claim-text><claim-text> Claim 40: The antisense oligonucleotide of claim 40, wherein the length of each LNA portion is 5 nucleotides. </claim-text><claim-text>Claim 41 : The antisense oligonucleotide of claim 34 having the formula: </claim-text><claim-text> zL*L*L*L*L*D*D*D*D*D*D*D*D*D*D*L*L*L*L*Lz 
<!-- EPO <DP n="92"/>-->
 wherein z is a napthyl-azo compound, D is DNA, L is LNA, and * is a phosphorothioate linkage. </claim-text><claim-text>Claim 42: The antisense oligonucleotide of claim 38, wherein the antisense </claim-text><claim-text>oligonucleotide has a reduced phosphorothioate group content. </claim-text><claim-text>Claim 43 : The antisense oligonucleotide of claim 43 having the formula: </claim-text><claim-text> z L L L L L* D* D * D* D * D* D* D * D* D * D* L L L L Lz </claim-text><claim-text>wherein z is a napthyl-azo compound, D is DNA, L is LNA, and * is a phosphorothioate linkage. </claim-text><claim-text>Claim 44: A method of reducing a level of a target mRNA in a cell, said method comprising contacting the cell with the molecule of claim 1, wherein said molecule is at least partially complementary to the target mRNA, in an amount sufficient to reduce the target mRNA. </claim-text><claim-text>Claim 45: A Dicer-substrate RNA (DsiRNA) oligonucleotide, comprising a sense strand and an antisense strand, wherein at least one modification on the antisense strand is incorporated near the 3 ' terminal end or between two bases of the antisense strand. </claim-text><claim-text>Claim 46: The DsiRNA oligonucleotide of claim 45, further comprising a chemical modification, wherein the chemical modification comprises 2'OMe RNA, 2'F RNA, or LNA bases. </claim-text><claim-text>Claim 47: The DsiRNA oligonucleotide of claim 45, further comprising one or more phosphorothioate groups. </claim-text><claim-text>Claim 48: The DsiRNA oligonucleotide of claim 47, wherein the phosphorothioate groups are near the 3 '-terminal internucleotide linkages. </claim-text><claim-text>Claim 49: The DsiRNA of claim 45, wherein the at least one modification is a napthyl- azo compound. 
<!-- EPO <DP n="93"/>-->
 Claim 50: The DsiRNA oligonucleotide of claim 49, wherein a napthyl-azo group is near the 3 '-end of the antisense strand. </claim-text><claim-text>Claim 51 : The DsiRNA oligonucleotide of claim 49, wherein a napthyl-azo group is near the 3 '-end of the antisense strand. </claim-text><claim-text>Claim 52: The DsiRNA oligonucleotide of claim 49, wherein a napthyl-azo group is between bases 1 and 2 from the 3 '-end of the antisense strand </claim-text><claim-text>Claim 53 : The DsiRNA oligonucleotide of claim 49, wherein a napthyl-azo group is between bases 3 and 4 from the 3 '-end of the antisense strand. </claim-text><claim-text>Claim 54: The DsiRNA oligonucleotide of claim 49, wherein a napthyl-azo group is near the 5'-end of the sense strand. </claim-text><claim-text>Claim 55: The DsiRNA oligonucleotide of claim 49, wherein a napthyl-azo group is near the 3 '-end and near the 5 '-end of the sense strand. </claim-text><claim-text>Claim 56: A method of reducing microRNA activity within a cell using an </claim-text><claim-text>oligonucleotide hybridization reaction, wherein said method comprises contacting the cell the DsiRNA oligonucleotide of claim 45. </claim-text><claim-text>Claim 57: The antisense oligonucleotide of claim 1 having the formula: z<sub>n</sub>M<sub>m</sub>*D<sub>y</sub> *M<sub>m</sub>*Mz<sub>n</sub> </claim-text><claim-text>where M = 2'OMe or LNA, D = DNA or a DNA analogue and z = a napthyl-azo compound Wherein at least one n = 1 and a second n = 0 or 1, where m = 2-5 and where y = 7-12 </claim-text><claim-text>Claim 58: An anti-miRNA oligonucleotide (AMO) comprising, </claim-text><claim-text> (a) at least one 2'-0-methyl RNA (2'OMe), and 
<!-- EPO <DP n="94"/>-->
 (b) at least one napthyl-azo compound modification that is incorporated at the terminal end of the AMO, wherein the modification increases stability of the AMO. </claim-text><claim-text>Claim 59: An RNase H antisense oligonucleotide (ASO) comprising, at least one napthyl-azo compound modification that is incorporated at the terminal end of the ASO, wherein each nucleotide is connected by a phosphorothioate group (PS) and wherein the modification increases stability of the ASO. 
</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
